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ABSTRACT 
Plasmodium falciparum is a leading cause of death among children under the age of five and 
pregnant women in sub-Saharan Africa. More than one third of the world’s population is at risk of 
contracting malaria, and 70 % of the cases are found in sub-Saharan Africa. Emerging drug resistance in 
parasites and limited effect of vector control calls for an effective vaccine. It is known that individuals 
living in malaria endemic countries develop naturally acquired immunity after repeated exposure. 
Antibodies are important components of acquired immunity, and it has been shown that passive transfer 
of antibodies from immune donors to individuals with P. falciparum infections reduced parasitemia and 
clinical symptoms. Antibodies against several P. falciparum merozoite antigens have been found to be 
associated with protective immunity. It is of great importance to understand the underlying functional 
role of antibodies in the development of protective immunity against severe malaria.  
In a cross-sectional study in Uganda, the quantitative and qualitative differences in antibody 
responses to a panel of merozoite antigens in children with uncomplicated or severe malaria were 
evaluated using a set of assays including ELISA, Invasion Inhibition Assays (IIA), NH4SCN-ELISA and 
Surface Plasmon Resonance (SPR). Children with uncomplicated malaria had higher antibody levels 
against PfEBA-181, MSP2-Fc27, MSP2-3D7 and PfAMA1 when compared to children with severe 
malaria. Acquired antibodies against PfRh2 and PfAMA1 in ELISA correlated with invasion inhibition of 
two clinical isolates in IIA, and anti-PfAMA1-antibodies in ELISA correlated with increased anti-
PfAMA1-antibody affinity in SPR. Importantly, the only assay that correlated with initial parasitemia in 
the children was the IIA. Both MSP2-Fc27 and MSP2-3D7 allelic variants were present in both children 
groups, but there was a higher number of genotypes in uncomplicated malaria compared to in children 
with severe malaria. 
P. falciparum clinical isolates collected from Ugandan children with uncomplicated malaria or 
severe malaria were further investigated for rosetting, parasite multiplication and RBC invasion. Optimal 
in vitro growth conditions were established, which allowed for phenotypic studies of clinical P. 
falciparum isolates. Presence of serum in growth cultures was found to be essential for optimal surface 
presentation of PfEMP1 and maintenance of rosettes. Higher peripheral parasitemia, higher rosetting 
levels and higher multiplication rates were observed in children with severe malaria and these correlated 
positively with one another. Rosetting might enhance successful merozoite invasion in vivo, hence could 
be the reason it is found to be associated with severe disease. Furthermore, parasite invasion into trypsin- 
and chymotrypsin-treated RBC differed between the uncomplicated and severe groups, and isolates from 
children with uncomplicated malaria showed higher sensitivity to enzyme treatment. The majority of 
clinical isolates used a sialic acid independent invasion pathway. Parasite invasion is central to parasite 
replication and virulence, and it is essential to know which invasion pathways are used for vaccine 
studies. 
Naturally acquired antibody responses to P. falciparum merozoite antigens was further studied  
in a longitudinal study over almost one year in children and adults from Nigeria. The malaria protective 
effects of the hemoglobin S (HbAS) allele were also investigated. In both children and adults, the 
antibody response against PfEBA175 was more prominent than that against PfRh2, and cytophilic IgG1 
and IgG3 against PfEBA175 were the predominant antibodies even though we could also see some 
response for IgG2 and IgG4. Individuals with higher total IgG responses against both PfEBA175 and 
PfRh2 had lower parasitemia over the course of the study period. Furthermore, children with HbAS had 
higher antibody responses against merozoite antigens compared to adults, and this might have protective 
effects against malaria. 
In conclusion this thesis emphasizes the great importance of using a combination of functional 
assays, such as SPR and IIA, to study the functional role of acquired antibodies in the development of 
protective immunological responses against severe malaria. Furthermore, investigations of parasite 
invasion and rosetting in the context of pathogenesis of severe malaria are crucial as both are important 
for parasite replication and virulence. Taken together, future vaccine studies should include functional 
assays that would allow the investigation of differences in immunological responses against severe and 
uncomplicated malaria. Also, to consider the protective effects of red blood polymorphisms and their role 
in acquired immunity in the populations, would be of great value for future vaccine studies. 
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1 INTRODUCTION 
 
1.1 PRESENT MALARIA BURDEN 
Plasmodium falciparum malaria is a major global health issue. More than one third of 
the world’s population is at risk of contracting malaria, and up to 70 % of the cases are found in 
sub-Saharan Africa (Figure 1). There were around 219 million cases and 660 000 deaths in 
2010, mainly children under the age of five and pregnant women (WHO, 2012). It is estimated 
that a child dies from malaria every 40-th second, resulting in approximately 2 000 lives lost 
daily around the world (Sachs, 2002). 
Malaria mortality rates are the highest in countries with the lowest Gross National 
Income (GNI) (WHO, 2012). The prevention and treatment, and loss of income due to malaria 
morbidity or mortality have a great toll on a poor agriculture household (Malaney et al., 2004). 
Population movement into regions of high malaria transmission, changes in agriculture, 
deforesting and long-term climate changes are risk factors that can have an effect on the 
emerging malaria pattern (Sachs and Malaney, 2002).  
The coverage of vector control intervention has increased in the past decade in sub-
Saharan Africa. The households owning insecticide-treated bed nets  (ITN) have increased from 
5 % in 2000 to 53 % in 2012 (WHO, 2012). Implementation of control programs using drug 
treatment of malaria infected individuals, preventive drug treatment of populations at risk, 
mosquito control with ITN and indoor insecticide spraying have contributed to a decrease of 
malaria morbidity and mortality (Kappe et al., 2010; WHO, 2012). Between 2000 and 2010, the 





Figure 1. Global limits and endemicity of Plasmodium falciparum as estimated in 2007. (Adapted from 
(Hay et al., 2010)). 
 
1.2 APICOMPLEXAN PROTOZOA 
Apicomplexan protozoa is a very large group including 4 000 - 5 000 species that both 
infect invertebrates and vertebrates. Apicomplexan protozoa are unicellular organisms 
characterized by unique organelles, apicoplast and apical complex structures, such as 
mirconemes and rhoptries located at the apical end of the cells. These organelles have a key 
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role in the invasion of animal cells. Plasmodium spp belong to the apicomplexan phylum. Other 
medical important parasites in this phylum include Toxoplasma spp and Cryptosporidium spp, 
and in agriculture there are Theileria spp, Babesia spp, and Eimeria spp. Species in this group 
have complex life cycles and are transmitted by insect vectors (Murray, 2009). 
 
1.2.1 PLASMODIUM SPECIES 
Plasmodium spp. consists of more than a hundred species that infect a wide range of 
animals, monkeys, birds and rodents.  At least 5 species are known to infect humans: 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmoidum malariae and 
Plasmodium knowlesi. Globally, P.  falciparum cause the deadliest form of malaria and is the 
major cause of morbidity and mortality. P. vivax is mainly found in South America and Asia, 
and is a major cause of morbidity outside Africa (Anstey et al., 2012; Price et al., 2007). P. 
vivax was historically described as “ benign tertian malaria”, but this term is misleading since P. 
vivax has been reported to cause major morbidity and in worst case mortality (Barcus et al., 
2007; Price et al., 2009). P. malariae and P. ovale cause a relatively mild form of malaria and 
are less frequent to infect humans. P. knowlesi was recently recognized as a fifth malaria 
species and was found to cause malaria in macaques but also proven to infect humans (White, 
2008). 
The scope of this thesis is the P. falciparum and the antibody responses to P. 
falciparum merozoite antigens. 
 
1.2.2 LIFE CYCLE 
The Plasmodium spp. life cycle involves a mosquito vector and a vertebrate animal, 
with asexual and sexual developmental stages (Figure 2). 
The host life cycle consists of the pre-erythrocytic stage and the erythrocytic stage. In 
the pre-erythrocytic stage, the female Anopheles mosquito injects sporozoites (harboured in the 
salivary glands) into the dermis of the host during a blood meal. Real time imaging in animal 
studies using GFP expressing P.  berghei parasites showed that 20 sporozoites were injected 
under the dermis and had a robust forward gliding locomotion movement (Amino et al., 2006). 
The sporozoites eventually interact with the blood vessels in the dermis through gliding 
movements, and reach the blood circulation and lymphatic vessels, before entering the liver 
circulation. The sporozoites invading the lymphatic vessels are eventually drained in the 
lymphatic node (Amino et al., 2006). The gliding movement used by the sporozoites is essential 
and allows them to migrate through cells, and to pass through biological barriers, the 
cytoplasma of host cells (Amino et al., 2008; Frevert et al., 2005). The sporozoites express 
surface antigens, such as circumsporozoite protein (CSP) that has been shown to have a vital 
role in the sporozoite development, motility, invasion and subversion of hepatocytes (Frevert 
and Nardin, 2008; Kappe et al., 2004; Singh et al., 2007). Once the sporozoites have reached 
the liver circulation, it takes only minutes before they reach the liver. By using the gliding 
movement, the sporozoites migrate through the Kuppfer cells lining and several hepatocytes, 
before invading a heaptocyte and forming a parasitophorous vacuole (PV) (Baer et al., 2007b; 
Mota et al., 2002; Mota et al., 2001; Pradel and Frevert, 2001). During a time period of around 
6-15 days depending on Plasmodium spp., the sporozoites undergo differentiation and 
replicates into thousands of haploid forms called merozoites per hepatocyte cell (Baer et al., 
2007a; Tarun et al., 2006). The merozoites exit the hepatocyte and re-enter the blood 
circulation.  
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This stage is referred to as the erythrocytic stage. The free merozoites invade red blood 
cells (RBC), and replication takes place through asexual forming and releasing of new 
merozoites from rupturing RBC. The parasitized RBC (pRBC) develops into ring form, 
trophozoite, and finally a mature schizont (this process is known as schizogony), which after 
mitotic nuclear division bursts and releases 8-16 new merozoites into the blood circulation. This 
stage takes 24-72 hours (depending on Plasmodium spp). The formation of a parasitophorous 
vacuolar membrane (PVM) is essential for the parasite’s survival and growth. It is formed 
during the invasion process and surrounds the parasite during the intra-erythrocytic 
development and is critical for structural and transport functions (Boddey and Cowman, 2013; 
Cooke et al., 2004; Haase and de Koning-Ward, 2010). The replication of merozoites can result 
in thousands of pRBC in the blood circulation. The erythrocytic stage is a complex process and 
is responsible for the symptoms and illness caused by malaria if not treated.  
Some of the pRBC in the blood circulation develop into the sexual form of the malaria 
parasite, female and male gametocytes. The switch may be due to a genetic response to a 
specific stimulus by host or parasite origin (Alano and Carter, 1990; Bruce et al., 1990; Talman 
et al., 2004). Furthermore, it has been shown that merozoites from a single schizont either 
continue the asexual cycle or develop into either female or male gametocytes (Bruce et al., 
1990; Smith et al., 2000). During a blood meal, a feeding female Anopheles mosquito ingests 
female and male gametocytes. The female and male gametocytes are released into the midgut of 
the mosquito, and develop to female and male gametes, which fuse to form diploid zygotes. 
The zygote further develops into an elongated and motile ookinete. The ookinete invades the 
midgut wall and develops into an oocyte. The oocyte develops and matures, and finally ruptures 
to release sporozoites. The sporozoites migrate to the salivary gland of the mosquito, and during 
the next blood meal they will be injected into the human host, thus the continuation of the 
Plasmodium life cycle (Pimenta et al., 1994; Touray et al., 1992). 
 
Figure 2. The Life Cycle of P. falciparum in the Human Host (Adapted from (Cowman and Crabb, 
2006) and published with permission from Nature Publishing Group).  
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1.3 DISEASE CHARACTERISTICS 
Malaria gives rise to a wide variety of symptoms, ranging from asymptomatic, mild to 
severe symptoms with high mortality rate. Malaria is categorized as uncomplicated or severe, 
and is described as flu like manifestations (7-15 days post infection), with the classical “cold 
stage”, a combination of shivering and feeling cold (despite elevated body temperature) for an 
hour.  The “hot stage” lasts for 2-6 h and includes fever, headache, vomiting, nausea, and 
maybe seizures in children. This is followed by the “sweating stage”, with body temperature 
decline and malaise.  At the end of this stage, the patient feels complete exhaustion and 
tiredness. The sudden onset of these clinical symptoms is also known as a malaria paroxysm.  
The clinical symptoms that are manifested during the disease are caused by the erythrocytic 
stage of the parasites. Febrile attacks occur periodically every 24, 48 or 72 hours (depending on 
the Plasmodium spp.). During the blood stage, the pRBC ruptures releasing fever associated 
substances, including hemozoin and other toxic factors, which stimulate macrophages and 
dendritic cells to produce proinflammatory cytokines. The secretion of high levels of tumor 
necrosis factor α (TNFα) into the circulation has an adverse effect on disease progression (Kern 
et al., 1989; Molyneux et al., 1991), and is more often found in patients with severe than 
uncomplicated malaria (Kwiatkowski, 1990). 
P.  vivax, P.  ovale and P.  malariae have onsets of malaria paroxysms every 48 hours 
(tertian) or 72 hours (quartian) (depending on the species) while P. knowlesi comes every 24 
hours (semi-tertian). Other symptoms seen in malaria patients include hemolytic anaemia with a 
dramatical drop in hemogloblin during onset of disease (Jakeman et al., 1999; Lamikanra et al., 
2007). Splenomegaly can be observed during the acute malaria onset, and increase in size with 
repeated infections (Chaves et al., 2011; Del Portillo et al., 2012). Jaundice can be due to 
hemolysis and seen in all types of malaria. However, P. falciparum has been shown to be the 
leading cause of malaria hepatopathy, and an increasing number of cases have been reported in 
Asian countries (Anand and Puri, 2005; WHO, 2000b). 
During the P. falciparum infection, mature trophozoites sequester within the 
microvasculature of the brain, lung, kidney, intestines, skin and placenta, and major organs. The 
sequestration will be discussed in detail in section 1.4.4. 
 
1.3.1 SEVERE MALARIA 
The clinical outcomes of P. falciparum infection are numerous and diverse, with severe 
and complicated manifestations. The progression from uncomplicated malaria disease to severe 
malaria with fatal outcome can be rapid, within hours. Severe malaria is a number of different 
conditions that can appear alone or in combination. The complications and severe 
manifestations are severe anaemia, renal failure, acute respiratory distress syndrome (ARDS), 
pulmonary edema, unrousable coma (cerebral coma), multiple convulsions, circulatory 
collapse, renal failure, hypoglycemia, abnormal bleeding, acidosis, hyperlactemia and 
hyperparasitemia (WHO, 2000b). P. falciparum can also cause pregnancy-associated malaria 
(PAM), which causes complications in both the mother and infant. The mortality rate for severe 
malaria with treatment falls to 15-20 % (WHO, 2010).  
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1.3.2 SEVERE ANAEMIA 
Severe anaemia is defined as having a hemogloblin level <5g/dl in children or <7g/dl in 
adults (WHO, 2000a) or a hematocrit below 15%. The fatality rate due to severe anaemia in 
malaria is lower than in ARDS and cerebral malaria (Murphy and Breman, 2001). However, 
together with cerebral malaria, severe anaemia is a leading cause of mortality, between 6-16% 
in children (Marsh et al., 1995), and 6% in pregnant woman (Shulman et al., 1996). Malaria 
patients have an increased risk of hemolysis (90%) compared to healthy individuals (Jakeman 
et al., 1999). An average of 8.5 unparasitized RBC are destroyed for every invaded RBC, 
resulting in anaemia due to destruction of healthy RBC and pRBC.  
A study using a rodent model demonstrated that the clearance of pRBC was due to the 
uptake of phagocytic monocytes and macrophages, and this caused anaemia (Evans et al., 
2006). Hemozoin released from rupturing pRBC has been associated with anaemia by 
inhibiting erythroid development, and this caused induction of apoptosis (Lamikanra et al., 
2009). Macrophage ingestion of hemozoin caused macrophages to release macrophage 
migration inhibitor factor (MIF), which inhibits erythroid progenitor derived colony formation 
(Martiney et al., 2000). Malaria toxins stimulated macrophages to produce the pro-
inflammatory cytokines TNF-α, INF-γ and IL-12 during the acute blood stage, and they have 
been shown in vitro and in vivo to mediate chronic disease, including malaria (Taverne et al., 
1994). During the chronic stages of malaria, bone marrow hypoplasia and subsequent 




1.3.3 ACUTE RESPIRATORY DISTRESS SYNDROME 
There are different types of respiratory distress found in malaria patients. It is defined 
as a respiratory rate that reaches above 40 breaths per minute. Hyperventilation is the result of 
metabolic acidosis, caused by renal dysfunction and insufficient clearance of lactic acid and this 
cause low blood pH and an increased respiratory rate. Hyperventilation is the most common 
type of respiratory distress found in African children with malaria, and it is also found in adults 
(English et al., 1996; Marsh et al., 1995). 
The acute respiratory distress syndrome (ARDS) is a severe condition associated with 
high risk of death, and is increasingly associated with malaria. ARDS is associated with 
alveolar inflammation, damage to the alveolar-capillary membrane and severe hypoxemia 
(Taylor et al., 2006). Malaria-associated ARDS is mainly found in adults, with mortality rates 
up to 80 %, even with treatment. ARDS can also occur in children, but is rare. Most cases of 
ARDS are found in low transmission areas or in non-immune travellers. Pregnant women with 
severe malaria are at higher risk to develop malaria-associated ARDS. It has been shown that 
the prevalence of ARDS ranges from 2 % up to 20 % in adults with severe malaria, but it 
depends on the study area and parasite species (Taylor et al., 2006; Taylor et al., 2012). The 
pathogenesis of ARDS is not fully understood. Damage to the endothelial barrier results in 
interstitial edema, and edema fluids leak out to the alveoli. This results in formation of 
eosinophilic hyaline membranes, surrounding the alveolar walls (Valecha et al., 2009). Post 
mortem histo-pathological studies have shown presence of monocytes and macrophages inside 
the blood capillaries and intersititium, and in alveolar spaces (Duarte et al., 1985). Hemozoin 
has also been seen in pulmonary macrophages, due to phagocytosis, causing production of 
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cytokines and inflammatory mediators (Valecha et al., 2009). P. falciparum parasites sequester 
within the capillaries of the lung, and are believed to be involved in the pathogenesis.  
 
1.3.4 CEREBRAL MALARIA 
The most severe neurological complication of P. falciparum infection is cerebral 
malaria (CM), and it is a major cause of acute non-traumatic encephalopathy in tropical 
countries. According to WHO guidelines, CM as clinical syndrome is characterized by 
unrousable coma (inability to respond to a painful stimuli) at least 1 hour after a seizure 
(scoring <3 on the Blantyre scale), positive P. falciparum blood smears, and exclusion of other 
causes of encephalopathy (Molyneux et al., 1989; WHO, 2000b). Hospital admitted children 
with cerebral malaria often have a history of 1-3 days of fever, vomiting, coughing and main 
neurological signs including coma, seizures and brainstem signs (Molyneux et al., 1989; 
Newton et al., 2000). Mortality due to CM is high, about 20% in children and adults, and the 
majority of deaths occur within 24 hours from hospital admission, before the anti-malarial 
drugs have had any effect. Mortality is high among children with shock, hypoglycaemia, 
multiple and prolonged seizures or coma (Faiz et al., 1998; Idro et al., 2004).  The onset of CM 
in children is very rapid within a few days of fever, while in adults it develops gradually 
(Kochar et al., 2002; Molyneux et al., 1989). Around 60 % of children with cerebral malaria 
develop seizures after hospital admission (Crawley et al., 1996; Crawley et al., 2001). Seizures 
are thought to be an important cause of impairment for consciousness in children. Around 10% 
of malaria patients who survive cerebral malaria have neurological sequelae, caused by 
seizures, prolonged and deep coma and hypoglycaemia (Bondi, 1992; Walker et al., 1992). The 
majority of patients with cerebral malaria have full recovery but there has been recognized an 
increasing number of reported cases of brain injury, especially in African children, over the past 
20 years.  Long-term neurological or cognitive deficits include effect on memory, motor 
deficits, epilepsy, speech and language difficulties, and difficulties in concentration and 
attention (Ngoungou and Preux, 2008; van Hensbroek et al., 1997). Neurological sequelae are 
less common in adults.   
Pathogenesis studies of CM have mainly been post mortem surveys, in vitro studies or 
animal studies. Sequestration of P. falciparum parasites in the microvasculature of the brain has 
been observed in several post mortem examinations of children and adults, who died from CM.  
Sequestration is believed to be central to the pathogenesis of CM, and extensive sequestration 
leads to obstruction of blood flow and causes tissue hypoxia (Pongponratn et al., 1991). The 
hypoxia causes metabolic exchange and release of pro-inflammatory cytokines, which are 
protective or inflammatory for the malaria patient. Increased levels of INF-γ and TNFα have 
been shown in both in human and murine studies to be implicated in the pathogenesis of CM 
(Hunt and Grau, 2003). 
 
 
1.3.5 PREGNANCY-ASSOCIATED MALARIA 
Individuals living in malaria endemic areas become semi-immune to severe malaria after 
repeated exposure.  However, women become susceptible to severe malaria during pregnancy. 
The risk of contracting pregnancy-associated malaria (PAM) is highest among primigravide 
women, with lower incidence and severity in women of higher parity. Women living in 
unstable or low transmission areas have a higher risk of severe malaria, CM and respiratory 
distress, while women in high transmission areas more often suffer from severe anaemia (Duffy 
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and Fried, 2005). PAM causes infant low birth weight, prematurity, still birth, anaemia in 
newborns, maternal anaemia and is responsible for,100 000-250 000 infant and fetal deaths and 
1 500 maternal deaths in sub-Saharan Africa each year (Duffy and Fried, 2005). During 
PAM, the pRBC sequester in the intervillous space of the placenta, which restricts the blood 
flow and nutrient passage across the placenta (Beeson et al., 1999; Fried and Duffy, 1996). 
There is a harmful inflammatory response, with increased infiltration of monocytes in the 




1.4 PLASMODIUM FALCIPARUM PATHOGENESIS 
1.4.1 HOST REMODELING 
The pRBC undergoes host cell remodeling to sustain the survival and development of 
the parasite. The host remodeling occurs as follows: I) P.  falciparum proteins interact with the 
RBC cytoskeleton, and alter the cell´s mechanical properties or II) modify cell architecture of 
the host cell membrane or III) participate in the transport machinery responsible for protein 
trafficking to the RBC surface.  
The main membrane structures involved in the trafficing machinery and that are also 
found in the RBC cytosol, are the tubulovesicular network (TVN) and Mauers clefts (MC) 
(Atkinson and Aikawa, 1990; Bannister and Dluzewski, 1990; Langreth et al., 1978). The TVN 
is the most prominent of the membrane structures and comprises an interconnected network of 
tubular and vesicular membranes that extends from the PV into the cytoplasma (Elmendorf and 
Haldar, 1994).  Additionally, TVN is thought to be involved in nutrient import (Lauer et al., 
1997). MCs are characterized by a translucent lumen and electron-dense coats found in the 
RBC cytosol, and are located close to the RBC membrane (Atkinson and Aikawa, 1990; Kriek 
et al., 2003). MCs are found in the cytosol of late stage rings, and recently they were found to 
be present from 2-6 hours post infection (Bannister et al., 2004; Langreth et al., 1978). Several 
exported proteins including PfEMP1, RIFIN (repetitive interspersed proteins), SURFIN 
(surface-associated interspersed protein) and Pf332, interact with MC and are thought to be 
involved in the protein transportation between PV and the RBC membrane. However, the MC 
transportation is not fully understood (Haeggstrom et al., 2004; Kriek et al., 2003; Wickham et 
al., 2001). Several integral proteins have been shown to be important for the correct MC 
formation. P. falciparum skeleton binding protein 1 (PfSBP1), and also membrane-associated 
histidine rich protein 1 (MAHRP1), ring exposed protein 1 (REX1) and P. falciparum 
erythrocyte membrane 3 (PfEMP3) (Maier et al., 2009b) have been shown to be of interest.  
Knobs are found on the surface of the pRBC during the trophozoite and schizont 
development. Knobs are dense electron protrusions and have been shown to serve as 
sequestration attachments during sequestration in the microvasculature (Aikawa, 1988b). 
Electron microscopy studies of patients who died from CM showed pRBC attached to the 
endothelium via knobs (Aikawa, 1988a). The P. falciparum knob-associated histidine-rich 
protein (KAHRP) is essential for knob formation, and found on the cytoplasmic side of RBC. 
KAHRP interacts with spectrin, actin and ankyrin and anchor PfEMP1 to the cytoskeleton of 
RBCs (Crabb et al., 1997; Culvenor et al., 1987; Oh et al., 2000; Waller et al., 1999). Gene 
disruption of KAHRP has demonstrated impaired cytoadhesion, hence suggesting the 
importance of KAHRP as essential for PfEMP1 surface expression (Crabb et al., 1997). 
  8 
KAHRP has been shown to interact with the ATS domain of PfEMP1 (Waller et al., 1999), and 
also to interact with spectrin and actin implying a stabilizing function (Kilejian et al., 1991).  
 
 
1.4.2 PROTEIN TRAFFICKING 
The RBC lacks the secretory apparatus found in other nucleated cells, and the parasite 
can’t use host mechanisms for protein transport and export and it must establish a de novo 
secretory system within the host cell cytoplasm. The protein transport system is complex, 
involving sorting and signalling events inside the mature pRBC. The parasite proteins need to 
reach the RBC cytosol, and to do so they have to cross two membranes; the parasite plasma 
membrane (PM) and parasitophorous vacuolar membrane (PVM) that encloses the parasite, 
then cross into to the host cell cytosol. Major routes for protein transport are the secretory and 
endocytic pathways in eukaryotic cells. Key components such as the endoplasmatic reticulum 
(ER) and the Golgi apparatus are required for the classical secretory pathway. Secreted proteins 
are co-translationally inserted into ER, and then directed from ER to the Golgi, endosomes and 
lysosomes by the anterograde secretory pathway. The parasites have a range of unique 
organelles fed by secretory pathways including food vacuole, apicoplast and three secretory 
granules essential for merozoite invasion (rhoptories, dense granules and micromeres) (Waller 
et al., 2000; Wickham et al., 2001).  
Proteins that are transported to the surface contain a conserved amino acid motif known 
as the Plasmodium export element (PEXEL) (Marti et al., 2004), or also called the vacuolar 
transport signal (VTS) (Hiller et al., 2004). The motif is conserved in all Plasmodium spp. 
Around 200-400 soluble and membrane bound proteins carry the motif, and are known as P. 
falciparum exportome (Sargeant et al., 2006; van Ooij et al., 2008). PfEMP1 is one of the most 
important and well-characterized export proteins in P. falciparum. PfEMP1 proteins are over 
300 kDa, and do not have a signal sequence but have a C-terminal trans-membrane domain that 
is important for the entry into the ER (Knuepfer et al., 2005). PfEMP1 has a conserved N-
terminal sequence, with partial homology to the PEXEL motif. However, the PfEMP1 PEXEL-
like motif is not cleaved by plasmepsin V, suggesting it is functionally distinct (Goldberg and 
Cowman, 2010). PfSBP1 is required for the localization of PfEMP1 into the surface of RBCs 
(Cooke et al., 2006; Maier et al., 2007). It has been reported that gene disruption of PfSBP1 and 
membrane-associated histidine-rich-protein-1 (MAHRP1) will limit the export of PfEMP1 to 
the RBC surface (Cooke et al., 2006; Maier et al., 2007; Spycher et al., 2008). This shows the 
essential role of MC in the protein trafficking. 
 
1.4.3 ANTIGENIC VARIATION IN PLASMODIUM FALCIPARUM 
Many pathogens have developed an ability known as antigenic variation to avoid 
immune recognition. Antigenic variation involves a coordinated expression of variant surface 
antigens to evade the host immune response, establish infection and transmission to new host. 
Recurrence of infection caused by a pathogen indicates a pathogen with sophisticated immune 
evasive mechanisms. Antigenic variation is found in a selection of infectious pathogens 
including P. falciparum, Trypanosoma brucei, Borrelia hermsii and Candida spp (Hoyer, 2001; 
Smith et al., 1995; Turner, 1999). Antigenic variation in P. falciparum was shown in vivo using 
squirrel monkeys for experimental blood stage infections (Hommel et al., 1983). Below the 
surface antigens involved in antigenic variation by P. falciparum are discussed. 
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1.4.3.1 SURFACE ANTIGENS OF P. FALCIPARUM: PfEMP1 
 
PfEMP1 is a major adhesion protein responsible for rosetting and sequestration of the 
pRBC in the deep vasculature (Chen et al., 1998).  PfEMP1 is encoded by a highly diverse var 
gene family that undergoes antigenic variation and generates diverse adhesive proteins (Baruch 
et al., 1996; Smith et al., 1995; Su et al., 1995). The var genes have a two exon-structure with 
total length of 8-14 kb, and there are approximately 60 var genes per parasite genome located 
mainly in the highly polymorphic subtelomeric regions and central parts of the 14 
chromosomes (Gardner et al., 2002; Su et al., 1995). The singly expressed var gene determines 
the antigenic, cytoadherence and virulence phenotype. This phenomenon is known as mutually 
exclusive expression, and studies have shown that it is regulated on a translational level 
independent of antigen production (Dzikowski et al., 2006; Voss et al., 2006).  
PfEMP1 consists of multi-domains (200-350 kDa) and the first exon encodes for a 
protein with a hypervariable extracellular binding part composed of a variable N-terminal 
segment (NTS), various Duffy binding-like domains (DBL), and cysteine rich interdomain  
(CIDR) with interspersed C2 interdomains. The second exon encodes for a conserved 
intracellular acid terminal segment (ATS) (Lavstsen et al., 2003; Smith et al., 2000; Su et al., 
1995). The domains are involved in different binding specificities for host receptors (Baruch et 
al., 1996; Bir et al., 2006; Smith et al., 2000). PfEMP1 proteins across parasite isolates have 
shown a significant sequence variation, contributing to the repertoire of PfEMP1 variants. The 
high level of sequence diversity in the var gene family is due to the gene conversion and 
recombination (Flick and Chen, 2004; Freitas-Junior et al., 2000). The chromosomal location 
and transcription orientation of the var gene family have been shown to resemble the 
similarities in the 5´upstream of ups. var genes are classified into three major groups (A, B, C) 
and two intermediate groups (B/A and B/C) based on the four main upstream sequences (Ups); 
UpsA, UpsB, UpsC, and Ups E. The previously known UpsD is grouped with UpsA (Bull et 
al., 2005; Kraemer et al., 2007; Lavstsen et al., 2003). var genes in rosetting parasites  belong to 
group A, while both groups A and B are often transcribed in severe malaria patients (Bull et al., 
2005; Jensen et al., 2004; Normark et al., 2007).   
varcsa1  (also termed as varCOMMON), var2csa and var 3 are var genes shown to be 
conserved in sequenced parasite isolates, and they do not fit the classification described above. 
var1csa is flanked by UpsA2 and transcribed in the majority of all clinical isolates from 
different geographical regions, and has an atypical transcription pattern throughout the blood 
stage life cycle. var2csa is highly conserved and is flanked by 5´UpsE and shown to be strongly 
linked with mediating PAM through sequestration of pRBC to CSA in the placenta (Kyes et al., 
1999; Lavstsen et al., 2003; Rowe et al., 2002a). var3 is smallest known var gene, and groups 
within the upsA. It has been found in isolates from different geographic regions (Gardner et al., 
2002; Trimnell et al., 2006).   
The extracellular domains of PfEMP1 generate diverse adhesive proteins to different 
domains. For example Duffy binding like-1 (DBL1) have shown to bind CR1, blood group A 
and heparan sulfate on endothelial cells and RBCs (Barragan et al., 2000 a; Barragan et al., 
2000 b; Rowe et al., 1997; Vogt et al., 2003). CIDR1 has been shown to bind to CD36 and IgM 
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1.4.3.2 OTHER SURFACE ANTIGENS 
 
Besides PfEMP1 there are other parasite proteins that have been suggested to be 
exposed on the surface of pRBC. There are the rif genes encoding for the repetitive interspersed 
protein (RIFINs) family, which have been shown to be expressed on the surface of pRBC. The 
highly polymorphic rif genes are composed of two exons with a subtelomeric location, 
centrometric to the var genes (Kyes et al., 1999). The exons encode for the 30-45 kDa RIFIN 
proteins, and the proteins are expressed in a clone dependent manner. The rif gene family holds 
160 gene copies in the genome, and can be subdivided into two sub classes, group A and group 
B (Gardner et al., 2002; Joannin et al., 2008), which differ from one another by 25 amino acids 
in the semi-conserved domain. Group A appears to be exported into the host cell via Maurer´s 
cleft, whereas group B accumulate inside the parasite (Khattab and Klinkert, 2006; Petter et al., 
2007). However, the function of the RIFINs is unclear, but is thought to be involved in the 
immune evasion due to the high gene copy number. It has been observed that asymptomatic 
children have higher antibody titers against RIFINs compared to children with severe malaria 
(Abdel-Latif et al., 2003; Abdel-Latif et al., 2002). Another study showed that high titers of 
antibodies against recombinant RIFIN in children with cerebral malaria were not protective 
(Schreiber et al., 2006). The presence of RIFINs has been demonstrated in P. falciparum 
gametocytes as well as in the asexual stages, but the function remains speculative (Petter et al., 
2008). The RIFIN family is clustered together with the var and the subtelomeric variable open 
reading frame (stevor).  
         The STEVOR proteins are around 30-40 kDa, and less polymorphic than the RIFIN 
proteins. There are approximately around 30-40 copies per genome found in all chromosomes, 
thus making them the third largest gene family in P. falciparum. STEVORs have been shown to 
be transcribed during the asexual and sexual life cycle stages (Cheng et al., 1998; Florens et al., 
2002; Sutherland, 2001), thus maybe contributing to the survival of the parasite. Clinical 
isolates have been show to express STEVORs more than laboratory strains.  Studies have 
shown STEVOR proteins to be localized inside the MC, and on the pRBC membrane  (Blythe 
et al., 2008; Kaviratne et al., 2002; Lavazec et al., 2006; Niang et al., 2009). STEVORs might 
have a role in merozoite invasion, since they have been detected in the apical end of merozoites 
and in the rhoptries (Blythe et al., 2008; Khattab and Klinkert, 2006; Khattab and Meri, 2011). 
The surface associated interspersed (SURFIN) gene family consists of 10 surf gene 
members, located within or close to the subtelomers in five out of the 14 chromosomes 
(Gardner et al., 2002). The high molecular SURFIN proteins are related to the P. vivax 
transmembrane protein, PvSTP1 (Plasmodium vivax subtelomeric transmembrane protein 1) 
and the VIR protein (of the P.vivax). Studies have shown that SURFIN proteins might be 
involved in merozoite invasion, and they are found in the MC and the surface of pRBC 




During the P. falciparum infection only the early stages are seen in the peripheral blood 
circulation. The modifications of the pRBC are due to parasite-derived proteins transported to 
the surface of the pRBC, To avoid clearance by the spleen, the mature pRBC sequester in 
different organs. Sequestration is either adherence to endothelial cells lining of the blood 
vessels (cytoadhesion) or by binding to unparasitizied RBC (rosetting). 
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1.4.4.1 CYTOADHESION 
 
The term cytoadhesion is the ability of P. falciparum pRBC to adhere to vascular 
endothelium. This is seen in several organs such as brain, intestine, liver, lung, skin and the 
syncytiotrophoblast cell lining of the placenta. The cytoadhesion in the microvasculature not 
only protects the mature pRBC from splenic clearance, but also provides a relative hypoxic 
environment for parasite proliferation and RBC invasion. 
P. falciparum has evolved to bind to receptors on different cell-types, and a number of 
endothelial receptors have been identified as targets for pRBC.  The endothelial receptors 
include cluster of differentiation (CD36), intracellular adhesion molecule-1 (ICAM-1), 
chondroitin-sulfate A (CSA), thrombospondin (TSP), vascular cell adhesion molecule 1 
(VCAM-1) and E-selectin. 
CD36 is a glycoprotein that is widely expressed on the microvascular endothelium, and 
is also found on monocytes, macrophages, dendritic cells and platelets (Silverstein and 
Febbraio, 2009). CD36 binding has been shown to be a common adhesion phenotype by 
clinical  P . falciparum isolates, in static and flow conditions in vitro (Cooke et al., 1994; Hasler 
et al., 1990; Newbold et al., 1997; Ockenhouse et al., 1991). CD36 is a frequent target of 
isolates from patients with both uncomplicated and severe malaria (Turner et al., 1994).  
ICAM-1 is an essential cell adhesion molecule involved in inflammation and 
immunity. Several tissues and cells, including endothelial cells, monocytes and lymphocytes, 
express ICAM-1. Soluble ICAM-1 is found in plasma, or released by cell surface ICAM-1 in 
response to inflammatory cytokines or endothelial damage (Lawson and Wolf, 2009). The 
receptor is one of several adhesion molecules important in P. falciparum malaria. Expression of 
ICAM-1 can be both beneficial and harmful to the pRBC.  The surface expression of ICAM-1 
is required for INF- γ response of natural killer cells to pRBC (Baratin et al., 2007). Direct 
adhesion of pRBC to ICAM-1 on cerebral endothelial cells may contribute to cerebral malaria. 
Post mortem studies of brain tissue from patients who died from cerebral malaria demonstrated 
adhesion of pRBC, platelets, and leukocytes to brain endothelium, and were associated with 
increased ICAM-1 expression (Silamut et al., 1999). Laboratory studies have shown that in 
vitro CD36 binding was more common among cerebral malaria patients (Newbold et al., 1997). 
A study from Kenya showed a correlation between cerebral malaria and ICAM-1 binding under 
flow conditions (Ochola et al., 2011). Earlier studies of ICAM-1 binding in clinical isolates in 
static assays did not show any significant correlation with severe malaria disease (Heddini et 
al., 2004; Newbold et al., 1997; Rogerson et al., 1999).  
Chondroitin-sulfate A (CSA) is a glycosamino-glycan and is a main receptor involved 
in PAM. CSA is found on the syncytiotrophoblasts in the placenta. Placental parasites bind to 
CSA but not to CD36, while non placental parasites rarely bind to CSA (Rogerson et al., 2007). 
IgG in serum from multigravid women living in malaria endemic areas are able to block CSA 
binding (Beeson et al., 1999; Fried and Duffy, 1996; Maubert et al., 2000). Now it is well 
established that the adhesion of pRBC to CSA depends on a particular PfEMP1 variant called 
VAR2CSA (Salanti et al., 2004; Salanti et al., 2003).  Hyalonic acid (HA) is another receptor 
on the placenta, and a majority of placenta parasites have been shown to bind both CSA and 
HA (Beeson et al., 2000; Rasti et al., 2006). Additionally, non-immune immunoglobulins 
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1.4.4.2 ROSETTING  
 
The rosetting phenomena was first observed in laboratory strains in vitro, but also ex 
vivo in fresh clinical isolates from malaria infected individuals (Carlson et al., 1990; 
Udomsangpetch et al., 1989; Wahlgren et al., 1992). Rosetting is defined as one mature 
trophozoite-stage pRBC binding to two or more unparasitized RBCs (Figure 3), and are 
apparent 16-18-h post infection and remain throughtout parasite maturation and schizogony up 
until they rupture (Treutiger et al., 1992).  Rosetting parasites causing obstruction in the 
microvasculature of the brain and other organs are believed to contribute to the severity of the 
disease, causing blockage of blood flow resulting in hypoxia and tissue damage. Studies have 
shown correlation between rosetting and severe malaria (CM and severe anaemia) in Africa 
(Carlson et al., 1994; Heddini et al., 2001; Newbold et al., 1997; Rowe et al., 1995; Treutiger et 
al., 1992). However, the rosetting phenotype is not present in all P. falciparum isolates.  
There are a number of RBC surface receptors and serum factors that have been shown 
to be involved in rosetting.  Rosetting isolates have a preference for A or B blood groups, and 
form larger and stronger rosettes (Barragan et al., 2000 b; Carlson and Wahlgren, 1992; Rowe 
et al., 1995; Rowe et al., 2007; Udomsangpetch et al., 1989). The rosettes in blood group O are 
smaller and weaker, compared to rosettes formed in the A or B blood groups (Barragan et al., 
2000 b). Blood group A has been associated with severe malaria (Pathirana et al., 2005; Rowe 
et al., 2007), while blood group O has shown protection against severe malaria disease due to 
reduction of rosettes (Loscertales et al., 2007; Rowe et al., 2007). 
Complement receptor 1 (CR1) is a membrane glycoprotein found on the surface of 
RBC, monocytes, granulocytes, dendritic cells, B cells and T cells. CR1 is an immune-
regulatory protein involved in the control of complement activation and immune clearance 
(Krych-Goldberg et al., 2002; Vik and Wong, 1993).  The expression of CR1 on RBCs surface 
varies and is in the range of 50- 1 200 molecules per cell (Wilson et al., 1986). A study showed 
that CR1-deficient RBCs were unable to form rosettes with laboratory strains (Rowe et al., 
1997). This was later confirmed with a monoclonal antibody against CR1 that showed to 
reverse rosettes in laboratory strains and clinical isolates from Africa (Rowe et al., 2000). CR1 
gene polymorphisms have been reported to be highly frequent in populations living in endemic 
areas of Papua New Guinea, and have been linked to protection against severe malaria disease 
(Cockburn et al., 2004). 
Heparan sulphate (HS) is found on the surface of RBC and is involved in rosetting.  HS 
and other sulfated glycans inhibit or disrupt rosettes, at variable levels for different 
P.falciparum isolates and laboratory strains (Barragan et al., 2000 a; Carlson et al., 1992; Rowe 
et al., 1994). Modified heparin without anti-coagulant activity was shown to effectively inhibit 
rosettes in clinical isolates and laboratory strain (Vogt et al., 2006). 
Serum proteins including non-immune IgM, non-immune IgG, von Willebrand factor 
and fibrinogen are  involved in rosette formation in P. falciparum laboratory strains and clinical 
isolates (Flick et al., 2001; Scholander et al., 1998; Treutiger et al., 1999). Binding of non-
immune immunoglobulin to the surface of pRBC in clinical isolates from children is common 
and associated with severe malaria disease (Heddini et al., 2001; Scholander et al., 1998). The 
role of IgM in rosetting has been thoroughly studied and IgM polymerization is essential for 
binding (Ghumra et al., 2008).  
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Figure 3. Rosetting trophozoite pRBC binding to several unparasitized RBC. (Adapted from 
(Heddini et al., 2001)). 
 
1.5 PLASMODIUM FALCIPARUM MEROZOITE INVASION 
Merozoite invasion of the RBC is a well-orchestrated high-specific multistep process 
(Figure 4), mediated by specific molecular interactions and signal transduction events between 
host receptors and parasite ligands. Invasion is executed with remarkable precision and retains 
the host cell integrity. Greater in depth knowledge understanding of this complex mechanism 
would aid the vaccine development. The micronemes and rhoptries located in the apical 
organelles play a crucial role in the host cell invasion (Cowman and Crabb, 2006). Parasite 
invasion occurs approximately 28 seconds after primary contact. The invasion is divided into 
two distinct dynamic “pre-invasion” and “classical invasion” stages. During the “pre-invasion”, 
the merozoite attach to the RBC and is involved in RBC deformation. This allows the 
merozoite to be enfolded at the point of attachment. This process takes 11 seconds and the RBC 
returns to its biconcave shape before second stage. The “classical invasion” involves the 
internalization of the merozoite within the RBC in 17 seconds.  This is followed by 
echinocytosis, a deformation of the pRBC lasting for 10-15 minutes before the cell resumes 
normal shape (Dvorak et al., 1975). The rapid invasion event and the small size of merozoites 
(1.5 µm) contribute to the challenges to study the multi-step processes involved in the invasion. 
However, studies using light microscopy and electron microscopy have suggested that the 
merozoite invasion includes four main steps; I) egress of the merozoite, II) initial attachment, 
III) merozoite reorientation and irreversible tight junction formation and IV) merozoite entry 
(Aikawa et al., 1978; Cowman and Crabb, 2006; Dvorak et al., 1975; Gilson and Crabb, 2009).  
 
1.5.1 EGRESS OF MEROZOITES 
The initial step in merozoite invasion is the process known as egress. This process 
involves discharge from the parasitophorous vacuole (PV) and the host cell membrane of a 
mature schizont, containing 16 or more merozoites. Biochemical changes and intra-cellular 
pressure in the late stage mature pRBC cause a destabilization of the cytoskeleton, and results 
in an explosive rupture event releasing merozoites (Glushakova et al., 2005). Proteases are 
believed to be involved in egress, and this is a two step process including destruction and 
rupture of PVM followed by host cell membrane (Salmon et al., 2001).  Proteases involved in 
the egress include cytoskeleton-degrading cysteine protease falcipain-2, aspartic protease 
plasmepsin II and serine repeat antigen (SERA) family localized in the PMV (Hanspal et al., 
2002; Hodder et al., 2003; Miller et al., 2002b). The SERA protein family is also involved in 
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the sporozoite egress from oocysts (mosquito stage), indicating a role in the cell rupture (Aly 
and Matuschewski, 2005). Furthermore, a plant-like calcium dependent protein kinase, 
PfCDPK5, which is expressed in merozoites, is  involved in egress (Dvorin et al., 2010b). 
 
1.5.2 INITIAL ATTACHMENT 
The primary contact between the merozoite and the RBC is reversible, and occurs 
possibly through glycosylphosphatidylinositol (GPI) anchored merozoite surface proteins 
(MSPs) and their associated partners. There are nine GPI anchored proteins found on the 
merozoite surface. These proteins share other similarities besides the GPI anchor, including 
cystein rich domains that could be significant in adherence. The most dominant and abundant 
GPI anchored MSP is the merozoite surface protein-1 (MSP-1), which is thought to be essential 
for parasite survival and is a major vaccine candidate (Holder and Freeman, 1982; Miller et al., 
1993). MSP-1 has been considered to be essential for initiating the primary contact to the RBC. 
The initial contact is of low affinity and reversible, but important, and the parasite must 
differentiate the RBC’s components for invasion (Bannister and Dluzewski, 1990). Initial 
attachment of the polar merozoites occurs at any point of the surface. 
Peripheral proteins found in one of the broad protein families such as the MSP-3/MSP-
6, the MSP-7 family, acidic basic repeat antigen (ABRA), glutamine rich protein (GLURP), 
Pf41 and the SERA protease family are candidates for binding to RBC receptors. These 
proteins are secreted into the PVM during the mature pRBC stage, and bind to the surface of 
developing merozoites, via interaction with a GPI anchored protein such as MSP-1 (Pachebat et 
al., 2001; Sanders et al., 2006). Besides the MSPS, there are a number of proteins stored in the 
apical organelles that bind specifically to the RBC receptor and are involved in the invasion. 
There is especially the P.falciparum apical membrane antigen-1 (PfAMA-1) that is highly 
conserved in the apicomplexan phylum. PfAMA-1 is crucial for establishing the interaction to 
initiate the invasion of P.falciparum and T.gondii (Mital et al., 2005; Triglia et al., 2000). 
Before invasion, the PfAMA-1 is translocated to the merozoite surface. PfAMA-1 has also been 
shown to be expressed in P.falciparum sporozoites and is believed to be essential for invasion 
of hepatocytes (Silvie et al., 2004). The secretion regulation of rhoptries and micronemes to the 
merozoite surface that allows receptor binding is an essential step in the invasion.  Singh et al. 
demonstrated in a recent study that released merozoites experience a rise in cytoplasmic 
calcium as response to a rise in potassium ion concentration and exposure to the extracellular 
milieu of the blood. Subsequently, this process triggers sequential secretion of merozoite 
antigens, such as PfEBA175 and PfAMA-1, to the merozoite surface and initiates binding. The 
receptor and ligand interaction restores cytoplasmic calcium levels and releases the rhoptry 
content. Blockage or inhibition of this signal pathway involved in apical organelle discharge 
could be a target for drug development (Singh et al., 2010). 
 
 
1.5.3 MEROZOITE REORIENTATION AND IRREVERSIBLE TIGHT 
JUNCTION FORMATION 
The initial contact results in RBC deformation, and this allows reorientation of the 
merozoite so that the apical end points towards the RBC membrane. There is an irreversible 
tight-junction formation between the merozoite and the RBC membrane. The tight junction is a 
ring of close contact. After the tight junction formation there is activation of the invasion 
process involving a release of proteins from the mircronemes and rhoptries. Activation of the 
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invasion process involves a release of proteins from the mircronemes and rhoptries. There are 
two main protein families; the erythrocytic binding like (EBL) family and the reticulocyte 
binding homolog (PfRh or PfRBL) family (Duraisingh et al., 2003b; Miller et al., 2002a; 
Stubbs et al., 2005; Triglia et al., 2005), which are prime candidates for tight junction 
formation. The EBL family are found in the micronemes and include six erythrocyte binding 
antigens (EBAs) in the P. falciparum; PfEBA-175, PfEBA-140 (or BAEBL), PfEBA-181 
(JSEBL), PfEBL-1, PfEBA-165 (PEBL) and MAEBL (Blair et al., 2002; Camus and Hadley, 
1985; Maier et al., 2003; Peterson and Wellems, 2000; Triglia et al., 2001). The PfRh proteins 
were identified as homologs of rhoptry proteins in P . yoelii and P . vivax (Galinski et al., 1992; 
Preiser et al., 2002). P. falciparum express five members of PfRh; PfRh1 (PfRBP1), PfRh2a 
(PfRBP2a), PfRh2b (PfRBP2b), PfRh4 (PfRBP4), and PfRh5 (PfRBP5), and a sixth PfRh3 that 
is not expressed as a protein (Duraisingh et al., 2003b; Stubbs et al., 2005; Triglia et al., 2005). 
Both protein families are believed to be essential for merozoite invasion (Duraisingh et al., 
2003a; Duraisingh et al., 2003b; Lopaticki et al., 2011; Maier et al., 2003; Stubbs et al., 2005; 
Triglia et al., 2005), as well as PfAMA1. During merozoite invasion, PfAMA-1 has multiple 
roles; apical reorientation (Mitchell et al., 2004), erythrocyte binding (Fraser et al., 2001; Kato 
et al., 2005), attachment and rhoptry secretion (Mital et al., 2005), formation of the moving 
junction and intracellular replication (Collins et al., 2009; Treeck et al., 2009). PfAMA-1 is 
believed to be essential for the apical interaction through adhesins located at the neck of the 
rhoptries and in the micronemes. It is thought to form an important link between the weak link 
of MSPs and the irreversible tight formation with micronemal proteins (Mitchell et al., 2004). 
Recent studies have shown that the interaction between PfAMA1 and rhoptry neck protein 2 
(RON2) is critical for tight junction formation with RBC, and is an irreversible step that allows 
parasite invasion (Srinivasan et al., 2011). Specific antibodies against PfAMA-1 have been 
shown not to prevent initial attachment, but to block the reorientation of the merozoite 
(Mitchell et al., 2004). 
After apical attachment there may be a discharge of mediators into the RBC by the 
merozoite, but these have not been clearly identified. Electron microscopy of the merozoite 
invasion has suggested that there is a transfer of material (Aikawa and Miller, 1983). 
 
 
1.5.4 MEROZOITE ENTRY 
During the merozoite entry, the tight junction moves from the apical to the posterior 
end of the merozoite in multiple steps of events driven by the actin-myosin motor. The motor 
complex has been studied in T . gondii, and this seems to be conserved in the apicomplexa, 
including Plasmodium spp. The thrombospondin-related anonymous protein (TRAP) is thought 
to link extracellular adhesins to the parasite cytoskeleton (Kappes et al., 1999; Sultan et al., 
1997). Both TRAP and circumsporozoite protein (CSP) are believed to be involved in the 
sporozoite invasion of hepatocytes. A study suggests that the cytoplasmic tail of TRAP in P . 
falciparum links to the actin-myosin motor through aldolase (Buscaglia et al., 2007). Merozoite 
TRAP (MTRAP) is thought to provide a similar function for merozoite invasion in RBC (Baum 
et al., 2005). As the tight junction is moving towards the posterior end, proteins involved in the 
invasion process need to be removed. This process is known as the “shedding” or removal of 
the fuzzy coat covering the merozoite surface, and involves a serine protease (subtilase) called 
SUB2 localized in the micronemes (Harris et al., 2005). Once the merozoite has entered the 
RBC the PV encloses it. When the merozoite has been internalized in the RBC it undergoes 
echinocytosis, due to water loss stimulated by an efflux of potassium and chloride ions. The 
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calcium efflux could also be due to the formation of PV and PVM around the invading 
merozoite (Desai et al., 1993; Lew and Tiffert, 2007). The PVM is formed from invagination of 
the RBC membrane during invasion.  The PVM fuses and separates a biochemical and physical 
barrier between the host cytosol and the parasite. The parasites remain enclosed within the 
PVM during the intra-erythrocytic development phase (Aikawa et al., 1979). 
Dense granules are believed to be discharged after complete parasite entry, and are 
thought to be involved in host cell modifications. 
 
 
Figure 4. Plasmodium falciparum merozoite invasion into red blood cells (Adapted from (Miller et al., 
2013) and published with permission from Nature Publishing Group). 
 
1.6 SIALIC ACID PATHWAYS 
Invasion phenotypes utilized by parasites can be divided into two main pathways I) sialic 
acid (SA)-dependent invasion, demonstrated by poor invasion of neuraminidase treated RBC 
(neuraminidase cleaves SA on the RBC surface), and II) SA-independent invasion, 
demonstrated by efficient invasion of neuraminidase treated RBC (neuraminidase sensitive) 
(Camus and Hadley, 1985; Duraisingh et al., 2003b; Maier et al., 2003; Reed et al., 2000; Sim 
et al., 1994). 
Besides the fact that both PfRh and PfEBA proteins are able to employ alternative 
invasion pathways, it is believed that each parasite ligand binds to a specific receptor (Figure 5). 
There must be reasons for why the parasites maintain a large number of genes and mechanisms 
to regulate the expression. Firstly, the RBC surface is highly diverse among individuals, and 
each individual RBC formula can vary by age and sex, and in response to infection and 
nutrients. Secondly, in endemic areas most individuals have acquired some kind of mechanism 
to avoid binding to specific parasite ligands. Finally, flexible invasion pathways increase 
chances for parasite survival, and optimize the ability to establish infection in an individual. 




Figure 5. Host cell receptors on the RBC shown to bind specific P.falciparum ligands (Adapted from 
(Tham et al., 2012) and published with permission from Trends in Parasitology). NOTE: Receptor for 
PfRh5 was recently identified as Basigin ((Crosnier et al., 2011)). 
 
1.7 PLASMODIUM FALCIPARUM MEROZOITE ANTIGENS 
To date a number of merozoite antigens have undergone extensive studies as potential 
candidates for vaccine development. A panel of merozoite antigens were selected and included 
in the studies discussed in this thesis. In the following section the apical membrane antigen 1 
(AMA-1), the merozoite surface proteins (MSP1, MSP2), erythrocyte binding like proteins 
(PfEBA-175, PfEBA-140, PfEBA-181) and finally reticulocyte binding ligand proteins 
(PfRh2a, PfRh2b, PfRh4) will be discussed.  
 
1.7.1 APICAL MEMBRANE ANTIGEN 1 (AMA-1) 
P .  falciparum apical membrane antigen 1 (PfAMA-1) (Peterson MG, 1989) is one of 
the most extensively studied and best characterized invasion ligands. It was initially discovered 
30 years ago in P . knowlesi  (Deans et al., 1988).  Additionally, PfAMA-1 was the first rhoptry 
gene to be sequenced and is also a promising vaccine candidate (Dutta et al., 2002; Kocken et 
al., 2002; Peterson MG, 1989).  
PfAMA-1 is expressed during P . falciparum schizogony, and is synthesized to an 83 
kDa precursor that is proteolytically processed in the micronemes to yield a 66 kDa surface 
protein (Narum and Thomas, 1994). The mature 66 kDa form of PfAMA-1 is found in the 
micronemes (Healer et al., 2002), and it is proteolytically processed into smaller fragments (44-
48 kDa molecules) during translocation to the merozoite surface before invasion. PfAMA-1 is a 
type 1 integral membrane protein with large extracellular domain and a short cytoplasmic tail. 
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The ectodomain of AMA-1 is mainly composed of three domains; the N-terminal domain I, the 
central domain II and the C-terminal domain III (Nair et al., 2002; Pizarro et al., 2005).  The 
PfAMA-1 sequence is highly conserved among the Plasmodium spp. (Cheng and Saul, 1994; 
Dutta et al., 1995; Marshall et al., 1989; Waters et al., 1990). Even though PfAMA-1 lacks the 
low-complexity regions found in other merozoite proteins, a relative large number of point 
mutations are found in this gene. Population genetic analyses have shown that these 
polymorphisms are especially found in domains I and III (Cortes et al., 2003; Polley and 
Conway, 2001) and are under balancing selection, and are targets of protective immune 
response which makes them immunologically significant. Studies have shown that conserved 
and strain-specific epitopes of PfAMA1 are targets of invasion inhibitory antibodies (Cortes et 
al., 2005; Healer et al., 2004; Kocken et al., 2002; Narum et al., 2006). Multi-allele 




1.7.2 MEROZOITE SURFACE PROTEIN 1  
The merozoite surface protein 1 (MSP1) was described in the 1980s, and is well-
studied merozoite antigen. Early vaccine studies with purified MSP1 showed protection against 
P . yoelii infection in a rodent model (Holder and Freeman, 1981). MSP1 is believed to be 
involved in initial contact with the RBC binding via the surface receptor Band 3 and also 
heparin-like-molecules (Boyle et al., 2010; Goel et al., 2003; Li et al., 2004). MSP1 is the most 
abundant surface protein and constitute approximately 40% of all GPI-anchored MSPs. MSP1 
is synthesized during schizongony to a 195 kDa precursor, and undergoes multiple proteolytic 
cleavages (Holder, 1988; Holder et al., 1992). At the time of merozoite egress, MSP1 is 
primarily processed by a subtilisin-like protease, SUB1, to produce four polypeptide fragments; 
an 83 kDa N-terminal fragment (MSP1-83), two internal fragments of 30 and 38 kDa (MSP1-
30 and MSP1-38) and a C-terminal 42 kDa fragment (MSP1-42) with an anchor (Pachebat et 
al., 2001; Stafford et al., 1996). The MSP1 complex on the merozoite surface undergoes a 
secondary process with shedding during invasion. SUB2 cleaves MSP1-42 into 2 fragments; 33 
kDa (MSP1-33) and 19 kDa (MSP1-19). The MSP1 complex and MSP1-33 are shed from the 
surface in a soluble form, and the C-terminal of MSP1-19 is membrane bound via GPI anchor 
(10% of the protein) and enters the newly invaded RBC (Blackman et al., 1990; Harris et al., 
2005). MSP1-19 has two epidermal growth factor (EGF)-like domains, and after the invasion 
they are transferred to the forming food vacuole and remain during the intracellular parasite 
development (Dluzewski et al., 2008). 
The MSP1 gene has 17 variable and conserved blocks separated by semi-conserved or 
conserved regions (Tanabe et al., 1987). The N-terminal region of MSP-1, known as block 2, is 
a highly polymorphic region with numerous known variant sequences from globally various 
parasite isolates (Jiang et al., 2000; Miller et al., 1993). The block 2 sequence can be divided 
into four major allelic types (K1, MAD20, RO33 and MR) (Roy et al., 2008; Takala et al., 
2002). The sequence of MSP1-19 is highly conserved with six non-synonymous single 
nucleotide polymorphisms (SNPs) at amino acid positions. New genetic variants can be derived 
from the single nucleotide mutations maintained by positive natural selection (Ferreira et al., 
2003; Miller et al., 1993). 
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1.7.3 MEROZOITE SURFACE PROTEIN 2 
Merozoite surface protein 2 (MSP2) is another potential vaccine candidate (Anders et 
al., 2010). MSP2 is a  ~25 kDa highly abundant GPI-anchored membrane protein. It was 
initially identified using a monoclonal antibody in P. falciparum, and a couple of years later the 
gene was identified in an expression library (Anders et al., 2010; Smythe et al., 1988; Stanley et 
al., 1985). Sequence polymorphisms in MSP2 genes have described in laboratory strains and 
field isolates (Anders et al., 2010; Felger et al., 1994; Fenton et al., 1991; Prescott et al., 1994; 
Smythe et al., 1988; Stanley et al., 1985). The MSP2 gene is one of the most polymorphic of all 
merozoite protein genes and consists of 5 blocks (Snewin et al., 1991). The MSP2 gene 
includes a highly conserved 5´and 3´sequence (N- and C-terminally) flanked by a central 
variable region. The variable region has sequence repeats flanked by non-repetitive dimorphic 
sequences, and these form two distinct MSP2 alleles, grouped into the 3D7 and FC27 allelic 
families (Felger et al., 1994; Fenton et al., 1991; Smythe et al., 1990). The polymorphism has 
probably arisen from the selection pressure of protective immune responses (Barry et al., 2009; 
Weedall and Conway, 2010). The variable central repeats define the individual alleles of MSP2 
and point mutations have been found in both allele families (Felger et al., 1994). Furthermore, 
MSP2 is commonly used as single marker for molecular characterization of field malaria 
parasites. PCR typing of MSP2 gene allows the determination of malaria infection indicators 
such as diversity of P.falciparum strains and multiplicity of infection (MOI), which may give a 
description of the malaria situation in a given study location (Kiwuwa et al., 2013; Ntoumi et 
al., 1995) and MSP2 assessment is equally reliable to MSP1 in field diagnosis of malaria 
(Smith et al., 1999). 
 
1.7.4 ERYTHROCTYE BINDING LIKE (EBL) PROTEIN FAMILY 
The EBL protein family is thought to play a crucial role in the RBC recognition, tight 
junction formation and eventually in the invasion. P. falciparum can invade Duffy negative and 
positive RBC, and can use a number of distinct receptors (Dolan et al., 1990; Miller et al., 1977; 
Mitchell et al., 1986). The EBLs are located in the sub-telomeric region of different 
chromosomes, and encoding genes are associated with parasite virulence and pathology. The  
proteins have conserved exon-intron structures, splicing boundaries and contain two 
extracellular regions that have conserved cysteine and hydrophobic amino acid residues 
(Adams et al., 1992; Gardner et al., 2002). 
The EBA proteins found in P. falciparum bind to sialic acid dependent receptors, and 
this is known as sialic acid dependent pathway, which is important for mediation of alternative 
invasion pathways (Pasvol, 2003). 
 
1.7.4.1 ERYTHROCYTE BINDING ANTIGEN 175  
 
P . falciparum erythrocyte binding antigen 175 (PfEBA-175) consists of a 175 kDa 
protein and  is localized in the micronemes (Camus and Hadley, 1985; Orlandi et al., 1990). 
The single copy eba-175 gene is found on chromosome 7, and is constituted of four exons and 
seven regions, I to VII. The region II is found in the central part of the gene, a highly dimorphic 
segment in this region, and is conserved among strains of P. falciaprum. The region III-V (RIII-
V) of PfEBA-175 is dimorphic, and the parasites strains encode either a C (Camp strain) or F 
(FCR3 strain) allelic haplotype (Sim et al., 1990; Toure et al., 2006; Toure et al., 2001). 
  20 
The RBC receptor for PfEBA-175 is glycophorin A (Gly A), which is present as a 
dimer on the RBC surface. It seems like the majority of cultured parasites use the PfEBA-
175/GlyA pathway, and a minority use alternative ligand-receptor combinations. Enzyme 
treatment of RBC with neuraminidase (which removes sialic acid) or trypsin (removes other 
proteins) did not completely inhibit the invasion but forced the parasite to use other receptors 
for invasion in one study (Dolan et al., 1990; Gaur et al., 2003; Sim et al., 1994). At first the 
parasite replication was dramatically reduced on initial exposure to enzyme treated RBC, but 
the parasites adapted with time and invaded with the same efficiency as for untreated RBC. 
This is strong evidence that P. falciparum can adapt and switch to using a new receptor on the 
RBC, resulting in using different invasion pathways. Interestingly, once the parasites are 
removed from treated RBC and cultured in untreated RBC it reverts back to the 
PfEBA175/GlyA pathway. These findings have been confirmed with PfEBA-175 knock out 
parasites, that were unable to invade through the GlyA receptor (Duraisingh et al., 2003b; Reed 
et al., 2000). However, the parasites have the ability to switch invasion pathways. Stubbs et al. 
found that gene disruption of PfEBA175 was associated with upregulation of PfRh4 and the 
loss of using the sialic acid dependent pathway (Stubbs et al., 2005). The PfEBA175/GlyA 
interaction could be a potential target to consider for vaccine-induced antibodies.  
 
 
1.7.4.2 ERYTHROCYTE BINDING ANTIGEN 140  
 
P. falciparum erythrocyte binding antigen 140 (PfEBA-140) is a 140-kDa protein. 
The eba140 gene has identical intron/exon structure as that described for PfEBA-175. PfEBA-
140 share 30% similarity to the EBA175 protein sequence, and PfEBA-181 has 37% sequence 
similarity to PfEBA-140 (Adams et al., 1992; Gilberger et al., 2003; Maier et al., 2003). GlyC 
on the RBC has been identified as receptor for PfEBA-140 (Maier et al., 2003; Mayer et al., 
2002). The binding profile of PfEBA-140 receptor is trypsin and neuraminidase sensitive, but 
chymotrypsin resistant. Soluble sialic acid was not capable of inhibiting PfEBA-140 RBC 
binding. These findings demonstrate that receptor glycans containing sialic acids are crucial for 
receptor recognition, and that the backbone of GlyC plays a role in the binding (Jiang et al., 
2000; Mayer et al., 2006). Functional studies of PfEBA-140 knock out parasites showed 
binding to GlyA and GlyB, although the binding was dramatically reduced compared to its 
GlyC binding (Maier et al., 2003). To date, only four polymorphic mutants have been identified 
in RII PfEBA-140, and they are found in the F1 domain. The polymorphisms in PfEBA-140 
changes the binding profile of the ligand to enzyme treated RBC. The change in binding profile 
suggests that the PfEBA-140 has an ability to interact with other receptors, and to mediate 
alternative invasion pathways independent from GlyC. Additionally, polymorphisms has shown 
to diminish the affinity of PfEBA-140 for RBC (Maier et al., 2009a; Mayer et al., 2002). Recent 
studies suggest that the PfEBA-140 binds to glycosaminoglycans (GAGs) on the RBC and may 
have a functional role during PfEBA-140-mediated invasion (Boyle et al., 2010). 
In malaria endemic regions of Papua New Guinea there is a high frequency of 
Gerbich negativity.  This phenotype is due to loss of exon 3 within the GlyC gene. This 
prevents the PfEBA-140 RBC binding and inhibits the invasion. This phenotype is present in 
the Melanesian population and has probably arisen through natural selection by severe malaria 
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1.7.4.3 ERYTHROCYTE BINDING ANTIGEN 181  
 
P.  falciparum erythrocyte binding antigen 181 (PfEBA-181) is encoded by a 181 
kDa protein and it is expressed in merozoites and schizonts. Within the mirconemes, PfEBA-
181 is co-localized with PfEBA-175 at the apical end of free merozoites. Moreover, both 
PfEBAs are co-localized in the mature schizont (Gilberger et al., 2003). PfEBA-181 share 
sequence similarity with PfEBA-175 and PfEBA-140 (especially the F1/F2 domain), 25.3% 
and 24.6% respectively. Eight polymorphisms have been identified in the RBC binding domain 
of PfEBA-181. However, there are fewer mutations found in PfEBA-181 and PfEBA-140 
compared to PfEBA-175 (Gilberger et al., 2003; Mayer et al., 2004). The point mutations in 
PfEBA-181 lead to recognition of different receptors on the RBC. There is a possibility that the 
polymorphisms in the RBC binding domain of PfEBA-181 give the parasite population a 
survival advantage in a genetically diverse human population. 
The exact receptor for PfEBA-181 is unknown. Previous characterization of PfEBA-
181 showed binding to the RBC (sialic acid dependent manner) via a trypsin resistant, 
chymotrypsin sensitive and neuraminidase sensitive receptor. Moreover, disruption of the eba-
181 gene did not have any effect on the parasite invasion (Gilberger et al., 2003; Mayer et al., 
2004). PfEBA-181 has been shown to bind a highly conserved 10 kDa domain in 4.1R found 
on the RBC membrane. This interaction could have multiple functions during parasite invasion, 
however the significance of this in vivo is unknown (Lanzillotti and Coetzer, 2004; Lauterbach 
et al., 2003). 
 
1.7.5 RETICULOCYTE BINDING PROTEIN HOMOLOGUE (Rh) FAMILY 
The second family involved in merozoite invasion is the reticulocyte binding-like 
(RBL) proteins. These include PfRh1, PfRh2, PfRh4, and PfRh5 and are large proteins with a 
C-terminal trans-membrane domain. All PfRhs except PfRh4 share a homologous region of 
around 500 amino acids. There are some conserved parts shared between P. falciparum and P. 
vivax RBL proteins (Rayner et al., 2000). The expression patterns in the RBL proteins and 
apical location are consistent with the role during the invasion process. The PfRh proteins 
invade mainly through the sialic acid independent pathway (except for PfRh1). 
 
1.7.5.1 RETICULOCYTE BINDING PROTEIN HOMOLOGUE 2 (Rh2) 
 
There are two P. falciparum reticulocyte protein homologues 2, (PfRh2a and 
PfRh2b), and they are encoded by two genes that are adjacent to each other on chromosome 13, 
and are thought to have arisen by gene duplication. These genes are around 9 kb in length and 
are highly homologous in sequence (80%) and share more than 8 kb of nucleotide sequence at 
the 5´end before a divergent and unique 3´end (Rayner et al., 2000). However, the difference in 
the gene sequence is at the C-terminal domain, which determines the phenotype (Dvorin et al., 
2010a). The proteins are large hydrophilic proteins and they are predicted to be more than 350 
kDa, with a N-terminal signal sequence and a single trans-membrane domain near the C-
terminal end (Duraisingh et al., 2003b; Rayner et al., 2000). The proteins are found at the apical 
end of the merozoite, more closely in the neck of the rhoptries (Cowman and Crabb, 2006), and 
they are located at the junction during invasion.  It has been proposed that they have an 
important adhesive function during invasion. Most strains have the PfRh2a and PfRh2b genes, 
but not all parasites express the proteins (Duraisingh et al., 2003b; Taylor et al., 2002). Both 
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PfRh2a and PfRh2b have been knocked out in the parasite 3D7 (Duraisingh et al., 2003b). 
PfRh2b disrupted parasites showed a significantly altered invasion in enzyme treated RBC 
compared to the wild type clone. PfRh2b have been implicated to have an important role in 
invasion by mediating alternative pathways, and trypsin resistant receptor Z has been shown as 
essential for the binding to the RBC (Cowman and Crabb, 2006). On the other hand, knock-out 
of PfRh2a did not show any difference in invasion phenotype compared to the wild type 3D7 
parasite (Duraisingh et al., 2003b). Moreover, disruption of PfRh2a and PfRh2b has also in 
other studies been shown to be important for sialic acid independent invasion (DeSimone et al., 
2009). 	  
1.7.5.2 RETICULOCYTE BINDING PROTEIN HOMOLOGUE  4 (Rh4) 
 
P.  falciparum reticulocyte binding protein homologue 4 (PfRh4) is  found on 
chromosome 4. PfRh4 is a 220 kDa type I trans-membrane protein and is present in the 
rhoptries, and like all the other proteins in the PfRh family it undergoes processing to a 160 kDa 
protein (Cowman and Crabb, 2006; Gaur and Chitnis, 2011; Tham et al., 2012). Complement 
receptor 1 (CR1) was identified as a receptor for the sialic acid independent invasion pathway 
in numerous laboratory strains and field isolates (Spadafora et al., 2010). At the same time 
several studies showed that PfRh4 was essential for the sialic acid independent pathway. It was 
shown that PfRh4 binding strongly correlated with the CR1 level on the RBC surface. Invasion 
through sialic acid-independent pathways was reduced in low CR1 expressing RBC. 
Additionally, soluble CR1 competitively blocked binding of PfRh4 to the RBC surface, and 
hence inhibited sialic acid independent invasion (Tham et al., 2009). Activation of PfRh4 
expression allowed the parasite to switch usage of receptors from sialic acid dependent to sialic 
acid independent pathways, and this provides alternative invasion pathways utilized by the 
parasite (Stubbs et al., 2005). 
Expression of the PfRh4 protein varies among parasite isolates but has been found in 
both field isolates from Africa (Gomez-Escobar et al., 2010; Nery et al., 2006) and laboratory-
adapted isolates (Gaur et al., 2006; Stubbs et al., 2005; Tham et al., 2011). 
 
 
1.8 NATURALLY ACQUIRED IMMUNITY TO MALARIA 
Acquired immunity can either be active or passive. Active acquired immunity is obtained 
from development of antibodies in response to an antigen, either from vaccination or infectious 
diseases. Passive acquired immunity is developed by the prenatal or postnatal transfer of 
protective immunoglobulin from mother to child or by injection of antiserum. 
Naturally acquired immunity to malaria is not sterile, and individuals living in endemic 
countries only acquire protective immunity after repetitively exposure to the parasite (Figure 6) 
(Bull et al., 1999; Trape et al., 1994). There is high P. falciparum malaria associated morbidity 
and mortality among infants and young children, but older children and adults have circulating 
parasites, with or without clinical disease. Studies have shown that immunity to severe malaria 
is the first in line immunity that develops in children in malaria endemic countries (Bull et al., 
1999; Gupta et al., 1999a; Trape et al., 1994).  Naturally acquired immunity is comprised in 
pregnant women, and adults that move from endemic countries loose their acquired immunity 
temporarily. Women become resistant to PAM after repeated pregnancies and infection (Fried 
et al., 1998). Severe malaria in newborn infants born to mothers in endemic areas is rare in the 
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first months, most likely because of the placental transfer of immunoglobulin G (IgG) (Snow et 
al., 1998). 
Individuals living in high malaria transmission areas reach immunity faster compared to 
individuals in low transmission areas. During the 1980s malaria interventions reduced malaria 
exposure in Madagascar, and natural acquired immunity was lost. This lead to a catastrophic 
event with a malaria endemic killing more than 40 000 people (Romi et al., 2002). The 
recurrent exposure to hyper- and holo-endemic malaria protects the majority of the individuals 
and kills only a minority. Malaria immunity is dependent on age, transmission intensity and 
exposure to parasite. 
Protective immunity to malaria is multi-faceted and includes immunological responses to 
both pre-erythrocytic and erythrocytic stages (Langhorne et al., 2008; Marsh and Kinyanjui, 
2006). Studies have demonstrated that passive transfer of IgG from clinically immune donors to 
individuals infected with P.falciparum resulted in reduced parasitemia and clearance of clinical 
symptoms (Bouharoun-Tayoun et al., 1990; Cohen et al., 1961; McGregor et al., 1963). 
 
 
Figure 6. Acquisition of immunity to malaria in endemic areas (Adapted from (Langhorne et al., 2008) 
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1.8.1 IMMUNOGLOBULIN M (IgM), IgG AND SUBCLASS IgG1-4 IN 
MALARIA 
In malaria, there are a wide range of antibodies of different isotypes that are capable of 
inducing protective effects against malaria. In the following section, IgG and IgM will be 
briefly discussed. 
 
1.8.1.1 IMMUNOGLOBULIN M (IgM) 
 
Immunoglobulin M (IgM) is part of the first line host defense (Leoratti et al., 2008). 
The pentamer structure of IgM equips the molecule with functions such as multivalent binding 
to both antigens and receptors (Ye et al., 2010). Natural IgM has been shown to bind to the 
surface of pRBC via the Fc-part of the molecule, and is correlated with severe malaria in both 
laboratory strains and clinical isolates (Ghumra et al., 2008; Rowe et al., 2002b).  
Some P. falciparum strains bind natural IgM, and this is found in parasites with 
specific virulence phenotypes such as rosetting (Rowe et al., 2002b), and CSA binding has been 
linked to placental malaria infection (Creasey et al., 2003; Fried et al., 1998). Studies suggested 
that elevated IgM levels are important for agglutination (Doolan et al., 2009), and for 
neutralization of pathogens (Czajkowsky et al., 2010). IgM is also a potent complement 
activator (Czajkowsky and Shao, 2009). 
 
 
1.8.1.2 IMMUNOGLOBULIN  G (IgG) 
 
Immunoglobulin G (IgG) is the most abundant isotype found in humans. There are 
four IgG subclasses, IgG1-IgG4, named in order of their abundance in serum. The subclasses 
differ both in structure and in immunological functions (Nimmerjahn and Ravetch, 2008). IgG 
and IgG subclass responses have been reported in malaria. IgG1 and IgG3 are known as 
cytophilic antibodies and have been suggested to be the predominant antibody responses in P . 
falciparum infections (Bouharoun-Tayoun and Druilhe, 1992; Dobano et al., 2012; Roussilhon 
et al., 2007; Sarthou et al., 1997). Cytophilic IgG1 or IgG3 have been reported to be associated 
with lower parasitemia, lower risk for malaria attacks and with clinical protection from disesase 
(Shi et al., 1996; Taylor et al., 1998). 
IgG2 and IgG4 are non-cytophilic, and are speculated to be non-protective. However, 
elevated levels of IgG2 have been shown to be correlated with decreased risk of malaria 
infection, and more specifically in individuals that carry an allelic variant of FcγRIIA, which 
binds to IgG2 (Aucan et al., 2000; Garraud et al., 2003; Nasr et al., 2009). IgG4 is believed to 
compete with the binding of IgG1 and IgG3, and might be involved in blocking the cytophilic 
activity (Aucan et al., 2000; Garraud et al., 2003). 
In malaria, the dynamics of subclass responses and their association with protection is 
probably important, but more studies are required to fully understand the immune responses 
against specific antigens and this knowledge could add in vaccine development. 
 
1.8.2 ANTIBODY RESPONSES TO THE P. FALCIPARUM MEROZOITE ANTIGENS 
Antibodies against P. falciparum are directed against different stages of the parasite 
during its life cycle. The function of antibodies in malaria infection and disease are the 
following; I) inhibition of merozoite invasion/intracellular growth, II) antibody-dependent 
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cellular killing with opsonization, and III) clearance of pRBC by antibody binding to the host 
cell surface, and inhibition of sequestration in the microvasculature (Blackman et al., 1990; 
Bouharoun-Tayoun et al., 1995). 
It has been demonstrated that antibodies against several P. falciparum merozoite 
antigens are associated with protective immunity in longitudinal studies (Branch et al., 1998; 
Egan et al., 1996; Fowkes et al., 2010; John et al., 2005). Previous studies have reported 
associations between high levels of antibodies against several merozoite antigens and protection 
against symptomatic malaria, while others considered it more as marker of malaria exposure 
(Gupta et al., 1999b; Metzger et al., 2003; Polley et al., 2004; Richards et al., 2010). Several 
studies described invasion/growth inhibitory activities in sera from individuals living in malaria 
endemic areas (Bouharoun-Tayoun et al., 1990; Cohen et al., 1969; Dent et al., 2008). It has 
been reported that there are significant associations between growth inhibitory antibodies and 
reduced risk of clinical malaria (Crompton et al., 2010; Dent et al., 2008; John et al., 2004), 
while other findings were inconclusive (Corran et al., 2004; Perraut et al., 2005). 
The following sections will discuss previous studies on antibody responses to the P. falciparum 
merozoite antigens included in this thesis work. 
 
 
1.8.2.1 ANTIBODIES AGAINST PfAMA1 
 
Individuals living in malaria endemic areas can have increased levels of antibodies 
against PfAMA1, which are strong inhibitors of parasite invasion (Bouharoun-Tayoun et al., 
1990; Courtin et al., 2009; Nair et al., 2002). Few studies have directly measured inhibitory 
antibodies in relation to protection from malaria. Those conducted reported presence of 
antibodies against PfAMA1 associated with a reduced incidence of malaria (Greenhouse et al., 
2011; Keh et al., 2012; Polley et al., 2004). 
There is limited knowledge on acquired antibodies against the polymorphic and 
conserved epitopes of PfAMA1 (Polley et al., 2004). A recent study showed that antibodies that 
target the functional and polymorphic epitopes of PfAMA1, are acquired with altering exposure 
to malaria, and indicates some association with decreased risk of clinical malaria. These 
findings suggest that PfAMA1 could target of naturally acquired antibody response (Mugyenyi 
et al., 2013). 
 
1.8.2.2 ANTIBODIES AGAINST MSP1-19 
 
Several mechanisms have been suggested for how MSP1-19 antibodies mediate 
protection against malaria, including antibody binding and inhibition of MSP1-19 function and 
merozoite invasion, disruption of secondary processing of the protein, agglutination of 
merozoites, and opsonization of parasites by phagocytic cells (Blackman et al., 1990; 
Blackman and Holder, 1992; Gilson et al., 2008; McIntosh et al., 2007). It has been reported 
that antibodies against MSP1-19 are associated with control of malaria or protection from 
symptomatic P. falciparum malaria (Branch et al., 1998; Egan et al., 1996; Perraut et al., 2005; 
Riley et al., 1992), and was found in both infants and young children indicating that protection 
associated with MSP1-19 develops early (Branch et al., 1998; Shi et al., 1996). A recent study 
of IgG against MSP1-19 reported lack of association between growth inhibitory activity and 
protection from malaria or re-infection. This study suggests that antibodies against MSP1-19 
might be marker of protective immunity and not directly involved in the protective 
mechanisms such as growth inhibition (Wilson et al., 2011). 
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1.8.2.3 ANTIBODIES AGAINST MSP2 
 
Early studies showed that MSP2 specific monoclonal antibodies could inhibit parasite 
growth in vitro (Clark 98 MBP; Epping 88 MBP). Since then several studies have reported that 
antibodies to MSP2 might be involved in protection against malaria. A study in Papua New 
Guinea showed that antibodies against MSP2-3D7, but not against MSP2-Fc27, were 
associated with decreased incidence of clinical malaria (al-Yaman et al., 1995). Two studies in 
The Gambia reported significant association of IgG3 antibodies against MSP2 with reduced 
morbidity (Metzger et al., 2003; Taylor et al., 1998). A more recent study demonstrated that 
antibodies against MSP2 bound to the merozoite surface but did not inhibit invasion and instead 
got carried into the pRBC during invasion, and remained there up to 20 hours post infection 
without inhibiting intra-erythrocytic development (Boyle et al., 2013). These findings indicate 
that MSP2 specific antibodies might not be directly involved in invasion inhibition, but could 
still be involved in opsonization of merozoites and antibody-dependent cellular inhibition 
mediated by monocytes, and these are considered as important mechanisms in acquired 
immunity (Bouharoun-Tayoun et al., 1990; Flueck et al., 2009).  
 
1.8.2.4 ANTIBODIES AGAINST PfEBAs 
 
Antibody responses against PfEBA175 have been associated with age in endemic 
areas (Noland et al., 2008; Okenu et al., 2000; Persson et al., 2008; Richards et al., 2010). 
Studies in The Gambia observed that increasing antibody levels to PfEBA-175 were maintained 
for a period of time, and in a way dependent on age, seasonality and infection status. These 
findings suggest that increasing antibody response to clinical malaria may consequently boost 
antibody memory responses in individuals with malaria (Akpogheneta et al., 2008; 
Akpogheneta et al., 2010). However, some studies reported failed association between antibody 
levels to PfEBA-175 and protection against disease (Fowkes et al., 2010; John et al., 2005; 
Noland et al., 2008; Osier et al., 2008). These observations could be due to differences in study 
protocols (Fowkes et al., 2010), malaria exposure and antibody responses in the different 
malaria endemic settings (Kinyanjui et al., 2003). 
For the other EBAs, it has been shown that antibody responses to PfEBA-140 RII and 
RII-V could play a role in protection against malaria, but antibodies against PfEBA-181 RIII-V 
have not been associated with protection (Richards et al., 2010). Naturally acquired antibodies 
against PfEBA140 was shown to be surprisingly inhibitory, compared to the other EBAs, when 
functional assays were applied. Subclass responses to the PfEBAs was in one study 
predominantly of IgG1 and IgG3 subclasses (Ford et al., 2007; Okenu et al., 2000; Persson et 
al., 2013). IgG3 was reported to be more protective than IgG1 against PfEBAs (Richards et al., 
2010).  
In conclusion, the antibodies against PfEBAs could have an important role in protection and 
invasion inhibition, and as result control parasitemia burden and decrease morbidity cases 
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1.8.2.5 ANTIBODIES AGAINST PfRhs 
 
There is limited knowledge regarding the antibody responses to PfRh antigens. 
Antibody responses to PfRh2a and PfRh2b have been reported to be associated with protection 
from clinical disease. A study in Papua New Guinea reported a significant correlation between 
high levels of antibodies against PfRh2a/b and reduced risk of symptomatic malaria. 
Furthermore, cytophilic IgG1 and IgG3 were the predominating responses in this study 
(Reiling et al., 2010). High levels of antibodies against PfRh4 have been shown to be strongly 
associated with a reduced malaria risk (Reiling et al., 2010). These findings suggest that 
PfRh2a/2b and PfRh4 could be important targets of protective immunity and potential vaccine 




1.9 HUMAN RED BLOOD CELL POLYMORPHIMS AND MALARIA 
Genetic factors are major determinants to consider in child survival in malaria endemic 
countries. In sub-Saharan Africa, the red blood cell polymorphisms (hemoglobin S (HbAS), α-
thalassemia, β- thalassemia, glucose-6-phosphate-dehydrogenase (G6PD) deficiency, 
hemogloblin E, and ovalocytosis) have protective effects against severe P.falciparum malaria, 
and epidemiological evidence links the distribution of these polymorphisms to areas with high 
malaria endemicity (May et al., 2007; Rowe et al., 2007; Williams et al., 2005c). In this thesis 
we studied the protective effects of HbAS in malaria, and the following section will focus on 
HbAS and malaria. 
 
1.9.1 MALARIA PROTECTION BY HbAS 
Hemoglobin S in the heterozygous form (HbAS, sickle cell trait) has been reported to 
have a protective effect against malaria (Aidoo et al., 2002; Williams et al., 2005b). A single 
point mutation (β6 Glu to Val) in the sixth codon of the β chain results in HbAS (Ingram, 1957). 
In sub-Saharan Africa this is thought to contribute to a survival benefit. The exact mechanism 
of how HbAS confers protection in malaria is still unclear. Proposed mechanisms include: I) 
reduced parasite invasion and/or growth in RBC (HbAS) (Friedman et al., 1978; Pasvol et al., 
1978)., II) increased phagocytosis of pRBC (HbAS) by macrophages, and III) impaired 
cytoadherence of pRBC (HbAS) to microvascular endothelial and other cells (Bunn, 2013; 
Fairhurst et al., 2005; Williams, 2006).  
It has been reported that individuals with HbAS have 70-90% protection against severe 
malaria (Aidoo et al., 2002; Jallow et al., 2009; May et al., 2007) and 50% protection against 
uncomplicated malaria compared to individuals with HbAA (Crompton et al., 2008; Williams 
et al., 2005b). The protection against uncomplicated malaria has been shown to increase with 
age (Williams et al., 2005a). Even though the above studies showed that HbAS protected 
against uncomplicated malaria, it has not been consistent in other studies (Allen et al., 1992; 
Lell et al., 1999). Numerous studies showed individuals with HbAS to have lower parasite 
densities compared to HbAA, which might indicate that HbAS enhance control of infection 
once parasitemia is established (Aidoo et al., 2002; Crompton et al., 2008; May et al., 2007; 
Williams et al., 2005b). The underlying mechanism of the antibody response mediated 
protection and the impact of Hb variants on protective antibody response has not been 
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completely solved. It has been hypothesized that both an innate and an acquired mechanism 
mediate protection that is conferred by HbAS.  
 
 
1.10 MALARIA VACCINES 
A major public health intervention that has had an enormous impact on the global health 
is vaccination. It is used to control and eradicate diseases such as smallpox, polio, rabies, 
diphtheria, tetanus, yellow fever, measles, mumps, rubella and hepatitis B.  
At the moment several malaria control interventions are being used to reduce the burden 
of malaria. The malaria interventions are broadly divided into I) vector control (indoor residual 
spraying (IRS), insecticide treated nets (ITN), and larval control, II) intermittent preventative 
therapy (IPT) and III) immediate diagnosis and treatment (WHO, 2012). These interventions 
have contributed to effective reduction of P.falciparum malaria transmission and mortality 
(WHO, 2010, 2012). However, the P. falciparum parasite is highly complex and adaptable with 
emerging drug resistance (Dondorp et al., 2009). Based on this, developing a safe, effective and 
affordable vaccine would provide a much-needed tool to combat the morbidity and mortality of 
malaria. 
The vaccine studies in malaria target the sporozoite, pre-erythrocytic (liver stage), 
erythrocytic (blood stage) and sexual stages. Comprehensive immuno-epidemiological studies 
have provided insight to the best candidate antigens to be included in vaccine development. 
One needs to remember that natural immunity targets a wider range of P. falciparum antigens 
and no specific antigens appears to be especially important to providing protection (Marsh and 
Kinyanjui, 2006). Most malaria antigens selected for vaccine candidates are targets of natural 
immunity, and display significant genetic polymorphisms. Additionally, the difficulties vaccine 
developers face with P.falciparum is that no adequate rodent model exists. 
A new formulation of P.falciparum cirumsporozoite protein, known as RTS,S, a hybrid 
protein particle formulated in a multi-component adjuvant named AS01, showed promising 
results in sporozoite challenge studies (Stoute et al., 1997), and this was then moved onto field 
testing in West Africa (Bojand Lancet 2001). At this time the importance of cellular immunity 
in protection against the liver stage malaria had been confirmed in animal studies (Schofield et 
al., 1987). RTS,S/ showed 30-50% sterile efficacy across a series of sporozoite challenges in 
volunteers (Kester et al., 2009) and demonstrated promising ability to induce high antibody 
levels, that target the conserved regions of the CS protein, and in some settings the level of the 
antibody responses correlated with protection against infection or disease (Moorthy MJ 2009). 
The RTS,S/AS01 challenge studies achieved a level efficacy that was a clear step forward for 
the field, and has undergone a series of phase I and II clinical trials in several African countries 
(Aide et al., 2010; Olotu et al., 2011). However, a recent report demonstrated that the efficacy 
of RTS,S/AS01 vaccine after 4 year period was only 16.8 % against P.  falciparum malaria 
among children vaccinated at 5 to 17 months of age in  malaria endemic areas (Olotu et al., 
2011). 
Other vaccine approaches are a whole parasite vaccine such as developing genetically 
attenuated parasites incapable to reach the liver stage. Yet the lack of irradiation in some cases 
raises issues of safety and the risk of developing the disease (Vaughan et al., 2010). Blood stage 
whole parasite vaccines have shown potential efficacy but problems arise such as the risk of 
growing large number of parasites in the blood or risk of unknown infections in donated human 
blood (Pombo et al., 2002). Vector vaccines are another approach in vaccine development, and 
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aim mainly to induce cellular immunity against liver stage malaria, and are being assessed 
clinically (Reyes-Sandoval et al., 2010). 
The progress with blood stage vaccines has been slow yielding mixed results 
(Goodman and Draper, 2010). A number of blood stage vaccine candidates have undergone 
clinical testing but not accomplished good protective efficacy against clinical malaria.  The 
vaccines are based on a few candidate antigens; MSP1, MSP2, MSP3 and AMA1  (Dicko et al., 
2008; Malkin et al., 2008; Ogutu et al., 2009; Sirima et al., 2007). Another blood stage vaccine 
candidate is PfEBA-175. A potential PfEBA-175 II vaccine was tested in malaria naïve subjects 
in the USA, and was shown to be safe and immunogenic. However, further studies are required 
in individuals living in malaria endemic areas (El Sahly et al., 2010). There are three challenges 
in blood stage vaccine development; expressing large antigens with the correct conformation, 
the modest antibody response and the extensive polymorphisms in many leading candidates.  
The struggle with blood stage vaccines has shifted the enthusiasm to the field of 
transmission-blocking vaccine development. The leading vaccine candidates are Pfs25/ Ps48/45 
and Pfs230 (Wu et al., 2008). Another approach is to use antigens from the Anopheles midgut 
wall, aminopeptidase APN1, as a suitable transmission-blocking vaccine component 
component (Dinglasan et al., 2013). These vaccine candidates have a particular advantage since 
they might be effective against more than one species of malaria, and been also considered as 
components for multi-stage vaccines. Consequently, this has renewed interest in development 
of mosquito stage vaccine candidates.   
An effective malaria vaccine is most likely to contain a combination of antigens from 
the same stage of the parasite´s life cycle or from different stages. Several combination 
vaccines have been developed and tested, as for example AMA-1 and MSP-1, CSP and AMA-1  
and MSP-1, MSP-2 and RESA (Genton, 2008; Malkin et al., 2008). However, there is limited 
evidence from human studies that these combinations have greater efficiency than single-
antigen vaccines, but animal studies indicate that this might still be the case. Nevertheless, it is 
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2 SCOPE OF THE THESIS 
The overall objective of the work presented in this thesis was to increase our 
understanding of acquired immunity to the P. falciparum merozoite antigens in children and 
adults, and to identify functional antibody responses in uncomplicated and severe malaria that 
may play a role in the development of protective immunity. The merozoite invasion, growth 






To investigate the quantitative and qualitative antibody responses to the merozoite antigens, and 




To study the role of merozoite invasion, parasite growth and rosetting in uncomplicated and 
severe P. falciparum malaria. 
 
PAPER III 
To investigate the natural acquired immunity against P. falciparum merozoite antigens over 





  31 
3 EXPERIMENTAL PROCEDURES 
3.1 STUDY POPULATIONS 
The studies included in this thesis work were conducted in populations living in P. 
falciparum endemic areas: north of Uganda (Paper I and II) and southwest of Nigeria (Paper 
III). 
 
3.1.1 UGANDA (PAPER I and II) 
Papers I and II were based on a cross-sectional study that included a total of 93 children 
under the age of five, with active P. falciparum infection. During 2002 children were recruited 
at the district hospital in Apac, Northern Uganda, a holo-endemic area having a very high 
entomological inoculation rate (EIR) of 1 500 per year (Okello et al., 2006; Yeka et al., 2005). 
Active P. falciparum infection was diagnosed by Giemsa blood smears and clinical 
examinations. The children were grouped according to the WHO guidelines (WHO, 2000a), 
and the modified Blantyre score (Molyneux et al., 1989). Fifty-one children were classified as 
having severe malaria and 42 children as having uncomplicated malaria. The severe malaria 
cases were further classified into sub-groups; respiratory distress (n=28), cerebral malaria 
(n=7), malaria NUD (n=10) (including convulsions, prostration, hyperparasitemia and 
hyperpyrexia), circulatory collapse (n=3), severe anaemia (n=2), one patient with cerebral 
malaria, severe anaemia, and respiratory distress (n=1). Paper I included 85 children (6 months 
to 3 years old), severe malaria (n= 46) and uncomplicated malaria (n=39). Paper II included 76 
children under the age of five, with severe malaria (n=36) and uncomplicated malaria (n=40). 
 
 
3.1.2 NIGERIA (PAPER III) 
Paper III was based on a longitudinal study conducted in a rural town, Igbo-Ora in 
southwestern Nigeria. Malaria is endemic with transmission peaks during the rainy season 
(April to October), with mean EIR of 131 per year (Noutcha and Anumdu, 2009). During the 
study from July 2009-July 2010, there initially 200 individuals ranging from 5-70 years old 
enrolled. Venous blood samples were collected at baseline for blood group typing, P. 
falciparum genotyping and immunological studies. Thick and thin smears were made for 
parasitological investigations. The participants were followed up monthly, for a period of 12 
months, checking their health status and the presence of malaria infection. Only participants 
who were permanent residents were included in the study. From 200 individuals 40 were 
randomly selected to be included in Paper III. 
 
3.2 ETHICAL CONSIDERATION 
Ethical approvals for the human participants in Paper I-III included in this thesis were 
obtained from the ethical research committees in Uganda, Nigeria and Karolinska Institutet, 
Sweden. Written informed consents were obtained from adult participants and parents or 
guardians of all children.  
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3.3 PARASITES AND IN VITRO CULTURES CONDITIONS 
P. falciparum laboratory and clinical parasite isolates were included in Papers I-II. All 
laboratory strains and clinical isolates were cultivated using standard methods with 
modifications (Moll K, 2008; Trager and Jensen, 1976). In brief all in vitro adapted Uganda 
isolates were cultivated in a gas mixture of 90% NO2, 5% O2 and 5% CO2, with constant and 
shaking instead of static candle-jar technique. This improved method has shown to facilitate the 
establishment of fresh clinical isolates to in vitro cultivation and to reduce the number of 
multiple infected RBCs.  
Parasites were kept synchronized using 5 % sorbitol (w/v) treatment. The parasitemia 
was counted and the rosetting rate was determined by calculating the number of trophozoite 
pRBCs within rosettes, relative to the total number of trophozoite pRBC in the culture. A 
rosette was defined as at least two unparasitizd RBCs bound to one pRBC. The rosetting 
phenotype was maintained with Ficoll enrichment. 
 
 
3.4 INVASION INHIBITION ASSAY 
The method described previously (Persson et al., 2006; Persson et al., 2008) allowed us 
to study the invasion inhibitory activities in patient plasma. Two Ugandan P. falciparum 
clinical isolates (UAM37, from a patient with uncomplicated malaria, and UAS31, from a 
severe malaria patient) were chosen as representative of clinical isolates in Paper I. Isolates 
were cultured in vitro in AB+ non-immune Swedish serum and gassed with 90% NO2, 5% O2 
and 5% CO2, and placed in a shaking incubator. In brief, parasites were synchronized (5% 
sorbitol, v/w) before starting the assay and used when the majority of the parasites had reached 
a late-pigmented trophozoite stage. 45 µl of parasite suspension and 5 µl of dialyzed test 
plasma were added to each well in duplicates. Plates were incubated in sealed, humidified and 
gassed box for 48 hours at 37 0C. Parasitemia was estimated using hydroethidine (10 µg/ml; 
Sigma Aldrich) in a flow cytometer (FACS Scan; BD). Parasite invasion for each sample was 
calculated relative to control samples (invasion in presence of dialyzed Swedish plasma). 
Parasite invasion was considered 100 %, if there was no invasion inhibitory activity in the 
added plasma sample. 
 
3.5 INVASION INTO ENZYME TREATED RED BLOOD CELLS 
To further characterize the clinical P. falciparum parasites, 21 isolates (11 uncomplicated 
and 10 severe) were examined for their RBC receptor specificities in invasion assays in Paper 
II. Human O+ RBCs were washed with RPMI 1640 (Gibco, Invitrogen), and subsequently 
treated with neuraminidase (62.5 uM/ml; Sigma), trypsin (1mg/ml; Sigma) and chymotrypsin 
(1 mg/ml; Sigma) for 45 minutes at 37 0C with periodic shaking. Control RBCs were only 
treated with RPMI 1640. After incubation the RBCs were washed once with RPMI 1640 
containing 20% human serum and twice with RPMI 1640 containing 10% human serum to 
inhibit enzyme activity (Persson et al., 2008). Late-pigmented trophozoite to schizont stages 
were enriched using magnetic bead column separation (Miltenyi Biotec, Germany). Invasion 
assays were performed in 96 U-bottom culture plates with a total of 50 µl of parasite suspension 
at 0.5–1.0% parasitemia and enzyme treated RBCs. All samples were run in triplicate. Plates 
were incubated in a gassed box for 48 hours at 37 0C. Parasitemia was estimated using 
hydroethidine (10 ug/ml; Sigma) in a flow cytometry (FACS Scan; BD) after 48 hours. 
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Invasion inhibition by enzyme treatment was determined as [1 - (proportion of enzyme-treated 
cells invaded/proportion of untreated cells invaded)] x 100. Results presented were comparative 
with control treated cells. 
 
 
3.6 RECOMBINANT MEROZOITE ANTIGENS 
A panel of P. falciparum merozoite antigens were selected and included in Paper I and 
III. The antigens were selected based on extensive studies suggesting them as potential 
candidates for vaccine development. All antigens were expressed in Escherichia coli, 
including following: the whole ectodomain of the P. falciparum D10 allelic form of PfAMA1 
(AMA1-D10) (Hodder et al., 2001); regions III to V; PfEBA140 (3D7; aa; 770 to 1064), 
PfEBA175 (3D7; aa; 761 to 1298), and PfEBA181 (3D7; aa; 769 to 1365) (Richards et al., 
2010); and PfRh2A9 (3D7; aa; 2027 to 2533) (Reiling et al., 2010) and PfRh4A3 (aa; 1160 to 
1370) (Persson et al., 2008; Stubbs et al., 2005). The MSP2 proteins corresponding to the 
FC27 and 3D7 gene sequences (Adda et al., 2009)were expressed as described previously. 
MSP1-19 from the 3D7 sequence was expressed as described previously) (Dutta et al., 2005). 
The recombinant antigens were all GST-tagged. 
 
 
3.7 MEASURING TOTAL IMMUNOGLOBULIN G (IGG) AGAINGST 
RECOMBINANT MEROZOITE ANTIGENS BY ELISA 
Antibody responses to P.falciparum merozoite antigens in patient plasma were assessed 
using ELISA. Total IgG levels against a panel of merozoite antigens (PfEBA140, PfEBA175, 
PfEBA181, PfRh2, PfRh4, MSP1-19, MSP2-3D7, MSP2-FC27, and PfAMA1) were measured 
using previously published ELISA protocols (Persson et al., 2008; Reddy et al., 2012). 
 
3.8 MEASURING SUBCLASS IG1-IGG4 AGAINGST RECOMBINANT 
MEROZOITE ANTIGENS BY ELISA 
This assay was adapted and optimized to quantify subclass antibodies against merozoite 
antigens PfEBA-175 and PfRh2 in patient plasma as described in Paper III. In brief the subclass 
reactivity was measured as follows: flat bottom 96-well plates (Nunc-immunoplate, Thermo 
Scientific) were coated with 1 µg/ml recombinant antigen in coating buffer (15 mM Na2CO3 
and 35 mM NaHCO3; pH 9.6) and incubated at 4 0C overnight. The plates were washed three 
times after incubation with blocking medium or antibodies. Plasma samples were diluted to 
1:25 in 5% skimmed milk in PBS- Tween 20, and incubated for 1.5 hours at 37°C. Mouse anti-
human antibodies (IgG1 A10630, IgG2 05-3500, IgG3 05-3600, IgG4 A10651 from Invitrogen 
Corporation, CA) were diluted in 5% skimmed milk in PBS-Tween 20 (1:500 for IgG1 and 
IgG3, and 1:250 for IgG2 and IgG4, dilutions chosen after optimization), and incubated for 1.5 
hours at 37 0C. Followed by antibody detection with goat anti-mouse IgG (H+L) horseradish 
peroxides (HRP) (G21040, Invitrogen Corporation, CA) diluted at 1:500 for IgG1 and IgG3, 
and at 1:1000 for IgG2 and IgG4, and incubated for 1.5 hours at 37 0C. Antibody reactivity was 
detected with a azino-bis(3-ethylbenthiazoline-6-sulfonic acid) (ABTS) tablet (Sigma Aldrich) 
dissolved in phosphate citrate buffer pH 5.0 (Sigma Aldrich); 30% H202 was added just prior to 
use. Plates were incubated at room temperature for 1 hour and optical density (OD) was read at 
414 nm. All assays were run in duplicate and OD was subtracted for non-specific binding of the 
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fusion tag, GST. Positive (pools of immune samples) and negative (Swedish non-immune) 
controls were included in all plates. 
 
 
3.9 SURFACE PLASMON RESONANCE 
To estimate the affinity of antibodies in plasma, binding to merozoite antigens in Paper 
I, the recombinant MSP2-3D7, MSP2-Fc27 and PfAMA1-D10 were bound to CM5 chips in 
Surface Plasmon Resonance assays (SPR) (Biacore 3000, Uppsala, Sweden) as described 
previously (Reddy et al., 2012). In brief, one lane was used as a control lane. Around 1000 
response units of each protein was bound to the chip. Plasma samples in at least two different 
dilutions (used as “internal controls”, since the off rate kd should be the same independent of 
concentration) were flowed over the antigen-coated surfaces, and the kd was measured in real 
time. When antibody levels were very high, the samples were diluted further until similar 
levels of response units were accomplished.  For every 20 samples, a control sample (a pool of 
adult immune plasma) was run to check that there was still enough protein bound to the chip to 
allow for measurement of reproducible kd values, and this was also used as a control between 
different chips. Swedish non-immune sera were used to determine the cut-off to be considered 
as background level (=100 RU).  Data was analyzed using BIAevaluation 4.1 software 




3.10 AMMONIUM THIOCYANATE (NH4SCN)-ELISA 
To estimate the strength of the antibody binding in Paper I, increasing concentrations of 
NH4SCN were added to ELISAs for the MSP2-3D7 and MSP2-FC27 proteins as described 
previously (Reddy et al., 2012). The affinity index was calculated from the absorbance reading 
in the presence of increasing concentrations of NH4SCN, which were converted to percentage 
of total bound antibody (in the absence of NH4SCN). The index was calculated from the molar 





3.11 DETERMINATION OF P.FALCIPARUM GENETIC DIVERSITY 
27 uncomplicated and 29 severe P. falciparum clinical cases were randomly selected 
from the clinical samples in Paper I for genotyping. A nested PCR was used to study the 
genetic markers for the MSP2 alleles (Fc27 and 3D7), for CSP, GLURP, and MSP1 alleles 
(K1, MAD20 and RO33). The primers and experimental conditions used have been described 
previously (Snounou, 2002), with some modifications (Ribacke et al., 2007). Multiplicity of 
infection (MOI) for each isolate was determined based on the highest number of allelic 
variants observed for a given genetic marker. 
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4 RESULTS AND DISCUSSION  
Results are discussed in detail in each respective study included in this thesis (Paper I-III). 
The original results and interpretations are also summarized here. 
 
4.1 PAPER I 
“ Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated 
or severe Plasmodium falciparum Malaria” 
 
Antibodies against several P.falciparum merozoite antigens have been found to be 
associated with protective immunity but very few studies have investigated the functional 
properties of acquired antibodies, or examined the role of antibodies to merozoite antigens in 
immunity to severe malaria in young children.  
In Paper I, we investigated the quantitative and qualitative differences in antibody 
responses in plasma against a panel of merozoite antigens, using a set of assays including 
ELISA, Invasion Inhibition Assays (IIA), NH4SCN-ELISA and Surface Plasmon Resonance 
(SPR) to identify antibody responses that may play a role in protective immunity, and evaluate 
which assay(s) are best predictors of immune differences between severe or uncomplicated 
malaria. Additionally, we studied the MOI in both the uncomplicated and severe malaria 
group.  
The IgG levels of antibodies against PfEBA181, MSP2-3D7, MSP2-Fc27 and 
PfAMA1 were significantly higher in children with uncomplicated compared to severe 
malaria. On the other hand, there was no significant difference in IgG levels of antibodies 
against PfEBA175, PfEBA140, MSP1, PfRh2 and PfRh4 in uncomplicated compared to severe 
malaria. Earlier studies have shown associations between high levels of antibodies against 
different merozoite antigens and protection against symptomatic malaria in general (severe 
malaria was not addressed in these studies), while other studies have defined high antibody 
levels as a marker of exposure (Osier et al., 2008; Polley et al., 2004; Richards et al., 2010). 
Based on previous findings showing inconsistencies in the correlations of antibody responses 
to recombinant antigens and protection from malaria using ELISA (McCallum et al., 2008), we 
further investigated the affinity properties of antibodies present in patients with uncomplicated 
or severe malaria, with SPR and the qualitative (functional) properties with IIA.  
In the first approach, we used an SPR method which allowed us to study antibody 
affinity under flow in real time (Hearty et al., 2010). Two allelic variants of the highly 
unstructured MSP2 protein, MSP2-Fc27 and MSP2-3D7, as well as PfAMA1 were selected for 
this purpose. Antibodies against PfAMA1 showed the highest affinity (i.e. lower kd values), 
while antibodies against MSP2-3D7 had lower affinity, and antibodies against MSP2-Fc27 had 
the lowest affinity. For all three antigens, there was a trend of higher affinity among the 
uncomplicated malaria cases, significant only for PfAMA1. These findings could indicate the 
importance of antibodies against PfAMA1 in this study group for a role in protection against 
severe malaria. These results are supported by a recent study using SPR that showed that 
individuals with high affinity antibodies directed against MSP2-3D7 had a prolonged time 
before developing clinical malaria, indicating that presence of high affinity antibodies may be 
important in protection against malaria (Reddy et al., 2012). 
In our second approach, we studied the inhibitory activities in plasma, in vitro, from 
children with uncomplicated or severe malaria, using IIA. All plasma samples from the 
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children were tested against two clinical parasite isolates, UAM37 and UAS31. The parasite 
UAM37 originated from a patient with uncomplicated malaria while UAS31 came from a 
patient with severe malaria. There was a trend of decreased invasion (58%) when plasma from 
children with uncomplicated malaria patients were used against UAS31, compared to severe 
malaria (70% invasion), but the difference was not significant. Furthermore, microscope and 
flow cytometry revealed that the major part of the invasion inhibition was found within the first 
hours of the parasite´s life cycle. We could clearly observe that both clinical isolates (UAM37 
and UAS31) showed significantly higher invasion in the presence of plasma from children with 
high initial parasitemia, indicating a lack of inhibitory antibodies in their plasma. However, we 
did not see any correlation between initial parasitemia and the presence of either IgG or IgM 
with any of the merozoite antigens tested by by ELISA or SPR. 
As a next step, the measurements of antibody responses were compared with the 
results of the functional assays. The most extensive analysis was carried out for the MSP2-3D7 
and MSP2-Fc27 antigens, for which we had access to two different allelic forms of the 
proteins. The IgG ELISA results for MSP2-3D7 and MSP2-Fc27 correlated very well with the 
NH4SCN-ELISA, which is not surprising since both methods are very similar. MSP2 contains 
both conserved and variable domains, and there might be a certain degree of overlap in 
antibody responses between the two allelic variants due to antibodies reacting against the same 
epitopes. Moreover, a significant correlation between parasite invasion of the two clinical 
isolates and presence of IgG/IgM in ELISA could be seen, between the results of the IIA on 
UAS31 and the IgG ELISA response against MSP2-Fc27, as well as between the for UAM37 
and the PfEBA175 ELISA results, for both IIA on UAS31 and UAM37 and PfRh2 ELISA. 
Furthermore, it was observed that plasma with higher levels of antibodies had an inhibitory 
effect on parasite invasion in IIA.  For PfAMA1, we observed the most interesting correlation 
in antibody response in the investigated functional assays. We saw a significant correlation of 
decreased UAS31 and UAM37 parasite invasion in IIA with increasing anti-PfAMA1-IgG in 
ELISA. We could also see a correlation between high levels of IgG in ELISA and high 
antibody affinity in SPR. For the other recombinant proteins used in IgG ELISA (PfEBA140, 
PfEBA181, PfRh4, MSP2-3D7 and MSP1), no significant correlations could be seen with IIA 
results. Several of the IgG ELISA results correlated with each other, but only PfAMA1 stood 
out as showing best correlations between methods (ELISA, IIA and SPR), compared to any of 
the other proteins.  
We also investigated the genotypes of the Ugandan isolates. The majority of 
analyzed samples were multi-clonal, including presence of both MSP2-FC27 and MSP2-3D7 
alleles. CSP, GLURP, and MSP1 (K1, MAD20, and RO33) and MSP2 (FC27 and 3D7) were  
analyzed and they showed a significantly larger heterogeneity in patients with uncomplicated 
compared to severe malaria for MSP1-K1 and MSP2-3D7. The total MOI in uncomplicated 
cases was significantly different as compared to severe cases, which has been previously 
shown in highly endemic settings (Farnert et al., 2009). Patients often harbour many variants of 
parasites at the same time (Arnot, 1998; Hoffmann et al., 2001) and there is conflicting data on 
whether multi-clonal infections are associated with the outcome of the infection (al-Yaman et 
al., 1997). There was a significant positive correlation between MOI and IgG in ELISA against 
the following merozoite antigens: MSP2-FC27, PfAMA1, PfEBA175, PfEBA-181 and PfRh2. 
A higher MOI correlated weakly with lower affinity of antibodies (in SPR) for MSP2-FC27 
and MSP2-3D7. In addition, age and the presence of IgM in ELISA against MSP2-FC27 
correlated positively as did age and IgG in ELISA against MSP2-FC27 and PfAMA1. Older 
children had higher levels of antibodies and they also had a higher antibody affinity against the 
MSP2 antigens measured by NH4SCN ELISAs, but not with SPR. 
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Our study is the first to show that by using a combination of assays we could increase the 
understanding of the immunological responses in children with uncomplicated or severe 
P.falciparum malaria. No single method has shown to be fully predictive of immunity 
(Bouharoun-Tayoun et al., 1990; Dent et al., 2008; Egan et al., 1996; Hodder et al., 2001), and 
the most commonly used method, ELISA, is a static method that does not reflect the function of 
antibodies. In our combination of assays, we found that the presence of antibodies against 
PfAMA1 (in ELISA) correlated to invasion for both tested clinical isolates, and that these 
antibodies against PfAMA1 in ELISA also correlated to affinity SPR results, indicating that this 
protein might be targeted by functionally important antibodies with high affinity that could 
contribute to protection from severe malaria in this study group.  Our observations are 
consistent with recent studies from Uganda (Greenhouse et al., 2011; Keh et al., 2012), which 
showed a strong association between antibodies against PfAMA1 and protection against 
malaria. Presence of antibodies against PfAMA1 has been shown to be associated with reduced 
incidence of malaria (Polley et al., 2004), and individuals living in malaria endemic areas have 
increased levels of anti-PfAMA1 antibodies, which can be strongly inhibitory to parasite 
invasion (Courtin et al., 2009; Hodder et al., 2001; Nair et al., 2002). Furthermore, antibodies 
against MSP2-3D7, but not against MSP2-FC27, have been associated with protection against 
malaria (al-Yaman et al., 1997), and for being more important in protection against severe 
malaria (Iriemenam et al., 2009). These previous findings are corroborated by our results that 
show a higher affinity of antibodies against the 3D7 allelic variant (compared to FC27) in SPR. 
Interestingly, the only assay that positively correlated with initial parasitemia in the patient was 
the IIA, which emphasis the importance of using functional assays. 
 
4.2 PAPER II 
“Improved in vitro culture of Plasmodium falciparum permits establishment of clinical 
isolates with preserved multiplication, invasion and rosetting phenotypes” 
 
Cytoadherence and rosetting in P. falciparum cause excessive micro-vascular 
sequestration, obstruction of blood flow and severe disease (Carlson et al., 1990; Rowe et 
al., 1995). The peripheral parasitemia and the sequestrated biomass of P.falciparum are higher 
in individuals with severe malaria than individuals with uncomplicated malaria. The study of 
rosetting, multiplication and RBC invasion has been limited by difficulties in adapting fresh 
isolates and cryo-preserved clinical isolates to in vitro cultures. The problems are poor 
outgrowth, low multiplication rates, loss of rosetting and cytoadherence phenotypes due to lack 
of appropriate environment and specific host factors.  
In Paper II, we evaluated the optimal in vitro growth conditions for the parasites that 
would mimic the environment of the human microvasculature. We used long-term propagated 
parasites not selected for rosetting or cytoadhesion (HB3, F32, 3D7AH1, FCR3, R29 and 
TM284), parasite clones selected by micromanipulation for high or low rosetting (FCR3S1.2, 
FCR3S1.6, TM284S2 and3D7S8.4) and 76 P.falciparum clinical isolates collected from 
children with uncomplicated or severe malaria in Apac, Uganda (also used in Paper I). 
A systematic evaluation was performed to establish 100% of the cryo-preserved 
clinical isolates with minimal parasite mass loss and preservation of the phenotype. Four 
different in vitro growth conditions were studied, and the cultivation involving growth in 
suspension on an orbital shaker (50 rev/min) with the use of a fixed gas composition (5% O2, 
5% CO2 and 90% N2) to maintain a stable micro-aerophilic environment was found to be  
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preferred compared to static cultivation with the same gas or the candle-jar method. 100% of 
isolates were established, with reduced multiple infected RBC, high multiplication rate and 
preserved capacity to form rosettes over time. 
We further investigated the rosetting in the parasites stains and clinical isolates, and we 
found that the dependence of rosetting in the presence or absence of serum varied in different 
parasites strains. The FCR3S1.2 pRBCs did not show any rosettes when grown in absence of 
human serum, while the rosetting rate was high, around 80%, in the presence of human serum. 
Switching of culture conditions rapidly re-established the rosetting phenotype in the presence of 
human serum, while it was lost by a change to conditions without human serum. Surface 
expression of PfEMP1 in FCR3S1.2 was significantly lower in pRBCs grown in the presence of 
Albumax as compared to human serum. Furthermore, expression of PfEMP1 was only detected 
between 22 h and 34 h post infection (pi) in Albumax while PfEMP1 in pRBCs grown with 
human serum was expressed between 18 h and 42 h pi. These findings argue for that serum 
components are necessary for correct display of PfEMP1 on the pRBC surface. We also 
observed that all 76 clinical isolates formed rosettes during schizogony, varying from 26 to 88 
%. Invasion of bound uninfected RBC at the time of rupture was frequently observed. Rosetting 
could be associated to the parasite’s ability to invade new RBC. Parasites previously selected 
for the rosetting phenotype at trophozoite stage showed high rosetting rates during schizogony. 
Of the 76 clinical isolates, 36 originated from children with severe malaria and 40 from 
children with uncomplicated disease. When the groups were compared, we found that the 
severe malaria parasites multiplied and rosetted (both at trophozoite and schizont stage) at 
significantly higher rates. Interestingly, positive and significant correlations of the 
multiplication rates of individual isolates to the original peripheral parasitemia at the time of 
blood collection were also observed. The ability of clinical isolates to multiply correlated to the 
rosetting rates of both trophozoite and schizont-infected RBCs.  
We further investigated if the correlation between rosetting and multiplication rate was 
due to facilitated invasion during rosette formation. Parasites, to which specific antibodies 
towards the expressed PfEMP1variant were available, were grown in presence and absence of 
those antibodies. However, no growth advantages and no correlation between rosetting and 
multiplication was observed. To further characterize the Ugandan clinical isolates, 21 (11 
uncomplicated and 10 severe) of the 76 clinical isolates were studied for different invasion 
pathways in merozoite invasion assays. The RBCs were treated with trypsin, chymotrypsin or 
neuraminidase before merozoite invasion assays. The majority of isolates were neuraminidase 
resistant, trypsin and chymotrypsin sensitive. Parasite invasion into the enzyme treated RBC 
differed slightly between the uncomplicated and severe group. Isolates from children with 
uncomplicated malaria showed significantly higher sensitivity to trypsin and chymotrypsin.  
There was no difference in sensitivity towards neuraminidase treatment of erythrocytes 
observed between the groups. The Ugandan clinical isolates to a large extent use sialic acid 
independent pathways. 
In this study, we established improved in vitro culture conditions in suspension and a 
controlled micro-aerophilic environment for cryo-preserved clinical P.falciparum isolates, 
which allowed us to study multiplication rates, rosetting phenotypes and merozoite invasion. 
We also found it to be the preferred conditions for both fresh and established parasites for 
maintaining their phenotypes. This study further emphasizes the importance of human serum 
during the cultivation of P. falciparum isolates and laboratory strains to guarantee the display of 
the parasite’s adhesive phenotype and correct expression of PfEMP1. The role of PfEMP1 in 
the close interaction between infected and uninfected RBCs in rosettes may facilitate merozoite 
invasion by bridging molecules or merely by being in the proximity of the pRBC during 
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schizont rupture. The surprising presence in all fresh isolates of high levels of schizont rosettes 
could suggest that rosetting must have an important biological function and can give an 
advantage in survival/growth. The peripheral parasitemia, the level of rosetting and the rate of 
multiplication correlated positively to one another for individual isolates and were all found to 
be higher among isolates from children with severe malaria than from children with 
uncomplicated malaria. This suggests that rosetting may contribute to a higher parasite burden 
in vivo. In addition, other traits than rosetting such as the rate of replication, number of formed 
merozoites and the invasion ligand repertoire are also likely to contribute to the superior growth 
of some, but not all, parasites. In this case, sialic acid independent invasion pathways were 
mainly used by these clinical isolates and this pathway is known to by used by the parasite 
ligand PfRh4. This is important information for future vaccine studies. 
 
 
4.3 PAPER III 
“Antibody responses against PfEBA175 and PfRh2 in naturally acquired immunity 
against Plasmodium falciparum malaria” 
 
Acquired immunity to malaria develops after repeated exposure in individuals living in 
endemic areas (Doolan et al., 2009; Langhorne et al., 2008). In Paper III, we investigated the 
naturally acquired antibody responses to P.falciparum merozoite antigens in 40 children and 
adults in Igbo-Ora, a rural area of Nigeria, over a time period of almost one year (July 2009 to 
June 2010). The malaria protective effect of having hemoglobin S (HbAS), which is relatively 
common in this area, was also investigated. The total IgG and subclass IgG1-4 responses 
against PfEBA175 and PfRh2 during one year were investigated in Nigerian children and 
adults. 
In both children and adults, the antibody responses (total IgG and subclass IgG1-IgG4) 
against PfEBA175 and PfRh2 increased from August with a peak in November followed by 
decline in the following months. In children and adults, the cytophilic IgG1 and IgG3 responses 
against PfEBA175 dominated and IgG2 and IgG4 responses against PfRh2 were also detected. 
Additionally, we found that the total IgG levels against PfEBA175 and PfRh2 showed a 
positivly significant correlation with each other. Furthermore, when the total IgG and subclass 
responses within PfEBA-175 were investigated and we observed that the total IgG responses 
significantly correlated with all four subclasses, and the subclasses significantly correlated with 
each other. While for PfRh2 we saw that total IgG significantly correlated with IgG1, and IgG2 
significantly correlated with IgG3 and IgG4. We further looked into the acquired antibody 
responses in the context of age, and found that age significantly correlated to the levels of total 
IgG, IgG1 and IgG3 for PfEBA175.  
Patient parasitemia was carefully monitored over the one-year study period. We 
observed that the parasitemia reached its peak in the month of October (mean: 749.7 
parasites/µl), while the lowest peak was observed in May (mean: 3.7 parasites/µl). These 
findings could explain the peak of antibody levels arising just after the peak in parasitemia. 
Additionally, it is concordant with the transmission intensity being highest during the rainy 
season, which ends in October. There was no significant difference in parasitemia between 
children and adults.  
We compared the antibody levels with parasitemia to determine if the antibody 
responses against PfEBA175 and PfRh2 correlated with control of parasitemia during the study 
period. We found that higher IgG1, IgG2 and IgG3 levels for PfEBA175 and total IgG for 
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PfRh2 correlated significantly with lower parasitemia.  We observed that individuals with the 
highest quartiles of levels of total IgG against PfEBA175 or PfRh2 showed a correlation with 
reduction of parasitemia, and when individuals with high levels of both antibodies against 
PfEBA175 and PfRh2 were considered, they had lower parasitemia compared to those with 
raised levels of only one of the antibodies. These findings indicate that these antibodies are 
important for protection against malaria, and support previous studies showing that high levels 
of total IgG, IgG1 and IgG3 against PfEBA175 associate with protection from malaria 
(McCarra et al., 2011; Richards et al., 2010). 
We further investigated the impact of HbAA and HbAS in protective effects against 
malaria. When all individuals in the study group were considered together we found that total 
IgG, IgG1 and IgG3 against PfEBA175 were significantly higher in individuals with HbAA 
compared to HbAS. For PfRh2, only the IgG1 response was significantly higher in HbAA. 
When we divided the cohort into two groups, children and adults, we found that children with 
HbAS had significantly higher levels of IgG, IgG1, IgG2 and IgG3 against PfEBA175 and 
higher levels of total IgG against PfRh2 compared to HbAA. On the other hand, the pattern in 
the adult group was the opposite with higher levels of IgG, IgG1 and IgG3 against EBA175 in 
HbAA individuals. Although there were very few samples in each group, these findings may 
give an idea of the role of HbAS and its malaria protective effects in this Nigerian population. 
In this study we showed that the antibody response against PfEBA175 was more 
evident than against PfRh2 in this Nigerian population. This could be explained by the fact that 
the expression of PfRh2 can vary between parasites (Duraisingh et al., 2003b), or that the used 
recombinant antigen of PfEBA175 was more similar to the protein variant within parasite 
population in that area. The part of the protein that was used, region III-V of PfEBA175 
(Richards et al., 2010) in our case, could also affect the results. The few studies that have 
investigated the subclass responses against merozoite antigens have concluded that IgG1 and 
IgG3 responses are predominant (Roussilhon et al., 2007; Stanisic et al., 2009).  Our results are 
concordant with dominant IgG1 and IgG3 responses, however we also observed responses 
against IgG2 and IgG4. The quality of IgG2 and IgG4 could be of importance in the 
development of protective immunity, even at low levels.  Furthermore, we observed higher 
levels of antibodies in children with HbAS that might have malaria protective effects. Previous 
studies in Nigeria (Fleming et al., 1979) and other African countries (Williams et al., 2005a) 
have shown that individuals with HbAS had lower parasite densities and lower prevalence of 
clinical malaria. 
Another important finding in this study is that individuals with high levels of both total 
IgG against EBA175 and PfRh2 had a lower parasitemia during the one-year follow up, 
compared to the high single antibody response. This observation of combined antibody 
response against two antigens emphasises the importance of aiming at the use of combined 
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5 CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
 
The main goal for malaria research is to decrease the global malaria burden. Even though 
there has been great achievements in malaria control and treatment during the last decade, the 
mortality rate is around 15-20 % for severe malaria, even in modern and well-equipped 
hospitals, and many patients die without receiving the correct care. To develop a safe, effective 
and affordable anti-malarial vaccine would provide a much-needed tool to combat the 
morbidity and mortality malaria is responsible for in the world. It is known that individuals 
living in malaria endemic countries develop naturally acquired immunity after repeated 
exposure (Doolan et al., 2009; Langhorne et al., 2008). Furthermore, antibodies are an 
important component of acquired immunity, and it has been shown that passive transfer of 
antibodies from immune donors to individuals with P.falciparum infections reduces parasitemia 
and clinical symptoms (Cohen et al., 1969). It is of great importance to understand the 
underlying role of antibodies in the development of protective immunity against severe malaria.  




I. Children with uncomplicated malaria had acquired more antibodies against a selection 
of merozoite antigens (PfEBA-181, MSP-Fc27, MSP2-3D7 and PfAMA1) compared 
to children with severe malaria. Acquired antibodies against PfRh2 and PfAMA1 in 
ELISA correlated to parasite invasion in both clinical isolates in the invasion inhibition 
assay (IIA), and anti-PfAMA1-antibodies in ELISA correlated with increased anti-
PfAMA1-antibody affinity in Surface plasmon resonance (SPR). Importantly, the only 
assay that correlated with initial parasitemia in the patient was the IIA. Both 
MSP2Fc27 and MSP23D7 allele variants were present in both groups, and considering 
total MOI of the parasite there was a higher number of genotypes in uncomplicated 
malaria. For future studies, in addition to ELISA, it is of importance to include a 
combination of functional assays such as IIA and SPR assays, to understand the 
development of protective immunological responses against malaria in individuals 
living in endemic countries. Additionally, vaccine studies including merozoite antigens 
should consider the difference in immunological responses between uncomplicated and 
severe malaria in their evaluations. 
 
II. Optimal in vitro growth conditions were achieved, which allowed for phenotypic 
studies of clinical P.falciparum isolates taken directly from the patients. Presence of 
serum in the cultures was found to be essential for optimal surface presentation of 
PfEMP1, and for maintaining of rosettes. Children with severe malaria had higher 
peripheral parasitemias, higher rosetting levels and higher multiplication rates and 
these correlated positively with each other. The majority of clinical isolates used a 
sialic acid independent invasion pathway. Isolates from children with uncomplicated 
malaria showed significantly higher sensitivity to trypsin and chymotrypsin. Rosetting 
might facilitate successful merozoite invasion in vivo, hence could be the reason it is 
found to be associated with severe disease. Parasite invasion is central to parasite 
replication and virulence.  Future studies should investigate alternative merozoite 
ligand expression in uncomplicated and severe malaria in the context pathogenesis.  
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III. The antibody response against PfEBA175 was more prominent than against PfRh2 in 
in both children and adults. Cytophilic IgG1 and IgG3 against PfEBA175 were the 
predominant antibody responses, but there was also some response for IgG2 and IgG4. 
Individuals with higher total IgG responses against both PfEBA175 and PfRh2 had 
lower parasitemia during the one-year study period. Higher antibody responses against 
merozoite antigens in children with HbAS might have protective effects against 
malaria. Future studies will include investigation of antibody responses against other 
relevant merozoite antigens, and evaluation of functional properties of these antibodies, 
such as the invasion/growth inhibitory effects and affinity in the context immunological 
responses during the study period. Additionally, to consider the red blood cells 
polymorphisms present in the study area, and their role in acquired immunity against 
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Ana aan mar walba u cararaayey shaqo adag. una samaynayey marwalba  wax run ahaantii aad uu 
sharaf badan ama wanaagsan. Is dhul dhigaaya  kuna faanayaa in aan leeyahay laba waalid oo idin koo 
kala ah.  





  46 
7 REFERENCES 
 
Abdel-Latif, M.S., Dietz, K., Issifou, S., Kremsner, P.G., and Klinkert, M.Q. (2003). Antibodies 
to Plasmodium falciparum rifin proteins are associated with rapid parasite clearance and 
asymptomatic infections. Infection and Immunity 71, 6229-6233. 
Abdel-Latif, M.S., Khattab, A., Lindenthal, C., Kremsner, P.G., and Klinkert, M.Q. (2002). 
Recognition of variant Rifin antigens by human antibodies induced during natural 
Plasmodium falciparum infections. Infection and Immunity 70, 7013-7021. 
Adams, J.H., Sim, B.K., Dolan, S.A., Fang, X., Kaslow, D.C., and Miller, L.H. (1992). A 
family of erythrocyte binding proteins of malaria parasites. P Natl Acad Sci USA 89, 
7085-7089. 
Adda, C.G., Murphy, V.J., Sunde, M., Waddington, L.J., Schloegel, J., Talbo, G.H., Vingas, K., 
Kienzle, V., Masciantonio, R., Howlett, G.J., et al. (2009). Plasmodium falciparum 
merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol Biochem 
Parasit 166, 159-171. 
Aide, P., Aponte, J.J., Renom, M., Nhampossa, T., Sacarlal, J., Mandomando, I., Bassat, Q., 
Manaca, M.N., Leach, A., Lievens, M., et al. (2010). Safety, immunogenicity and duration 
of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized 
controlled phase I/IIb trial. PLoS One 5, e13838. 
Aidoo, M., Terlouw, D.J., Kolczak, M.S., McElroy, P.D., ter Kuile, F.O., Kariuki, S., Nahlen, 
B.L., Lal, A.A., and Udhayakumar, V. (2002). Protective effects of the sickle cell gene 
against malaria morbidity and mortality. Lancet 359, 1311-1312. 
Aikawa, M. (1988a). Human cerebral malaria. The American journal of tropical medicine and 
hygiene 39, 3-10. 
Aikawa, M. (1988b). Morphological changes in erythrocytes induced by malarial parasites. Biol 
Cell 64, 173-181. 
Aikawa, M., Cochrane, A.H., Nussenzweig, R.S., and Rabbege, J. (1979). Freeze-fracture study 
of malaria sporozoites: antibody-induced changes of the pellicular membrane. The Journal 
of protozoology 26, 273-279. 
Aikawa, M., and Miller, L.H. (1983). Structural alteration of the erythrocyte membrane during 
malarial parasite invasion and intraerythrocytic development. Ciba Foundation symposium 
94, 45-63. 
Aikawa, M., Miller, L.H., Johnson, J., and Rabbege, J. (1978). Erythrocyte entry by malarial 
parasites. A moving junction between erythrocyte and parasite. The Journal of cell biology 
77, 72-82. 
Akpogheneta, O.J., Duah, N.O., Tetteh, K.K., Dunyo, S., Lanar, D.E., Pinder, M., and Conway, 
D.J. (2008). Duration of naturally acquired antibody responses to blood-stage Plasmodium 
falciparum is age dependent and antigen specific. Infection and Immunity 76, 1748-1755. 
Akpogheneta, O.J., Dunyo, S., Pinder, M., and Conway, D.J. (2010). Boosting antibody 
responses to Plasmodium falciparum merozoite antigens in children with highly seasonal 
exposure to infection. Parasite immunology 32, 296-304. 
al-Yaman, F., Awburn, M.M., and Clark, I.A. (1997). Serum creatinine levels and reactive 
nitrogen intermediates in children with cerebral malaria in Papua New Guinea. T Roy Soc 
Trop Med H 91, 303-305. 
al-Yaman, F., Genton, B., Anders, R., Taraika, J., Ginny, M., Mellor, S., and Alpers, M.P. 
(1995). Assessment of the role of the humoral response to Plasmodium falciparum MSP2 
compared to RESA and SPf66 in protecting Papua New Guinean children from clinical 
malaria. Parasite immunology 17, 493-501. 
Alano, P., and Carter, R. (1990). Sexual differentiation in malaria parasites. Annual review of 
microbiology 44, 429-449. 
Allen, S.J., Bennett, S., Riley, E.M., Rowe, P.A., Jakobsen, P.H., O'Donnell, A., and 
Greenwood, B.M. (1992). Morbidity from malaria and immune responses to defined 
Plasmodium falciparum antigens in children with sickle cell trait in The Gambia. T Roy 
Soc Trop Med H 86, 494-498. 
  47 
Aly, A.S., and Matuschewski, K. (2005). A malarial cysteine protease is necessary for 
Plasmodium sporozoite egress from oocysts. The Journal of experimental medicine 202, 
225-230. 
Amino, R., Giovannini, D., Thiberge, S., Gueirard, P., Boisson, B., Dubremetz, J.F., Prevost, 
M.C., Ishino, T., Yuda, M., and Menard, R. (2008). Host cell traversal is important for 
progression of the malaria parasite through the dermis to the liver. Cell host & microbe 3, 
88-96. 
Amino, R., Thiberge, S., Martin, B., Celli, S., Shorte, S., Frischknecht, F., and Menard, R. 
(2006). Quantitative imaging of Plasmodium transmission from mosquito to mammal. 
Nature Medicine 12, 220-224. 
Anand, A.C., and Puri, P. (2005). Jaundice in malaria. Journal of gastroenterology and 
hepatology 20, 1322-1332. 
Anders, R.F., Adda, C.G., Foley, M., and Norton, R.S. (2010). Recombinant protein vaccines 
against the asexual blood stages of Plasmodium falciparum. Human vaccines 6, 39-53. 
Anstey, N.M., Douglas, N.M., Poespoprodjo, J.R., and Price, R.N. (2012). Plasmodium vivax: 
clinical spectrum, risk factors and pathogenesis. Advances in parasitology 80, 151-201. 
Arias-Bouda, L.M., Kuijper, S., Van der Werf, A., Nguyen, L.N., Jansen, H.M., and Kolk, A.H. 
(2003). Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium 
tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin 
Diagn Lab Immun 10, 702-709. 
Arnot, D. (1998). Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity 
of Plasmodium falciparum infections in individuals exposed to variable levels of disease 
transmission. T Roy Soc Trop Med H 92, 580-585. 
Atkinson, C.T., and Aikawa, M. (1990). Ultrastructure of malaria-infected erythrocytes. Blood 
Cells 16, 351-368. 
Aucan, C., Traore, Y., Tall, F., Nacro, B., Traore-Leroux, T., Fumoux, F., and Rihet, P. (2000). 
High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human 
resistance to Plasmodium falciparum malaria. Infection and Immunity 68, 1252-1258. 
Baer, K., Klotz, C., Kappe, S.H., Schnieder, T., and Frevert, U. (2007a). Release of hepatic 
Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS pathogens 3, 
e171. 
Baer, K., Roosevelt, M., Clarkson, A.B., Jr., van Rooijen, N., Schnieder, T., and Frevert, U. 
(2007b). Kupffer cells are obligatory for Plasmodium yoelii sporozoite infection of the 
liver. Cellular microbiology 9, 397-412. 
Bannister, L.H., and Dluzewski, A.R. (1990). The ultrastructure of red cell invasion in malaria 
infections: a review. Blood Cells 16, 257-292; discussion 293-257. 
Bannister, L.H., Hopkins, J.M., Margos, G., Dluzewski, A.R., and Mitchell, G.H. (2004). 
Three-dimensional ultrastructure of the ring stage of Plasmodium falciparum: evidence for 
export pathways. Microscopy and microanalysis : the official journal of Microscopy 
Society of America, Microbeam Analysis Society, Microscopical Society of Canada 10, 
551-562. 
Baratin, M., Roetynck, S., Pouvelle, B., Lemmers, C., Viebig, N.K., Johansson, S., Bierling, P., 
Scherf, A., Gysin, J., Vivier, E., et al. (2007). Dissection of the role of PfEMP1 and 
ICAM-1 in the sensing of Plasmodium-falciparum-infected erythrocytes by natural killer 
cells. PLoS One 2, e228. 
Barcus, M.J., Basri, H., Picarima, H., Manyakori, C., Sekartuti, Elyazar, I., Bangs, M.J., 
Maguire, J.D., and Baird, J.K. (2007). Demographic risk factors for severe and fatal vivax 
and falciparum malaria among hospital admissions in northeastern Indonesian Papua. The 
American journal of tropical medicine and hygiene 77, 984-991. 
Barragan, A., Fernandez, V., Chen, Q., von Euler, A., Wahlgren, M., and Spillmann, D. (2000 
a). The duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane 
protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. Blood 95, 
3594-3599. 
Barragan, A., Kremsner, P.G., Wahlgren, M., and Carlson, J. (2000 b). Blood group A antigen 
is a coreceptor in Plasmodium falciparum rosetting. Infection and Immunity 68, 2971-
2975. 
  48 
Barry, A.E., Schultz, L., Buckee, C.O., and Reeder, J.C. (2009). Contrasting population 
structures of the genes encoding ten leading vaccine-candidate antigens of the human 
malaria parasite, Plasmodium falciparum. PLoS One 4, e8497. 
Baruch, D.I., Gormely, J.A., Ma, C., Howard, R.J., and Pasloske, B.L. (1996). Plasmodium 
falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte receptor for 
adherence to CD36, thrombospondin, and intercellular adhesion molecule 1. P Natl Acad 
Sci USA 93, 3497-3502. 
Baum, J., Maier, A.G., Good, R.T., Simpson, K.M., and Cowman, A.F. (2005). Invasion by P. 
falciparum merozoites suggests a hierarchy of molecular interactions. PLoS pathogens 1, 
e37. 
Beeson, J.G., Brown, G.V., Molyneux, M.E., Mhango, C., Dzinjalamala, F., and Rogerson, S.J. 
(1999). Plasmodium falciparum isolates from infected pregnant women and children are 
associated with distinct adhesive and antigenic properties. The Journal of infectious 
diseases 180, 464-472. 
Beeson, J.G., Rogerson, S.J., Cooke, B.M., Reeder, J.C., Chai, W., Lawson, A.M., Molyneux, 
M.E., and Brown, G.V. (2000). Adhesion of Plasmodium falciparum-infected erythrocytes 
to hyaluronic acid in placental malaria. Nature Medicine 6, 86-90. 
Bir, N., Yazdani, S.S., Avril, M., Layez, C., Gysin, J., and Chitnis, C.E. (2006). 
Immunogenicity of Duffy binding-like domains that bind chondroitin sulfate A and 
protection against pregnancy-associated malaria. Infection and Immunity 74, 5955-5963. 
Blackman, M.J., Heidrich, H.G., Donachie, S., McBride, J.S., and Holder, A.A. (1990). A 
single fragment of a malaria merozoite surface protein remains on the parasite during red 
cell invasion and is the target of invasion-inhibiting antibodies. The Journal of 
experimental medicine 172, 379-382. 
Blackman, M.J., and Holder, A.A. (1992). Secondary processing of the Plasmodium falciparum 
merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine 
protease: shedding of MSP133 as a noncovalently associated complex with other 
fragments of the MSP1. Mol Biochem Parasit 50, 307-315. 
Blair, P.L., Kappe, S.H., Maciel, J.E., Balu, B., and Adams, J.H. (2002). Plasmodium 
falciparum MAEBL is a unique member of the ebl family. Mol Biochem Parasit 122, 35-
44. 
Blythe, J.E., Yam, X.Y., Kuss, C., Bozdech, Z., Holder, A.A., Marsh, K., Langhorne, J., and 
Preiser, P.R. (2008). Plasmodium falciparum STEVOR proteins are highly expressed in 
patient isolates and located in the surface membranes of infected red blood cells and the 
apical tips of merozoites. Infection and Immunity 76, 3329-3336. 
Boddey, J.A., and Cowman, A.F. (2013). Plasmodium nesting: remaking the erythrocyte from 
the inside out. Annual review of microbiology 67, 243-269. 
Bondi, F.S. (1992). The incidence and outcome of neurological abnormalities in childhood 
cerebral malaria: a long-term follow-up of 62 survivors. T Roy Soc Trop Med H 86, 17-
19. 
Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T., and Druilhe, P. 
(1990). Antibodies that protect humans against Plasmodium falciparum blood stages do 
not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with 
monocytes. The Journal of experimental medicine 172, 1633-1641. 
Bouharoun-Tayoun, H., and Druilhe, P. (1992). Plasmodium falciparum malaria: evidence for 
an isotype imbalance which may be responsible for delayed acquisition of protective 
immunity. Infection and Immunity 60, 1473-1481. 
Bouharoun-Tayoun, H., Oeuvray, C., Lunel, F., and Druilhe, P. (1995). Mechanisms underlying 
the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual 
blood stages. The Journal of experimental medicine 182, 409-418. 
Boyle, M.J., Langer, C., Chan, J.A., Hodder, A.N., Coppel, R.L., Anders, R.F., and Beeson, 
J.G. (2013). Sequential processing of merozoite surface proteins during and after 
erythrocyte invasion by Plasmodium falciparum. Infection and Immunity. 
Boyle, M.J., Richards, J.S., Gilson, P.R., Chai, W., and Beeson, J.G. (2010). Interactions with 
heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. 
Blood 115, 4559-4568. 
  49 
Branch, O.H., Udhayakumar, V., Hightower, A.W., Oloo, A.J., Hawley, W.A., Nahlen, B.L., 
Bloland, P.B., Kaslow, D.C., and Lal, A.A. (1998). A longitudinal investigation of IgG 
and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of 
Plasmodium falciparum in pregnant women and infants: associations with febrile illness, 
parasitemia, and anemia. The American journal of tropical medicine and hygiene 58, 211-
219. 
Bruce, M.C., Alano, P., Duthie, S., and Carter, R. (1990). Commitment of the malaria parasite 
Plasmodium falciparum to sexual and asexual development. Parasitology 100 Pt 2, 191-
200. 
Bull, P.C., Berriman, M., Kyes, S., Quail, M.A., Hall, N., Kortok, M.M., Marsh, K., and 
Newbold, C.I. (2005). Plasmodium falciparum variant surface antigen expression patterns 
during malaria. PLoS pathogens 1, e26. 
Bull, P.C., Lowe, B.S., Kortok, M., and Marsh, K. (1999). Antibody recognition of 
Plasmodium falciparum erythrocyte surface antigens in Kenya: evidence for rare and 
prevalent variants. Infection and Immunity 67, 733-739. 
Bunn, H.F. (2013). The triumph of good over evil: protection by the sickle gene against 
malaria. Blood 121, 20-25. 
Buscaglia, C.A., Hol, W.G., Nussenzweig, V., and Cardozo, T. (2007). Modeling the 
interaction between aldolase and the thrombospondin-related anonymous protein, a key 
connection of the malaria parasite invasion machinery. Proteins 66, 528-537. 
Camus, D., and Hadley, T.J. (1985). A Plasmodium falciparum antigen that binds to host 
erythrocytes and merozoites. Science 230, 553-556. 
Carlson, J., Ekre, H.P., Helmby, H., Gysin, J., Greenwood, B.M., and Wahlgren, M. (1992). 
Disruption of Plasmodium falciparum erythrocyte rosettes by standard heparin and heparin 
devoid of anticoagulant activity. The American journal of tropical medicine and hygiene 
46, 595-602. 
Carlson, J., Helmby, H., Hill, A.V., Brewster, D., Greenwood, B.M., and Wahlgren, M. (1990). 
Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting 
antibodies. Lancet 336, 1457-1460. 
Carlson, J., Nash, G.B., Gabutti, V., al-Yaman, F., and Wahlgren, M. (1994). Natural protection 
against severe Plasmodium falciparum malaria due to impaired rosette formation. Blood 
84, 3909-3914. 
Carlson, J., and Wahlgren, M. (1992). Plasmodium falciparum erythrocyte rosetting is mediated 
by promiscuous lectin-like interactions. The Journal of experimental medicine 176, 1311-
1317. 
Chattopadhyay, R., Taneja, T., Chakrabarti, K., Pillai, C.R., and Chitnis, C.E. (2004). 
Molecular analysis of the cytoadherence phenotype of a Plasmodium falciparum field 
isolate that binds intercellular adhesion molecule-1. Mol Biochem Parasit 133, 255-265. 
Chaves, L.F., Taleo, G., Kalkoa, M., and Kaneko, A. (2011). Spleen rates in children: an old 
and new surveillance tool for malaria elimination initiatives in island settings. T Roy Soc 
Trop Med H 105, 226-231. 
Chen, Q., Barragan, A., Fernandez, V., Sundstrom, A., Schlichtherle, M., Sahlen, A., Carlson, 
J., Datta, S., and Wahlgren, M. (1998). Identification of Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1) as the rosetting ligand of the malaria parasite P. 
falciparum. The Journal of experimental medicine 187, 15-23. 
Cheng, Q., Cloonan, N., Fischer, K., Thompson, J., Waine, G., Lanzer, M., and Saul, A. (1998). 
stevor and rif are Plasmodium falciparum multicopy gene families which potentially 
encode variant antigens. Mol Biochem Parasit 97, 161-176. 
Cheng, Q., and Saul, A. (1994). Sequence analysis of the apical membrane antigen I (AMA-1) 
of Plasmodium vivax. Mol Biochem Parasit 65, 183-187. 
Cockburn, I.A., Mackinnon, M.J., O'Donnell, A., Allen, S.J., Moulds, J.M., Baisor, M., 
Bockarie, M., Reeder, J.C., and Rowe, J.A. (2004). A human complement receptor 1 
polymorphism that reduces Plasmodium falciparum rosetting confers protection against 
severe malaria. P Natl Acad Sci USA 101, 272-277. 
Cohen, S., Butcher, G.A., and Crandall, R.B. (1969). Action of malarial antibody in vitro. 
Nature 223, 368-371.
  50 
Cohen, S., Mc, G.I., and Carrington, S. (1961). Gamma-globulin and acquired immunity to 
human malaria. Nature 192, 733-737. 
Collins, C.R., Withers-Martinez, C., Hackett, F., and Blackman, M.J. (2009). An inhibitory 
antibody blocks interactions between components of the malarial invasion machinery. 
PLoS pathogens 5, e1000273. 
Cooke, B.M., Berendt, A.R., Craig, A.G., MacGregor, J., Newbold, C.I., and Nash, G.B. 
(1994). Rolling and stationary cytoadhesion of red blood cells parasitized by Plasmodium 
falciparum: separate roles for ICAM-1, CD36 and thrombospondin. Brit J Haematol 87, 
162-170. 
Cooke, B.M., Buckingham, D.W., Glenister, F.K., Fernandez, K.M., Bannister, L.H., Marti, M., 
Mohandas, N., and Coppel, R.L. (2006). A Maurer's cleft-associated protein is essential for 
expression of the major malaria virulence antigen on the surface of infected red blood 
cells. The Journal of cell biology 172, 899-908. 
Cooke, B.M., Lingelbach, K., Bannister, L.H., and Tilley, L. (2004). Protein trafficking in 
Plasmodium falciparum-infected red blood cells. Trends in parasitology 20, 581-589. 
Corran, P.H., O'Donnell, R.A., Todd, J., Uthaipibull, C., Holder, A.A., Crabb, B.S., and Riley, 
E.M. (2004). The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton 
merozoite surface protein 1-specific antibodies is associated with resistance to malarial 
parasitemia in a cross-sectional survey in The Gambia. Infection and Immunity 72, 6185-
6189. 
Cortes, A., Mellombo, M., Masciantonio, R., Murphy, V.J., Reeder, J.C., and Anders, R.F. 
(2005). Allele specificity of naturally acquired antibody responses against Plasmodium 
falciparum apical membrane antigen 1. Infection and Immunity 73, 422-430. 
Cortes, A., Mellombo, M., Mueller, I., Benet, A., Reeder, J.C., and Anders, R.F. (2003). 
Geographical structure of diversity and differences between symptomatic and 
asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infection 
and Immunity 71, 1416-1426. 
Courtin, D., Oesterholt, M., Huismans, H., Kusi, K., Milet, J., Badaut, C., Gaye, O., Roeffen, 
W., Remarque, E.J., Sauerwein, R., et al. (2009). The quantity and quality of African 
children's IgG responses to merozoite surface antigens reflect protection against 
Plasmodium falciparum malaria. PLoS One 4, e7590. 
Cowman, A.F., and Crabb, B.S. (2006). Invasion of red blood cells by malaria parasites. Cell 
124, 755-766. 
Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, 
M.E., Brown, G.V., Coppel, R.L., and Cowman, A.F. (1997). Targeted gene disruption 
shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear 
stress. Cell 89, 287-296. 
Crawley, J., Smith, S., Kirkham, F., Muthinji, P., Waruiru, C., and Marsh, K. (1996). Seizures 
and status epilepticus in childhood cerebral malaria. QJM : monthly journal of the 
Association of Physicians 89, 591-597. 
Crawley, J., Smith, S., Muthinji, P., Marsh, K., and Kirkham, F. (2001). 
Electroencephalographic and clinical features of cerebral malaria. Archives of disease in 
childhood 84, 247-253. 
Creasey, A.M., Staalsoe, T., Raza, A., Arnot, D.E., and Rowe, J.A. (2003). Nonspecific 
immunoglobulin M binding and chondroitin sulfate A binding are linked phenotypes of 
Plasmodium falciparum isolates implicated in malaria during pregnancy. Infection and 
Immunity 71, 4767-4771. 
Crompton, P.D., Miura, K., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G., Doumbo, S., 
Doumtabe, D., Kone, Y., Huang, C.Y., et al. (2010). In vitro growth-inhibitory activity 
and malaria risk in a cohort study in mali. Infection and Immunity 78, 737-745. 
Crompton, P.D., Traore, B., Kayentao, K., Doumbo, S., Ongoiba, A., Diakite, S.A., Krause, 
M.A., Doumtabe, D., Kone, Y., Weiss, G., et al. (2008). Sickle cell trait is associated with 
a delayed onset of malaria: implications for time-to-event analysis in clinical studies of 
malaria. The Journal of infectious diseases 198, 1265-1275. 
Crosnier, C., Bustamante, L.Y., Bartholdson, S.J., Bei, A.K., Theron, M., Uchikawa, M., 
Mboup, S., Ndir, O., Kwiatkowski, D.P., Duraisingh, M.T., et al. (2011). Basigin is a 
  51 
receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534-
537. 
Culvenor, J.G., Langford, C.J., Crewther, P.E., Saint, R.B., Coppel, R.L., Kemp, D.J., Anders, 
R.F., and Brown, G.V. (1987). Plasmodium falciparum: identification and localization of a 
knob protein antigen expressed by a cDNA clone. Experimental parasitology 63, 58-67. 
Czajkowsky, D.M., Salanti, A., Ditlev, S.B., Shao, Z., Ghumra, A., Rowe, J.A., and Pleass, R.J. 
(2010). IgM, Fc mu Rs, and malarial immune evasion. Journal of immunology 184, 4597-
4603. 
Czajkowsky, D.M., and Shao, Z. (2009). The human IgM pentamer is a mushroom-shaped 
molecule with a flexural bias. P Natl Acad Sci USA 106, 14960-14965. 
Deans, J.A., Knight, A.M., Jean, W.C., Waters, A.P., Cohen, S., and Mitchell, G.H. (1988). 
Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD 
merozoite antigen. Parasite immunology 10, 535-552. 
Del Portillo, H.A., Ferrer, M., Brugat, T., Martin-Jaular, L., Langhorne, J., and Lacerda, M.V. 
(2012). The role of the spleen in malaria. Cellular microbiology 14, 343-355. 
Dent, A.E., Bergmann-Leitner, E.S., Wilson, D.W., Tisch, D.J., Kimmel, R., Vulule, J., Sumba, 
P.O., Beeson, J.G., Angov, E., Moormann, A.M., et al. (2008). Antibody-mediated growth 
inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia 
in Kenyan children and adults. PLoS One 3, e3557. 
Desai, S.A., Krogstad, D.J., and McCleskey, E.W. (1993). A nutrient-permeable channel on the 
intraerythrocytic malaria parasite. Nature 362, 643-646. 
DeSimone, T.M., Bei, A.K., Jennings, C.V., and Duraisingh, M.T. (2009). Genetic analysis of 
the cytoplasmic domain of the PfRh2b merozoite invasion protein of Plasmodium 
falciparum. International journal for parasitology 39, 399-405. 
Dicko, A., Sagara, I., Ellis, R.D., Miura, K., Guindo, O., Kamate, B., Sogoba, M., Niambele, 
M.B., Sissoko, M., Baby, M., et al. (2008). Phase 1 study of a combination AMA1 blood 
stage malaria vaccine in Malian children. PLoS One 3, e1563. 
Dinglasan, R.R., Armistead, J.S., Nyland, J.F., Jiang, X., and Mao, H.Q. (2013). Single-dose 
microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting 
functional antibody response. Current molecular medicine 13, 479-487. 
Dluzewski, A.R., Ling, I.T., Hopkins, J.M., Grainger, M., Margos, G., Mitchell, G.H., Holder, 
A.A., and Bannister, L.H. (2008). Formation of the food vacuole in Plasmodium 
falciparum: a potential role for the 19 kDa fragment of merozoite surface protein 1 
(MSP1(19)). PLoS One 3, e3085. 
Dobano, C., Quelhas, D., Quinto, L., Puyol, L., Serra-Casas, E., Mayor, A., Nhampossa, T., 
Macete, E., Aide, P., Mandomando, I., et al. (2012). Age-dependent IgG subclass 
responses to Plasmodium falciparum EBA-175 are differentially associated with incidence 
of malaria in Mozambican children. Clinical and vaccine immunology : CVI 19, 157-166. 
Dolan, S.A., Miller, L.H., and Wellems, T.E. (1990). Evidence for a switching mechanism in 
the invasion of erythrocytes by Plasmodium falciparum. The Journal of clinical 
investigation 86, 618-624. 
Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., Lwin, K.M., Ariey, F., 
Hanpithakpong, W., Lee, S.J., et al. (2009). Artemisinin resistance in Plasmodium 
falciparum malaria. The New England journal of medicine 361, 455-467. 
Doolan, D.L., Dobano, C., and Baird, J.K. (2009). Acquired immunity to malaria. Clinical 
microbiology reviews 22, 13-36, Table of Contents. 
Duarte, M.I., Corbett, C.E., Boulos, M., and Amato Neto, V. (1985). Ultrastructure of the lung 
in falciparum malaria. The American journal of tropical medicine and hygiene 34, 31-35. 
Duffy, P.E., and Fried, M. (2005). Malaria in the pregnant woman. Current topics in 
microbiology and immunology 295, 169-200. 
Duraisingh, M.T., Maier, A.G., Triglia, T., and Cowman, A.F. (2003a). Erythrocyte-binding 
antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent 
and -independent pathways. P Natl Acad Sci USA 100, 4796-4801. 
Duraisingh, M.T., Triglia, T., Ralph, S.A., Rayner, J.C., Barnwell, J.W., McFadden, G.I., and 
Cowman, A.F. (2003b). Phenotypic variation of Plasmodium falciparum merozoite 
proteins directs receptor targeting for invasion of human erythrocytes. The EMBO journal 
22, 1047-1057. 
  52 
Dutta, S., Kaushal, D.C., Ware, L.A., Puri, S.K., Kaushal, N.A., Narula, A., Upadhyaya, D.S., 
and Lanar, D.E. (2005). Merozoite surface protein 1 of Plasmodium vivax induces a 
protective response against Plasmodium cynomolgi challenge in rhesus monkeys. 
Infection and Immunity 73, 5936-5944. 
Dutta, S., Lalitha, P.V., Ware, L.A., Barbosa, A., Moch, J.K., Vassell, M.A., Fileta, B.B., 
Kitov, S., Kolodny, N., Heppner, D.G., et al. (2002). Purification, characterization, and 
immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical 
membrane antigen 1 expressed in Escherichia coli. Infection and Immunity 70, 3101-3110. 
Dutta, S., Malhotra, P., and Chauhan, V.S. (1995). Sequence analysis of apical membrane 
antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelli. Mol Biochem Parasit 73, 267-
270. 
Dvorak, J.A., Miller, L.H., Whitehouse, W.C., and Shiroishi, T. (1975). Invasion of 
erythrocytes by malaria merozoites. Science 187, 748-750. 
Dvorin, J.D., Bei, A.K., Coleman, B.I., and Duraisingh, M.T. (2010a). Functional 
diversification between two related Plasmodium falciparum merozoite invasion ligands is 
determined by changes in the cytoplasmic domain. Molecular microbiology 75, 990-1006. 
Dvorin, J.D., Martyn, D.C., Patel, S.D., Grimley, J.S., Collins, C.R., Hopp, C.S., Bright, A.T., 
Westenberger, S., Winzeler, E., Blackman, M.J., et al. (2010b). A plant-like kinase in 
Plasmodium falciparum regulates parasite egress from erythrocytes. Science 328, 910-912. 
Dzikowski, R., Frank, M., and Deitsch, K. (2006). Mutually exclusive expression of virulence 
genes by malaria parasites is regulated independently of antigen production. PLoS 
pathogens 2, e22. 
Egan, A.F., Morris, J., Barnish, G., Allen, S., Greenwood, B.M., Kaslow, D.C., Holder, A.A., 
and Riley, E.M. (1996). Clinical immunity to Plasmodium falciparum malaria is associated 
with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, 
PfMSP-1. The Journal of infectious diseases 173, 765-769. 
El Sahly, H.M., Patel, S.M., Atmar, R.L., Lanford, T.A., Dube, T., Thompson, D., Sim, B.K., 
Long, C., and Keitel, W.A. (2010). Safety and immunogenicity of a recombinant 
nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy 
adults living in an area where malaria is not endemic. Clinical and vaccine immunology : 
CVI 17, 1552-1559. 
Elmendorf, H.G., and Haldar, K. (1994). Plasmodium falciparum exports the Golgi marker 
sphingomyelin synthase into a tubovesicular network in the cytoplasm of mature 
erythrocytes. The Journal of cell biology 124, 449-462. 
English, M., Waruiru, C., Amukoye, E., Murphy, S., Crawley, J., Mwangi, I., Peshu, N., and 
Marsh, K. (1996). Deep breathing in children with severe malaria: indicator of metabolic 
acidosis and poor outcome. The American journal of tropical medicine and hygiene 55, 
521-524. 
Evans, K.J., Hansen, D.S., van Rooijen, N., Buckingham, L.A., and Schofield, L. (2006). 
Severe malarial anemia of low parasite burden in rodent models results from accelerated 
clearance of uninfected erythrocytes. Blood 107, 1192-1199. 
Fairhurst, R.M., Baruch, D.I., Brittain, N.J., Ostera, G.R., Wallach, J.S., Hoang, H.L., Hayton, 
K., Guindo, A., Makobongo, M.O., Schwartz, O.M., et al. (2005). Abnormal display of 
PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature 
435, 1117-1121. 
Faiz, M.A., Rahman, M.R., Hossain, M.A., and Rashid, H.A. (1998). Cerebral malaria--a study 
of 104 cases. Bangladesh Med Res Counc Bull 24, 35-42. 
Farnert, A., Williams, T.N., Mwangi, T.W., Ehlin, A., Fegan, G., Macharia, A., Lowe, B.S., 
Montgomery, S.M., and Marsh, K. (2009). Transmission-dependent tolerance to 
multiclonal Plasmodium falciparum infection. The Journal of infectious diseases 200, 
1166-1175. 
Felger, I., Tavul, L., Kabintik, S., Marshall, V., Genton, B., Alpers, M., and Beck, H.P. (1994). 
Plasmodium falciparum: extensive polymorphism in merozoite surface antigen 2 alleles in 
an area with endemic malaria in Papua New Guinea. Experimental parasitology 79, 106-
116. 
Fenton, B., Clark, J.T., Khan, C.M., Robinson, J.V., Walliker, D., Ridley, R., Scaife, J.G., and 
McBride, J.S. (1991). Structural and antigenic polymorphism of the 35- to 48-kilodalton 
  53 
merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. 
Molecular and Cellular Biology 11, 963-971. 
Ferreira, M.U., Ribeiro, W.L., Tonon, A.P., Kawamoto, F., and Rich, S.M. (2003). Sequence 
diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 
(MSP-1) of Plasmodium falciparum. Gene 304, 65-75. 
Fleming, A.F., Storey, J., Molineaux, L., Iroko, E.A., and Attai, E.D. (1979). Abnormal 
haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and 
relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasit 73, 
161-172. 
Flick, K., and Chen, Q. (2004). var genes, PfEMP1 and the human host. Mol Biochem Parasit 
134, 3-9. 
Flick, K., Scholander, C., Chen, Q., Fernandez, V., Pouvelle, B., Gysin, J., and Wahlgren, M. 
(2001). Role of nonimmune IgG bound to PfEMP1 in placental malaria. Science 293, 
2098-2100. 
Florens, L., Washburn, M.P., Raine, J.D., Anthony, R.M., Grainger, M., Haynes, J.D., Moch, 
J.K., Muster, N., Sacci, J.B., Tabb, D.L., et al. (2002). A proteomic view of the 
Plasmodium falciparum life cycle. Nature 419, 520-526. 
Flueck, C., Frank, G., Smith, T., Jafarshad, A., Nebie, I., Sirima, S.B., Olugbile, S., Alonso, P., 
Tanner, M., Druilhe, P., et al. (2009). Evaluation of two long synthetic merozoite surface 
protein 2 peptides as malaria vaccine candidates. Vaccine 27, 2653-2661. 
Ford, L., Lobo, C.A., Rodriguez, M., Zalis, M.G., Machado, R.L., Rossit, A.R., Cavasini, C.E., 
Couto, A.A., Enyong, P.A., and Lustigman, S. (2007). Differential antibody responses to 
Plasmodium falciparum invasion ligand proteins in individuals living in malaria-endemic 
areas in Brazil and Cameroon. The American journal of tropical medicine and hygiene 77, 
977-983. 
Fowkes, F.J., Richards, J.S., Simpson, J.A., and Beeson, J.G. (2010). The relationship between 
anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic 
review and meta-analysis. PLoS medicine 7, e1000218. 
Fraser, T.S., Kappe, S.H., Narum, D.L., VanBuskirk, K.M., and Adams, J.H. (2001). 
Erythrocyte-binding activity of Plasmodium yoelii apical membrane antigen-1 expressed 
on the surface of transfected COS-7 cells. Mol Biochem Parasit 117, 49-59. 
Freitas-Junior, L.H., Bottius, E., Pirrit, L.A., Deitsch, K.W., Scheidig, C., Guinet, F., Nehrbass, 
U., Wellems, T.E., and Scherf, A. (2000). Frequent ectopic recombination of virulence 
factor genes in telomeric chromosome clusters of P. falciparum. Nature 407, 1018-1022. 
Frevert, U., Engelmann, S., Zougbede, S., Stange, J., Ng, B., Matuschewski, K., Liebes, L., and 
Yee, H. (2005). Intravital observation of Plasmodium berghei sporozoite infection of the 
liver. PLoS biology 3, e192. 
Frevert, U., and Nardin, E. (2008). Cellular effector mechanisms against Plasmodium liver 
stages. Cellular microbiology 10, 1956-1967. 
Fried, M., and Duffy, P.E. (1996). Adherence of Plasmodium falciparum to chondroitin sulfate 
A in the human placenta. Science 272, 1502-1504. 
Fried, M., Nosten, F., Brockman, A., Brabin, B.J., and Duffy, P.E. (1998). Maternal antibodies 
block malaria. Nature 395, 851-852. 
Friedman, S., Back, B., Delivoria-Papadopoulos, M., Atwater, J., Asakura, T., and Schwartz, E. 
(1978). A simple test for detection of sickle hemoglobin in the neonatal period. American 
journal of clinical pathology 70, 85-88. 
Galinski, M.R., Medina, C.C., Ingravallo, P., and Barnwell, J.W. (1992). A reticulocyte-binding 
protein complex of Plasmodium vivax merozoites. Cell 69, 1213-1226. 
Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, 
A., Nelson, K.E., Bowman, S., et al. (2002). Genome sequence of the human malaria 
parasite Plasmodium falciparum. Nature 419, 498-511. 
Garraud, O., Mahanty, S., and Perraut, R. (2003). Malaria-specific antibody subclasses in 
immune individuals: a key source of information for vaccine design. Trends in 
immunology 24, 30-35. 
Gaur, D., and Chitnis, C.E. (2011). Molecular interactions and signaling mechanisms during 
erythrocyte invasion by malaria parasites. Current opinion in microbiology 14, 422-428. 
  54 
Gaur, D., Furuya, T., Mu, J., Jiang, L.B., Su, X.Z., and Miller, L.H. (2006). Upregulation of 
expression of the reticulocyte homology gene 4 in the Plasmodium falciparum clone Dd2 
is associated with a switch in the erythrocyte invasion pathway. Mol Biochem Parasit 145, 
205-215. 
Gaur, D., Storry, J.R., Reid, M.E., Barnwell, J.W., and Miller, L.H. (2003). Plasmodium 
falciparum is able to invade erythrocytes through a trypsin-resistant pathway independent 
of glycophorin B. Infection and Immunity 71, 6742-6746. 
Genton, B. (2008). Malaria vaccines: a toy for travelers or a tool for eradication? Expert review 
of vaccines 7, 597-611. 
Ghumra, A., Semblat, J.P., McIntosh, R.S., Raza, A., Rasmussen, I.B., Braathen, R., Johansen, 
F.E., Sandlie, I., Mongini, P.K., Rowe, J.A., et al. (2008). Identification of residues in the 
Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1). Journal of immunology 181, 1988-2000. 
Gilberger, T.W., Thompson, J.K., Reed, M.B., Good, R.T., and Cowman, A.F. (2003). The 
cytoplasmic domain of the Plasmodium falciparum ligand EBA-175 is essential for 
invasion but not protein trafficking. The Journal of cell biology 162, 317-327. 
Gilson, P.R., and Crabb, B.S. (2009). Morphology and kinetics of the three distinct phases of 
red blood cell invasion by Plasmodium falciparum merozoites. International journal for 
parasitology 39, 91-96. 
Gilson, P.R., O'Donnell, R.A., Nebl, T., Sanders, P.R., Wickham, M.E., McElwain, T.F., de 
Koning-Ward, T.F., and Crabb, B.S. (2008). MSP1(19) miniproteins can serve as targets 
for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the 
correct domains for cell surface trafficking. Molecular microbiology 68, 124-138. 
Glushakova, S., Yin, D., Li, T., and Zimmerberg, J. (2005). Membrane transformation during 
malaria parasite release from human red blood cells. Current biology : CB 15, 1645-1650. 
Goel, V.K., Li, X., Chen, H., Liu, S.C., Chishti, A.H., and Oh, S.S. (2003). Band 3 is a host 
receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion 
of erythrocytes. P Natl Acad Sci USA 100, 5164-5169. 
Goldberg, D.E., and Cowman, A.F. (2010). Moving in and renovating: exporting proteins from 
Plasmodium into host erythrocytes. Nature reviews Microbiology 8, 617-621. 
Gomez-Escobar, N., Amambua-Ngwa, A., Walther, M., Okebe, J., Ebonyi, A., and Conway, 
D.J. (2010). Erythrocyte invasion and merozoite ligand gene expression in severe and mild 
Plasmodium falciparum malaria. The Journal of infectious diseases 201, 444-452. 
Goodman, A.L., and Draper, S.J. (2010). Blood-stage malaria vaccines - recent progress and 
future challenges. Ann Trop Med Parasit 104, 189-211. 
Greenhouse, B., Ho, B., Hubbard, A., Njama-Meya, D., Narum, D.L., Lanar, D.E., Dutta, S., 
Rosenthal, P.J., Dorsey, G., and John, C.C. (2011). Antibodies to Plasmodium falciparum 
antigens predict a higher risk of malaria but protection from symptoms once parasitemic. 
The Journal of infectious diseases 204, 19-26. 
Gupta, S., Snow, R.W., Donnelly, C., and Newbold, C. (1999a). Acquired immunity and 
postnatal clinical protection in childhood cerebral malaria. Proceedings Biological sciences 
/ The Royal Society 266, 33-38. 
Gupta, S., Snow, R.W., Donnelly, C.A., Marsh, K., and Newbold, C. (1999b). Immunity to 
non-cerebral severe malaria is acquired after one or two infections. Nature Medicine 5, 
340-343. 
Haase, S., and de Koning-Ward, T.F. (2010). New insights into protein export in malaria 
parasites. Cellular microbiology 12, 580-587. 
Haeggstrom, M., Kironde, F., Berzins, K., Chen, Q., Wahlgren, M., and Fernandez, V. (2004). 
Common trafficking pathway for variant antigens destined for the surface of the 
Plasmodium falciparum-infected erythrocyte. Mol Biochem Parasit 133, 1-14. 
Hanspal, M., Goel, V.K., Oh, S.S., and Chishti, A.H. (2002). Erythrocyte calpain is dispensable 
for malaria parasite invasion and growth. Mol Biochem Parasit 122, 227-229. 
Harris, P.K., Yeoh, S., Dluzewski, A.R., O'Donnell, R.A., Withers-Martinez, C., Hackett, F., 
Bannister, L.H., Mitchell, G.H., and Blackman, M.J. (2005). Molecular identification of a 
malaria merozoite surface sheddase. PLoS pathogens 1, 241-251. 
Hasler, T., Handunnetti, S.M., Aguiar, J.C., van Schravendijk, M.R., Greenwood, B.M., 
Lallinger, G., Cegielski, P., and Howard, R.J. (1990). In vitro rosetting, cytoadherence, 
  55 
and microagglutination properties of Plasmodium falciparum-infected erythrocytes from 
Gambian and Tanzanian patients. Blood 76, 1845-1852. 
Hay, S.I., Okiro, E.A., Gething, P.W., Patil, A.P., Tatem, A.J., Guerra, C.A., and Snow, R.W. 
(2010). Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. 
PLoS medicine 7, e1000290. 
Healer, J., Crawford, S., Ralph, S., McFadden, G., and Cowman, A.F. (2002). Independent 
translocation of two micronemal proteins in developing Plasmodium falciparum 
merozoites. Infection and Immunity 70, 5751-5758. 
Healer, J., Murphy, V., Hodder, A.N., Masciantonio, R., Gemmill, A.W., Anders, R.F., 
Cowman, A.F., and Batchelor, A. (2004). Allelic polymorphisms in apical membrane 
antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium 
falciparum. Molecular microbiology 52, 159-168. 
Hearty, S., Conroy, P.J., Ayyar, B.V., Byrne, B., and O'Kennedy, R. (2010). Surface plasmon 
resonance for vaccine design and efficacy studies: recent applications and future trends. 
Expert review of vaccines 9, 645-664. 
Heddini, A., Keusch, G.T., and Davies, C.S. (2004). The multilateral initiative on malaria: past, 
present, and future. The American journal of tropical medicine and hygiene 71, 279-282. 
Heddini, A., Pettersson, F., Kai, O., Shafi, J., Obiero, J., Chen, Q., Barragan, A., Wahlgren, M., 
and Marsh, K. (2001). Fresh isolates from children with severe Plasmodium falciparum 
malaria bind to multiple receptors. Infection and Immunity 69, 5849-5856. 
Hiller, N.L., Bhattacharjee, S., van Ooij, C., Liolios, K., Harrison, T., Lopez-Estrano, C., and 
Haldar, K. (2004). A host-targeting signal in virulence proteins reveals a secretome in 
malarial infection. Science 306, 1934-1937. 
Hodder, A.N., Crewther, P.E., and Anders, R.F. (2001). Specificity of the protective antibody 
response to apical membrane antigen 1. Infection and Immunity 69, 3286-3294. 
Hodder, A.N., Drew, D.R., Epa, V.C., Delorenzi, M., Bourgon, R., Miller, S.K., Moritz, R.L., 
Frecklington, D.F., Simpson, R.J., Speed, T.P., et al. (2003). Enzymic, phylogenetic, and 
structural characterization of the unusual papain-like protease domain of Plasmodium 
falciparum SERA5. The Journal of biological chemistry 278, 48169-48177. 
Hoffmann, E.H., da Silveira, L.A., Tonhosolo, R., Pereira, F.J., Ribeiro, W.L., Tonon, A.P., 
Kawamoto, F., and Ferreira, M.U. (2001). Geographical patterns of allelic diversity in the 
Plasmodium falciparum malaria-vaccine candidate, merozoite surface protein-2. Ann Trop 
Med Parasit 95, 117-132. 
Holder, A.A. (1988). The precursor to major merozoite surface antigens: structure and role in 
immunity. Prog Allergy 41, 72-97. 
Holder, A.A., Blackman, M.J., Burghaus, P.A., Chappel, J.A., Ling, I.T., McCallum-Deighton, 
N., and Shai, S. (1992). A malaria merozoite surface protein (MSP1)-structure, processing 
and function. Mem I Oswaldo Cruz 87 Suppl 3, 37-42. 
Holder, A.A., and Freeman, R.R. (1981). Immunization against blood-stage rodent malaria 
using purified parasite antigens. Nature 294, 361-364. 
Holder, A.A., and Freeman, R.R. (1982). Biosynthesis and processing of a Plasmodium 
falciparum schizont antigen recognized by immune serum and a monoclonal antibody. The 
Journal of experimental medicine 156, 1528-1538. 
Hommel, M., David, P.H., and Oligino, L.D. (1983). Surface alterations of erythrocytes in 
Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of 
the spleen. The Journal of experimental medicine 157, 1137-1148. 
Hoyer, L.L. (2001). The ALS gene family of Candida albicans. Trends in microbiology 9, 176-
180. 
Hunt, N.H., and Grau, G.E. (2003). Cytokines: accelerators and brakes in the pathogenesis of 
cerebral malaria. Trends in immunology 24, 491-499. 
Idro, R., Karamagi, C., and Tumwine, J. (2004). Immediate outcome and prognostic factors for 
cerebral malaria among children admitted to Mulago Hospital, Uganda. Annals of tropical 
paediatrics 24, 17-24. 
Ingram, V.M. (1957). Gene mutations in human haemoglobin: the chemical difference between 
normal and sickle cell haemoglobin. Nature 180, 326-328. 
Iriemenam, N.C., Khirelsied, A.H., Nasr, A., ElGhazali, G., Giha, H.A., Elhassan, A.E.T.M., 
Agab-Aldour, A.A., Montgomery, S.M., Anders, R.F., Theisen, M., et al. (2009). 
  56 
Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in 
relation to clinical disease outcome in Sudan. Vaccine 27, 62-71. 
Ismail, M.R., Ordi, J., Menendez, C., Ventura, P.J., Aponte, J.J., Kahigwa, E., Hirt, R., Cardesa, 
A., and Alonso, P.L. (2000). Placental pathology in malaria: a histological, 
immunohistochemical, and quantitative study. Hum Pathol 31, 85-93. 
Jakeman, G.N., Saul, A., Hogarth, W.L., and Collins, W.E. (1999). Anaemia of acute malaria 
infections in non-immune patients primarily results from destruction of uninfected 
erythrocytes. Parasitology 119 ( Pt 2), 127-133. 
Jallow, M., Teo, Y.Y., Small, K.S., Rockett, K.A., Deloukas, P., Clark, T.G., Kivinen, K., 
Bojang, K.A., Conway, D.J., Pinder, M., et al. (2009). Genome-wide and fine-resolution 
association analysis of malaria in West Africa. Nature genetics 41, 657-665. 
Jensen, A.T., Magistrado, P., Sharp, S., Joergensen, L., Lavstsen, T., Chiucchiuini, A., Salanti, 
A., Vestergaard, L.S., Lusingu, J.P., Hermsen, R., et al. (2004). Plasmodium falciparum 
associated with severe childhood malaria preferentially expresses PfEMP1 encoded by 
group A var genes. The Journal of experimental medicine 199, 1179-1190. 
Jiang, G., Daubenberger, C., Huber, W., Matile, H., Tanner, M., and Pluschke, G. (2000). 
Sequence diversity of the merozoite surface protein 1 of Plasmodium falciparum in clinical 
isolates from the Kilombero District, Tanzania. Acta tropica 74, 51-61. 
Joannin, N., Abhiman, S., Sonnhammer, E.L., and Wahlgren, M. (2008). Sub-grouping and 
sub-functionalization of the RIFIN multi-copy protein family. BMC Genomics 9, 19. 
John, C.C., Moormann, A.M., Pregibon, D.C., Sumba, P.O., McHugh, M.M., Narum, D.L., 
Lanar, D.E., Schluchter, M.D., and Kazura, J.W. (2005). Correlation of high levels of 
antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection 
from infection. The American journal of tropical medicine and hygiene 73, 222-228. 
John, C.C., O'Donnell, R.A., Sumba, P.O., Moormann, A.M., de Koning-Ward, T.F., King, 
C.L., Kazura, J.W., and Crabb, B.S. (2004). Evidence that invasion-inhibitory antibodies 
specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a 
protective role against blood-stage Plasmodium falciparum infection in individuals in a 
malaria endemic area of Africa. Journal of immunology 173, 666-672. 
Kappe, S.H., Buscaglia, C.A., and Nussenzweig, V. (2004). Plasmodium sporozoite molecular 
cell biology. Annu Rev Cell Dev Biol 20, 29-59. 
Kappe, S.H., Vaughan, A.M., Boddey, J.A., and Cowman, A.F. (2010). That was then but this 
is now: malaria research in the time of an eradication agenda. Science 328, 862-866. 
Kappes, B., Doerig, C.D., and Graeser, R. (1999). An overview of Plasmodium protein kinases. 
Parasitology today 15, 449-454. 
Kato, K., Mayer, D.C., Singh, S., Reid, M., and Miller, L.H. (2005). Domain III of Plasmodium 
falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. P 
Natl Acad Sci USA 102, 5552-5557. 
Kaviratne, M., Khan, S.M., Jarra, W., and Preiser, P.R. (2002). Small variant STEVOR antigen 
is uniquely located within Maurer's clefts in Plasmodium falciparum-infected red blood 
cells. Eukaryotic cell 1, 926-935. 
Keh, C.E., Jha, A.R., Nzarubara, B., Lanar, D.E., Dutta, S., Theisen, M., Rosenthal, P.J., 
Dorsey, G., Nixon, D.F., and Greenhouse, B. (2012). Associations between antibodies to a 
panel of Plasmodium falciparum specific antigens and response to sub-optimal 
antimalarial therapy in Kampala, Uganda. PLoS One 7, e52571. 
Kern, P., Hemmer, C.J., Van Damme, J., Gruss, H.J., and Dietrich, M. (1989). Elevated tumor 
necrosis factor alpha and interleukin-6 serum levels as markers for complicated 
Plasmodium falciparum malaria. The American journal of medicine 87, 139-143. 
Kester, K.E., Cummings, J.F., Ofori-Anyinam, O., Ockenhouse, C.F., Krzych, U., Moris, P., 
Schwenk, R., Nielsen, R.A., Debebe, Z., Pinelis, E., et al. (2009). Randomized, double-
blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in 
malaria-naive adults: safety, efficacy, and immunologic associates of protection. The 
Journal of infectious diseases 200, 337-346. 
Khattab, A., and Klinkert, M.Q. (2006). Maurer's clefts-restricted localization, orientation and 
export of a Plasmodium falciparum RIFIN. Traffic 7, 1654-1665. 
Khattab, A., and Meri, S. (2011). Exposure of the Plasmodium falciparum clonally variant 
STEVOR proteins on the merozoite surface. Malaria J 10, 58. 
  57 
Kilejian, A., Rashid, M.A., Aikawa, M., Aji, T., and Yang, Y.F. (1991). Selective association of 
a fragment of the knob protein with spectrin, actin and the red cell membrane. Mol 
Biochem Parasit 44, 175-181. 
Kinyanjui, S.M., Bull, P., Newbold, C.I., and Marsh, K. (2003). Kinetics of antibody responses 
to Plasmodium falciparum-infected erythrocyte variant surface antigens. The Journal of 
infectious diseases 187, 667-674. 
Kiwuwa, M.S., Ribacke, U., Moll, K., Byarugaba, J., Lundblom, K., Farnert, A., Fred, K., and 
Wahlgren, M. (2013). Genetic diversity of Plasmodium falciparum infections in mild and 
severe malaria of children from Kampala, Uganda. Parasitology research 112, 1691-1700. 
Knuepfer, E., Rug, M., Klonis, N., Tilley, L., and Cowman, A.F. (2005). Trafficking of the 
major virulence factor to the surface of transfected P. falciparum-infected erythrocytes. 
Blood 105, 4078-4087. 
Kochar, D.K., Shubhakaran, Kumawat, B.L., Kochar, S.K., Halwai, M., Makkar, R.K., Joshi, 
A., and Thanvi, I. (2002). Cerebral malaria in Indian adults: a prospective study of 441 
patients from Bikaner, north-west India. The Journal of the Association of Physicians of 
India 50, 234-241. 
Kocken, C.H., Withers-Martinez, C., Dubbeld, M.A., van der Wel, A., Hackett, F., Valderrama, 
A., Blackman, M.J., and Thomas, A.W. (2002). High-level expression of the malaria 
blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and 
induction of antibodies that inhibit erythrocyte invasion. Infection and Immunity 70, 4471-
4476. 
Kraemer, S.M., Kyes, S.A., Aggarwal, G., Springer, A.L., Nelson, S.O., Christodoulou, Z., 
Smith, L.M., Wang, W., Levin, E., Newbold, C.I., et al. (2007). Patterns of gene 
recombination shape var gene repertoires in Plasmodium falciparum: comparisons of 
geographically diverse isolates. BMC Genomics 8, 45. 
Kriek, N., Tilley, L., Horrocks, P., Pinches, R., Elford, B.C., Ferguson, D.J., Lingelbach, K., 
and Newbold, C.I. (2003). Characterization of the pathway for transport of the 
cytoadherence-mediating protein, PfEMP1, to the host cell surface in malaria parasite-
infected erythrocytes. Molecular microbiology 50, 1215-1227. 
Krych-Goldberg, M., Moulds, J.M., and Atkinson, J.P. (2002). Human complement receptor 
type 1 (CR1) binds to a major malarial adhesin. Trends in molecular medicine 8, 531-537. 
Kusi, K.A., Faber, B.W., Thomas, A.W., and Remarque, E.J. (2009). Humoral immune 
response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad 
specificity. PLoS One 4, e8110. 
Kwiatkowski, D. (1990). Tumour necrosis factor, fever and fatality in falciparum malaria. 
Immunology letters 25, 213-216. 
Kyes, S.A., Rowe, J.A., Kriek, N., and Newbold, C.I. (1999). Rifins: a second family of 
clonally variant proteins expressed on the surface of red cells infected with Plasmodium 
falciparum. P Natl Acad Sci USA 96, 9333-9338. 
Lamikanra, A.A., Brown, D., Potocnik, A., Casals-Pascual, C., Langhorne, J., and Roberts, D.J. 
(2007). Malarial anemia: of mice and men. Blood 110, 18-28. 
Lamikanra, A.A., Theron, M., Kooij, T.W., and Roberts, D.J. (2009). Hemozoin (malarial 
pigment) directly promotes apoptosis of erythroid precursors. PLoS One 4, e8446. 
Langhorne, J., Ndungu, F.M., Sponaas, A.M., and Marsh, K. (2008). Immunity to malaria: 
more questions than answers. Nature immunology 9, 725-732. 
Langreth, S.G., Jensen, J.B., Reese, R.T., and Trager, W. (1978). Fine structure of human 
malaria in vitro. The Journal of protozoology 25, 443-452. 
Lanzillotti, R., and Coetzer, T.L. (2004). Myosin-like sequences in the malaria parasite 
Plasmodium falciparum bind human erythrocyte membrane protein 4.1. Haematologica 
89, 1168-1171. 
Lauer, S.A., Rathod, P.K., Ghori, N., and Haldar, K. (1997). A membrane network for nutrient 
import in red cells infected with the malaria parasite. Science 276, 1122-1125. 
Lauterbach, S.B., Lanzillotti, R., and Coetzer, T.L. (2003). Construction and use of 
Plasmodium falciparum phage display libraries to identify host parasite interactions. 
Malaria J 2, 47. 
  58 
Lavazec, C., Sanyal, S., and Templeton, T.J. (2006). Hypervariability within the Rifin, Stevor 
and Pfmc-2TM superfamilies in Plasmodium falciparum. Nucleic acids research 34, 6696-
6707. 
Lavstsen, T., Salanti, A., Jensen, A.T., Arnot, D.E., and Theander, T.G. (2003). Sub-grouping 
of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-
coding regions. Malaria J 2, 27. 
Lawson, C., and Wolf, S. (2009). ICAM-1 signaling in endothelial cells. Pharmacol Rep 61, 22-
32. 
Lell, B., May, J., Schmidt-Ott, R.J., Lehman, L.G., Luckner, D., Greve, B., Matousek, P., 
Schmid, D., Herbich, K., Mockenhaupt, F.P., et al. (1999). The role of red blood cell 
polymorphisms in resistance and susceptibility to malaria. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 28, 794-799. 
Leoratti, F.M., Durlacher, R.R., Lacerda, M.V., Alecrim, M.G., Ferreira, A.W., Sanchez, M.C., 
and Moraes, S.L. (2008). Pattern of humoral immune response to Plasmodium falciparum 
blood stages in individuals presenting different clinical expressions of malaria. Malaria J 7, 
186. 
Lew, V.L., and Tiffert, T. (2007). Is invasion efficiency in malaria controlled by pre-invasion 
events? Trends in parasitology 23, 481-484. 
Li, X., Chen, H., Oo, T.H., Daly, T.M., Bergman, L.W., Liu, S.C., Chishti, A.H., and Oh, S.S. 
(2004). A co-ligand complex anchors Plasmodium falciparum merozoites to the 
erythrocyte invasion receptor band 3. The Journal of biological chemistry 279, 5765-5771. 
Lopaticki, S., Maier, A.G., Thompson, J., Wilson, D.W., Tham, W.H., Triglia, T., Gout, A., 
Speed, T.P., Beeson, J.G., Healer, J., et al. (2011). Reticulocyte and erythrocyte binding-
like proteins function cooperatively in invasion of human erythrocytes by malaria 
parasites. Infection and Immunity 79, 1107-1117. 
Loscertales, M.P., Owens, S., O'Donnell, J., Bunn, J., Bosch-Capblanch, X., and Brabin, B.J. 
(2007). ABO blood group phenotypes and Plasmodium falciparum malaria: unlocking a 
pivotal mechanism. Advances in parasitology 65, 1-50. 
Maier, A.G., Baum, J., Smith, B., Conway, D.J., and Cowman, A.F. (2009a). Polymorphisms in 
erythrocyte binding antigens 140 and 181 affect function and binding but not receptor 
specificity in Plasmodium falciparum. Infection and Immunity 77, 1689-1699. 
Maier, A.G., Cooke, B.M., Cowman, A.F., and Tilley, L. (2009b). Malaria parasite proteins that 
remodel the host erythrocyte. Nature reviews Microbiology 7, 341-354. 
Maier, A.G., Duraisingh, M.T., Reeder, J.C., Patel, S.S., Kazura, J.W., Zimmerman, P.A., and 
Cowman, A.F. (2003). Plasmodium falciparum erythrocyte invasion through glycophorin 
C and selection for Gerbich negativity in human populations. Nature Medicine 9, 87-92. 
Maier, A.G., Rug, M., O'Neill, M.T., Beeson, J.G., Marti, M., Reeder, J., and Cowman, A.F. 
(2007). Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to 
traffic PfEMP1 to the Plasmodium falciparum-infected erythrocyte surface. Blood 109, 
1289-1297. 
Malaney, P., Spielman, A., and Sachs, J. (2004). The malaria gap. The American journal of 
tropical medicine and hygiene 71, 141-146. 
Malkin, E., Hu, J., Li, Z., Chen, Z., Bi, X., Reed, Z., Dubovsky, F., Liu, J., Wang, Q., Pan, X., 
et al. (2008). A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein 
vaccine for Plasmodium falciparum malaria. Vaccine 26, 6864-6873. 
Marsh, K., Forster, D., Waruiru, C., Mwangi, I., Winstanley, M., Marsh, V., Newton, C., 
Winstanley, P., Warn, P., Peshu, N., et al. (1995). Indicators of life-threatening malaria in 
African children. The New England journal of medicine 332, 1399-1404. 
Marsh, K., and Kinyanjui, S. (2006). Immune effector mechanisms in malaria. Parasite 
immunology 28, 51-60. 
Marshall, V.M., Peterson, M.G., Lew, A.M., and Kemp, D.J. (1989). Structure of the apical 
membrane antigen I (AMA-1) of Plasmodium chabaudi. Mol Biochem Parasit 37, 281-
283. 
Marti, M., Good, R.T., Rug, M., Knuepfer, E., and Cowman, A.F. (2004). Targeting malaria 
virulence and remodeling proteins to the host erythrocyte. Science 306, 1930-1933. 
Martiney, J.A., Sherry, B., Metz, C.N., Espinoza, M., Ferrer, A.S., Calandra, T., Broxmeyer, 
H.E., and Bucala, R. (2000). Macrophage migration inhibitory factor release by 
  59 
macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role 
in the pathogenesis of malarial anemia. Infection and Immunity 68, 2259-2267. 
Maubert, B., Fievet, N., Tami, G., Boudin, C., and Deloron, P. (2000). Cytoadherence of 
Plasmodium falciparum-infected erythrocytes in the human placenta. Parasite immunology 
22, 191-199. 
May, J., Evans, J.A., Timmann, C., Ehmen, C., Busch, W., Thye, T., Agbenyega, T., and 
Horstmann, R.D. (2007). Hemoglobin variants and disease manifestations in severe 
falciparum malaria. JAMA : the journal of the American Medical Association 297, 2220-
2226. 
Mayer, D.C., Jiang, L., Achur, R.N., Kakizaki, I., Gowda, D.C., and Miller, L.H. (2006). The 
glycophorin C N-linked glycan is a critical component of the ligand for the Plasmodium 
falciparum erythrocyte receptor BAEBL. P Natl Acad Sci USA 103, 2358-2362. 
Mayer, D.C., Mu, J.B., Feng, X., Su, X.Z., and Miller, L.H. (2002). Polymorphism in a 
Plasmodium falciparum erythrocyte-binding ligand changes its receptor specificity. The 
Journal of experimental medicine 196, 1523-1528. 
Mayer, D.C., Mu, J.B., Kaneko, O., Duan, J., Su, X.Z., and Miller, L.H. (2004). Polymorphism 
in the Plasmodium falciparum erythrocyte-binding ligand JESEBL/EBA-181 alters its 
receptor specificity. P Natl Acad Sci USA 101, 2518-2523. 
McCallum, F.J., Persson, K.E., Mugyenyi, C.K., Fowkes, F.J., Simpson, J.A., Richards, J.S., 
Williams, T.N., Marsh, K., and Beeson, J.G. (2008). Acquisition of growth-inhibitory 
antibodies against blood-stage Plasmodium falciparum. PLoS One 3, e3571. 
McCarra, M.B., Ayodo, G., Sumba, P.O., Kazura, J.W., Moormann, A.M., Narum, D.L., and 
John, C.C. (2011). Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 
are associated with protection from clinical malaria. The Pediatric infectious disease 
journal 30, 1037-1042. 
McGregor, I.A., Williams, K., and Goodwin, L.G. (1963). Pyrimethamine and Sulphadiazine in 
Treatment of Malaria. Brit Med J 2, 728-729. 
McIntosh, R.S., Shi, J., Jennings, R.M., Chappel, J.C., de Koning-Ward, T.F., Smith, T., Green, 
J., van Egmond, M., Leusen, J.H., Lazarou, M., et al. (2007). The importance of human 
FcgammaRI in mediating protection to malaria. PLoS pathogens 3, e72. 
Metzger, W.G., Okenu, D.M., Cavanagh, D.R., Robinson, J.V., Bojang, K.A., Weiss, H.A., 
McBride, J.S., Greenwood, B.M., and Conway, D.J. (2003). Serum IgG3 to the 
Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced 
prospective risk of malaria. Parasite immunology 25, 307-312. 
Miller, L.H., Ackerman, H.C., Su, X.Z., and Wellems, T.E. (2013). Malaria biology and disease 
pathogenesis: insights for new treatments. Nature Medicine 19, 156-167. 
Miller, L.H., Baruch, D.I., Marsh, K., and Doumbo, O.K. (2002a). The pathogenic basis of 
malaria. Nature 415, 673-679. 
Miller, L.H., McAuliffe, F.M., and Mason, S.J. (1977). Erythrocyte receptors for malaria 
merozoites. The American journal of tropical medicine and hygiene 26, 204-208. 
Miller, L.H., Roberts, T., Shahabuddin, M., and McCutchan, T.F. (1993). Analysis of sequence 
diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol 
Biochem Parasit 59, 1-14. 
Miller, S.K., Good, R.T., Drew, D.R., Delorenzi, M., Sanders, P.R., Hodder, A.N., Speed, T.P., 
Cowman, A.F., de Koning-Ward, T.F., and Crabb, B.S. (2002b). A subset of Plasmodium 
falciparum SERA genes are expressed and appear to play an important role in the 
erythrocytic cycle. The Journal of biological chemistry 277, 47524-47532. 
Mital, J., Meissner, M., Soldati, D., and Ward, G.E. (2005). Conditional expression of 
Toxoplasma gondii apical membrane antigen-1 (TgAMA1) demonstrates that TgAMA1 
plays a critical role in host cell invasion. Molecular biology of the cell 16, 4341-4349. 
Mitchell, G.H., Hadley, T.J., McGinniss, M.H., Klotz, F.W., and Miller, L.H. (1986). Invasion 
of erythrocytes by Plasmodium falciparum malaria parasites: evidence for receptor 
heterogeneity and two receptors. Blood 67, 1519-1521. 
Mitchell, G.H., Thomas, A.W., Margos, G., Dluzewski, A.R., and Bannister, L.H. (2004). 
Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close 
attachment of invasive merozoites to host red blood cells. Infection and Immunity 72, 154-
158. 
  60 
Moll K, L.I., Perlmann H, Scherf A & Wahlgren M (Eds.) (2008). Methods in Malaria 
Research, 5th edn. 
Molyneux, M.E., Taylor, T.E., Wirima, J.J., and Borgstein, A. (1989). Clinical features and 
prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian 
children. The Quarterly journal of medicine 71, 441-459. 
Molyneux, M.E., Taylor, T.E., Wirima, J.J., and Grau, G.E. (1991). Tumour necrosis factor, 
interleukin-6, and malaria. Lancet 337, 1098. 
Mota, M.M., Hafalla, J.C., and Rodriguez, A. (2002). Migration through host cells activates 
Plasmodium sporozoites for infection. Nature Medicine 8, 1318-1322. 
Mota, M.M., Pradel, G., Vanderberg, J.P., Hafalla, J.C., Frevert, U., Nussenzweig, R.S., 
Nussenzweig, V., and Rodriguez, A. (2001). Migration of Plasmodium sporozoites 
through cells before infection. Science 291, 141-144. 
Mphande, F.A., Ribacke, U., Kaneko, O., Kironde, F., Winter, G., and Wahlgren, M. (2008). 
SURFIN4.1, a schizont-merozoite associated protein in the SURFIN family of 
Plasmodium falciparum. Malaria J 7, 116. 
Mugyenyi, C.K., Elliott, S.R., McCallum, F.J., Anders, R.F., Marsh, K., and Beeson, J.G. 
(2013). Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of 
Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS One 8, 
e68304. 
Murphy, S.C., and Breman, J.G. (2001). Gaps in the childhood malaria burden in Africa: 
cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and 
complications of pregnancy. The American journal of tropical medicine and hygiene 64, 
57-67. 
Murray, P.R., Rosenthal K.S., Pfaller M.A. (2009). Medical Microbiology, Sixth edition edn 
(Philadelphia, PA, Mosby Elsevier). 
Nair, M., Hinds, M.G., Coley, A.M., Hodder, A.N., Foley, M., Anders, R.F., and Norton, R.S. 
(2002). Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium 
falciparum apical membrane antigen 1 (AMA1). Journal of molecular biology 322, 741-
753. 
Narum, D.L., Ogun, S.A., Batchelor, A.H., and Holder, A.A. (2006). Passive immunization 
with a multicomponent vaccine against conserved domains of apical membrane antigen 1 
and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage 
challenge infection. Infection and Immunity 74, 5529-5536. 
Narum, D.L., and Thomas, A.W. (1994). Differential localization of full-length and processed 
forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum 
merozoites. Mol Biochem Parasit 67, 59-68. 
Nasr, A., Iriemenam, N.C., Giha, H.A., Balogun, H.A., Anders, R.F., Troye-Blomberg, M., 
ElGhazali, G., and Berzins, K. (2009). FcgammaRIIa (CD32) polymorphism and anti-
malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern 
Sudan. Malaria J 8, 43. 
Nery, S., Deans, A.M., Mosobo, M., Marsh, K., Rowe, J.A., and Conway, D.J. (2006). 
Expression of Plasmodium falciparum genes involved in erythrocyte invasion varies 
among isolates cultured directly from patients. Mol Biochem Parasit 149, 208-215. 
Newbold, C., Warn, P., Black, G., Berendt, A., Craig, A., Snow, B., Msobo, M., Peshu, N., and 
Marsh, K. (1997). Receptor-specific adhesion and clinical disease in Plasmodium 
falciparum. The American journal of tropical medicine and hygiene 57, 389-398. 
Newton, C.R., Hien, T.T., and White, N. (2000). Cerebral malaria. Journal of neurology, 
neurosurgery, and psychiatry 69, 433-441. 
Ngoungou, E.B., and Preux, P.M. (2008). Cerebral malaria and epilepsy. Epilepsia 49 Suppl 6, 
19-24. 
Niang, M., Yan Yam, X., and Preiser, P.R. (2009). The Plasmodium falciparum STEVOR 
multigene family mediates antigenic variation of the infected erythrocyte. PLoS pathogens 
5, e1000307. 
Nimmerjahn, F., and Ravetch, J.V. (2008). Anti-inflammatory actions of intravenous 
immunoglobulin. Annual review of immunology 26, 513-533. 
Noland, G.S., Hendel-Paterson, B., Min, X.M., Moormann, A.M., Vulule, J.M., Narum, D.L., 
Lanar, D.E., Kazura, J.W., and John, C.C. (2008). Low prevalence of antibodies to 
  61 
preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable 
malaria transmission compared to prevalence in an area of stable malaria transmission. 
Infection and Immunity 76, 5721-5728. 
Normark, J., Nilsson, D., Ribacke, U., Winter, G., Moll, K., Wheelock, C.E., Bayarugaba, J., 
Kironde, F., Egwang, T.G., Chen, Q., et al. (2007). PfEMP1-DBL1alpha amino acid 
motifs in severe disease states of Plasmodium falciparum malaria. P Natl Acad Sci USA 
104, 15835-15840. 
Noutcha, M.A., and Anumdu, C.I. (2009). Entomological indices of Anopheles gambiae sensu 
lato at a rural community in south-west Nigeria. J Vector Dis 46, 43-51. 
Ntoumi, F., Contamin, H., Rogier, C., Bonnefoy, S., Trape, J.F., and Mercereau-Puijalon, O. 
(1995). Age-dependent carriage of multiple Plasmodium falciparum merozoite surface 
antigen-2 alleles in asymptomatic malaria infections. The American journal of tropical 
medicine and hygiene 52, 81-88. 
Ochola, L.B., Siddondo, B.R., Ocholla, H., Nkya, S., Kimani, E.N., Williams, T.N., Makale, 
J.O., Liljander, A., Urban, B.C., Bull, P.C., et al. (2011). Specific receptor usage in 
Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS One 6, 
e14741. 
Ockenhouse, C.F., Klotz, F.W., Tandon, N.N., and Jamieson, G.A. (1991). Sequestrin, a CD36 
recognition protein on Plasmodium falciparum malaria-infected erythrocytes identified by 
anti-idiotype antibodies. P Natl Acad Sci USA 88, 3175-3179. 
Ogutu, B.R., Apollo, O.J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., 
Waitumbi, J.N., Diggs, C., Wittes, J., et al. (2009). Blood stage malaria vaccine eliciting 
high antigen-specific antibody concentrations confers no protection to young children in 
Western Kenya. PLoS One 4, e4708. 
Oh, S.S., Voigt, S., Fisher, D., Yi, S.J., LeRoy, P.J., Derick, L.H., Liu, S., and Chishti, A.H. 
(2000). Plasmodium falciparum erythrocyte membrane protein 1 is anchored to the actin-
spectrin junction and knob-associated histidine-rich protein in the erythrocyte skeleton. 
Mol Biochem Parasit 108, 237-247. 
Okello, P.E., Van Bortel, W., Byaruhanga, A.M., Correwyn, A., Roelants, P., Talisuna, A., 
D'Alessandro, U., and Coosemans, M. (2006). Variation in malaria transmission intensity 
in seven sites throughout Uganda. The American journal of tropical medicine and hygiene 
75, 219-225. 
Okenu, D.M., Riley, E.M., Bickle, Q.D., Agomo, P.U., Barbosa, A., Daugherty, J.R., Lanar, 
D.E., and Conway, D.J. (2000). Analysis of human antibodies to erythrocyte binding 
antigen 175 of Plasmodium falciparum. Infection and Immunity 68, 5559-5566. 
Olotu, A., Lusingu, J., Leach, A., Lievens, M., Vekemans, J., Msham, S., Lang, T., Gould, J., 
Dubois, M.C., Jongert, E., et al. (2011). Efficacy of RTS,S/AS01E malaria vaccine and 
exploratory analysis on anti-circumsporozoite antibody titres and protection in children 
aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet 
infectious diseases 11, 102-109. 
Orlandi, P.A., Sim, B.K., Chulay, J.D., and Haynes, J.D. (1990). Characterization of the 175-
kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasit 
40, 285-294. 
Osier, F.H., Fegan, G., Polley, S.D., Murungi, L., Verra, F., Tetteh, K.K., Lowe, B., Mwangi, 
T., Bull, P.C., Thomas, A.W., et al. (2008). Breadth and magnitude of antibody responses 
to multiple Plasmodium falciparum merozoite antigens are associated with protection from 
clinical malaria. Infection and Immunity 76, 2240-2248. 
Pachebat, J.A., Ling, I.T., Grainger, M., Trucco, C., Howell, S., Fernandez-Reyes, D., 
Gunaratne, R., and Holder, A.A. (2001). The 22 kDa component of the protein complex on 
the surface of Plasmodium falciparum merozoites is derived from a larger precursor, 
merozoite surface protein 7. Mol Biochem Parasit 117, 83-89. 
Pasvol, G. (2003). How many pathways for invasion of the red blood cell by the malaria 
parasite? Trends in parasitology 19, 430-432. 
Pasvol, G., Weatherall, D.J., and Wilson, R.J. (1978). Cellular mechanism for the protective 
effect of haemoglobin S against P. falciparum malaria. Nature 274, 701-703. 
Pathirana, S.L., Alles, H.K., Bandara, S., Phone-Kyaw, M., Perera, M.K., Wickremasinghe, 
A.R., Mendis, K.N., and Handunnetti, S.M. (2005). ABO-blood-group types and 
  62 
protection against severe, Plasmodium falciparum malaria. Ann Trop Med Parasit 99, 119-
124. 
Perraut, R., Marrama, L., Diouf, B., Sokhna, C., Tall, A., Nabeth, P., Trape, J.F., Longacre, S., 
and Mercereau-Puijalon, O. (2005). Antibodies to the conserved C-terminal domain of the 
Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their 
relationship with in vitro inhibitory antibodies and protection against clinical malaria in a 
Senegalese village. The Journal of infectious diseases 191, 264-271. 
Persson, K.E.M, Fowkes, F.J., McCallum, F.J., Gicheru, N., Reiling, L., Richards, J.S., Wilson, 
D.W., Lopaticki, S., Cowman, A.F., Marsh, K., et al. (2013). Erythrocyte-binding antigens 
of Plasmodium falciparum are targets of human inhibitory antibodies and function to 
evade naturally acquired immunity. Journal of immunology 191, 785-794. 
Persson, K.E.M, Lee, C.T., Marsh, K., and Beeson, J.G. (2006). Development and optimization 
of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory 
antibodies. Journal of clinical microbiology 44, 1665-1673. 
Persson, K.E.M, McCallum, F.J., Reiling, L., Lister, N.A., Stubbs, J., Cowman, A.F., Marsh, 
K., and Beeson, J.G. (2008). Variation in use of erythrocyte invasion pathways by 
Plasmodium falciparum mediates evasion of human inhibitory antibodies. The Journal of 
clinical investigation 118, 342-351. 
Peterson, D.S., and Wellems, T.E. (2000). EBL-1, a putative erythrocyte binding protein of 
Plasmodium falciparum, maps within a favored linkage group in two genetic crosses. Mol 
Biochem Parasit 105, 105-113. 
Peterson MG, M.V.M., Smythe JA, Crewther PE, Lew A, Silva A, Anders R F, Kemp D J 
(1989). Integral membrane protein located in the apical complex of Plasmodium 
falciparum. Molecular and Cellular Biology 9, 3151-3154. 
Petter, M., Bonow, I., and Klinkert, M.Q. (2008). Diverse expression patterns of subgroups of 
the rif multigene family during Plasmodium falciparum gametocytogenesis. PLoS One 3, 
e3779. 
Petter, M., Haeggstrom, M., Khattab, A., Fernandez, V., Klinkert, M.Q., and Wahlgren, M. 
(2007). Variant proteins of the Plasmodium falciparum RIFIN family show distinct 
subcellular localization and developmental expression patterns. Mol Biochem Parasit 156, 
51-61. 
Pimenta, P.F., Touray, M., and Miller, L. (1994). The journey of malaria sporozoites in the 
mosquito salivary gland. The Journal of eukaryotic microbiology 41, 608-624. 
Pizarro, J.C., Vulliez-Le Normand, B., Chesne-Seck, M.L., Collins, C.R., Withers-Martinez, C., 
Hackett, F., Blackman, M.J., Faber, B.W., Remarque, E.J., Kocken, C.H., et al. (2005). 
Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308, 
408-411. 
Polley, S.D., and Conway, D.J. (2001). Strong diversifying selection on domains of the 
Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158, 1505-1512. 
Polley, S.D., Mwangi, T., Kocken, C.H., Thomas, A.W., Dutta, S., Lanar, D.E., Remarque, E., 
Ross, A., Williams, T.N., Mwambingu, G., et al. (2004). Human antibodies to 
recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 
(AMA1) and their associations with protection from malaria. Vaccine 23, 718-728. 
Pombo, D.J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., 
Anderson, K., Mahakunkijcharoen, Y., Martin, L.B., Wilson, D., et al. (2002). Immunity 
to malaria after administration of ultra-low doses of red cells infected with Plasmodium 
falciparum. Lancet 360, 610-617. 
Pongponratn, E., Riganti, M., Punpoowong, B., and Aikawa, M. (1991). Microvascular 
sequestration of parasitized erythrocytes in human falciparum malaria: a pathological 
study. The American journal of tropical medicine and hygiene 44, 168-175. 
Pradel, G., and Frevert, U. (2001). Malaria sporozoites actively enter and pass through rat 
Kupffer cells prior to hepatocyte invasion. Hepatology 33, 1154-1165. 
Preiser, P.R., Khan, S., Costa, F.T., Jarra, W., Belnoue, E., Ogun, S., Holder, A.A., Voza, T., 
Landau, I., Snounou, G., et al. (2002). Stage-specific transcription of distinct repertoires of 
a multigene family during Plasmodium life cycle. Science 295, 342-345. 
Prescott, N., Stowers, A.W., Cheng, Q., Bobogare, A., Rzepczyk, C.M., and Saul, A. (1994). 
Plasmodium falciparum genetic diversity can be characterised using the polymorphic 
  63 
merozoite surface antigen 2 (MSA-2) gene as a single locus marker. Mol Biochem Parasit 
63, 203-212. 
Price, R.N., Douglas, N.M., and Anstey, N.M. (2009). New developments in Plasmodium vivax 
malaria: severe disease and the rise of chloroquine resistance. Current opinion in infectious 
diseases 22, 430-435. 
Price, R.N., Tjitra, E., Guerra, C.A., Yeung, S., White, N.J., and Anstey, N.M. (2007). Vivax 
malaria: neglected and not benign. The American journal of tropical medicine and hygiene 
77, 79-87. 
Rasti, N., Namusoke, F., Chene, A., Chen, Q., Staalsoe, T., Klinkert, M.Q., Mirembe, F., 
Kironde, F., and Wahlgren, M. (2006). Nonimmune immunoglobulin binding and multiple 
adhesion characterize Plasmodium falciparum-infected erythrocytes of placental origin. P 
Natl Acad Sci USA 103, 13795-13800. 
Rayner, J.C., Galinski, M.R., Ingravallo, P., and Barnwell, J.W. (2000). Two Plasmodium 
falciparum genes express merozoite proteins that are related to Plasmodium vivax and 
Plasmodium yoelii adhesive proteins involved in host cell selection and invasion. P Natl 
Acad Sci USA 97, 9648-9653. 
Reddy, S.B., Anders, R.F., Beeson, J.G., Farnert, A., Kironde, F., Berenzon, S.K., Wahlgren, 
M., Linse, S., and Persson, K.E.M (2012). High affinity antibodies to Plasmodium 
falciparum merozoite antigens are associated with protection from malaria. PLoS One 7, 
e32242. 
Reed, M.B., Caruana, S.R., Batchelor, A.H., Thompson, J.K., Crabb, B.S., and Cowman, A.F. 
(2000). Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is 
associated with a switch toward a sialic acid-independent pathway of invasion. P Natl 
Acad Sci USA 97, 7509-7514. 
Reiling, L., Richards, J.S., Fowkes, F.J., Barry, A.E., Triglia, T., Chokejindachai, W., Michon, 
P., Tavul, L., Siba, P.M., Cowman, A.F., et al. (2010). Evidence that the erythrocyte 
invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum 
malaria. Journal of immunology 185, 6157-6167. 
Reyes-Sandoval, A., Berthoud, T., Alder, N., Siani, L., Gilbert, S.C., Nicosia, A., Colloca, S., 
Cortese, R., and Hill, A.V. (2010). Prime-boost immunization with adenoviral and 
modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of 
protective malaria CD8+ T-cell responses. Infection and Immunity 78, 145-153. 
Ribacke, U., Mok, B.W., Wirta, V., Normark, J., Lundeberg, J., Kironde, F., Egwang, T.G., 
Nilsson, P., and Wahlgren, M. (2007). Genome wide gene amplifications and deletions in 
Plasmodium falciparum. Mol Biochem Parasit 155, 33-44. 
Richards, J.S., Stanisic, D.I., Fowkes, F.J., Tavul, L., Dabod, E., Thompson, J.K., Kumar, S., 
Chitnis, C.E., Narum, D.L., Michon, P., et al. (2010). Association between naturally 
acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and 
protection from malaria and high-density parasitemia. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 51, e50-60. 
Riley, E.M., Allen, S.J., Wheeler, J.G., Blackman, M.J., Bennett, S., Takacs, B., Schonfeld, 
H.J., Holder, A.A., and Greenwood, B.M. (1992). Naturally acquired cellular and humoral 
immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium 
falciparum are associated with reduced malaria morbidity. Parasite immunology 14, 321-
337. 
Rogerson, S.J., Hviid, L., Duffy, P.E., Leke, R.F., and Taylor, D.W. (2007). Malaria in 
pregnancy: pathogenesis and immunity. The Lancet infectious diseases 7, 105-117. 
Rogerson, S.J., Pollina, E., Getachew, A., Tadesse, E., Lema, V.M., and Molyneux, M.E. 
(2003). Placental monocyte infiltrates in response to Plasmodium falciparum malaria 
infection and their association with adverse pregnancy outcomes. The American journal of 
tropical medicine and hygiene 68, 115-119. 
Rogerson, S.J., Tembenu, R., Dobano, C., Plitt, S., Taylor, T.E., and Molyneux, M.E. (1999). 
Cytoadherence characteristics of Plasmodium falciparum-infected erythrocytes from 
Malawian children with severe and uncomplicated malaria. The American journal of 
tropical medicine and hygiene 61, 467-472. 
Romi, R., Razaiarimanga, M.C., Raharimanga, R., Rakotondraibe, E.M., Ranaivo, L.H., Pietra, 
V., Raveloson, A., and Majori, G. (2002). Impact of the malaria control campaign (1993-
  64 
1998) in the highlands of Madagascar: parasitological and entomological data. The 
American journal of tropical medicine and hygiene 66, 2-6. 
Roussilhon, C., Oeuvray, C., Muller-Graf, C., Tall, A., Rogier, C., Trape, J.F., Theisen, M., 
Balde, A., Perignon, J.L., and Druilhe, P. (2007). Long-term clinical protection from 
falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface 
protein 3. PLoS medicine 4, e320. 
Rowe, A., Berendt, A.R., Marsh, K., and Newbold, C.I. (1994). Plasmodium falciparum: a 
family of sulphated glycoconjugates disrupts erythrocyte rosettes. Experimental 
parasitology 79, 506-516. 
Rowe, A., Obeiro, J., Newbold, C.I., and Marsh, K. (1995). Plasmodium falciparum rosetting is 
associated with malaria severity in Kenya. Infection and Immunity 63, 2323-2326. 
Rowe, J.A., Handel, I.G., Thera, M.A., Deans, A.M., Lyke, K.E., Kone, A., Diallo, D.A., Raza, 
A., Kai, O., Marsh, K., et al. (2007). Blood group O protects against severe Plasmodium 
falciparum malaria through the mechanism of reduced rosetting. P Natl Acad Sci USA 
104, 17471-17476. 
Rowe, J.A., Kyes, S.A., Rogerson, S.J., Babiker, H.A., and Raza, A. (2002a). Identification of a 
conserved Plasmodium falciparum var gene implicated in malaria in pregnancy. The 
Journal of infectious diseases 185, 1207-1211. 
Rowe, J.A., Moulds, J.M., Newbold, C.I., and Miller, L.H. (1997). P. falciparum rosetting 
mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. 
Nature 388, 292-295. 
Rowe, J.A., Rogerson, S.J., Raza, A., Moulds, J.M., Kazatchkine, M.D., Marsh, K., Newbold, 
C.I., Atkinson, J.P., and Miller, L.H. (2000). Mapping of the region of complement 
receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the 
importance of CR1 in rosetting in field isolates. Journal of immunology 165, 6341-6346. 
Rowe, J.A., Shafi, J., Kai, O.K., Marsh, K., and Raza, A. (2002b). Nonimmune IgM, but not 
IgG binds to the surface of Plasmodium falciparum-infected erythrocytes and correlates 
with rosetting and severe malaria. The American journal of tropical medicine and hygiene 
66, 692-699. 
Roy, S.W., Ferreira, M.U., and Hartl, D.L. (2008). Evolution of allelic dimorphism in malarial 
surface antigens. Heredity 100, 103-110. 
Sachs, J., and Malaney, P. (2002). The economic and social burden of malaria. Nature 415, 
680-685. 
Sachs, J.D. (2002). A new global effort to control malaria. Science 298, 122-124. 
Salanti, A., Dahlback, M., Turner, L., Nielsen, M.A., Barfod, L., Magistrado, P., Jensen, A.T., 
Lavstsen, T., Ofori, M.F., Marsh, K., et al. (2004). Evidence for the involvement of 
VAR2CSA in pregnancy-associated malaria. The Journal of experimental medicine 200, 
1197-1203. 
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A.T., Sowa, M.P., Arnot, D.E., Hviid, L., and 
Theander, T.G. (2003). Selective upregulation of a single distinctly structured var gene in 
chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated 
malaria. Molecular microbiology 49, 179-191. 
Salmon, B.L., Oksman, A., and Goldberg, D.E. (2001). Malaria parasite exit from the host 
erythrocyte: a two-step process requiring extraerythrocytic proteolysis. P Natl Acad Sci 
USA 98, 271-276. 
Sanders, P.R., Kats, L.M., Drew, D.R., O'Donnell, R.A., O'Neill, M., Maier, A.G., Coppel, 
R.L., and Crabb, B.S. (2006). A set of glycosylphosphatidyl inositol-anchored membrane 
proteins of Plasmodium falciparum is refractory to genetic deletion. Infection and 
Immunity 74, 4330-4338. 
Sargeant, T.J., Marti, M., Caler, E., Carlton, J.M., Simpson, K., Speed, T.P., and Cowman, A.F. 
(2006). Lineage-specific expansion of proteins exported to erythrocytes in malaria 
parasites. Genome biology 7, R12. 
Sarthou, J.L., Angel, G., Aribot, G., Rogier, C., Dieye, A., Toure Balde, A., Diatta, B., Seignot, 
P., and Roussilhon, C. (1997). Prognostic value of anti-Plasmodium falciparum-specific 
immunoglobulin G3, cytokines, and their soluble receptors in West African patients with 
severe malaria. Infection and Immunity 65, 3271-3276. 
  65 
Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., and Nussenzweig, 
V. (1987). Gamma interferon, CD8+ T cells and antibodies required for immunity to 
malaria sporozoites. Nature 330, 664-666. 
Scholander, C., Carlson, J., Kremsner, P.G., and Wahlgren, M. (1998). Extensive 
immunoglobulin binding of Plasmodium falciparum-infected erythrocytes in a group of 
children with moderate anemia. Infection and Immunity 66, 361-363. 
Schreiber, N., Brattig, N., Evans, J., Tsiri, A., Horstmann, R.D., May, J., and Klinkert, M.Q. 
(2006). Cerebral malaria is associated with IgG2 and IgG4 antibody responses to 
recombinant Plasmodium falciparum RIFIN antigen. Microbes and infection / Institut 
Pasteur 8, 1269-1276. 
Shi, Y.P., Sayed, U., Qari, S.H., Roberts, J.M., Udhayakumar, V., Oloo, A.J., Hawley, W.A., 
Kaslow, D.C., Nahlen, B.L., and Lal, A.A. (1996). Natural immune response to the C-
terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. 
Infection and Immunity 64, 2716-2723. 
Shulman, C.E., Graham, W.J., Jilo, H., Lowe, B.S., New, L., Obiero, J., Snow, R.W., and 
Marsh, K. (1996). Malaria is an important cause of anaemia in primigravidae: evidence 
from a district hospital in coastal Kenya. T Roy Soc Trop Med H 90, 535-539. 
Silamut, K., Phu, N.H., Whitty, C., Turner, G.D., Louwrier, K., Mai, N.T., Simpson, J.A., Hien, 
T.T., and White, N.J. (1999). A quantitative analysis of the microvascular sequestration of 
malaria parasites in the human brain. The American journal of pathology 155, 395-410. 
Silverstein, R.L., and Febbraio, M. (2009). CD36, a scavenger receptor involved in immunity, 
metabolism, angiogenesis, and behavior. Sci Signal 2, re3. 
Silvie, O., Franetich, J.F., Charrin, S., Mueller, M.S., Siau, A., Bodescot, M., Rubinstein, E., 
Hannoun, L., Charoenvit, Y., Kocken, C.H., et al. (2004). A role for apical membrane 
antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. The 
Journal of biological chemistry 279, 9490-9496. 
Sim, B.K., Chitnis, C.E., Wasniowska, K., Hadley, T.J., and Miller, L.H. (1994). Receptor and 
ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264, 
1941-1944. 
Sim, B.K., Orlandi, P.A., Haynes, J.D., Klotz, F.W., Carter, J.M., Camus, D., Zegans, M.E., 
and Chulay, J.D. (1990). Primary structure of the 175K Plasmodium falciparum 
erythrocyte binding antigen and identification of a peptide which elicits antibodies that 
inhibit malaria merozoite invasion. The Journal of cell biology 111, 1877-1884. 
Singh, A.P., Buscaglia, C.A., Wang, Q., Levay, A., Nussenzweig, D.R., Walker, J.R., Winzeler, 
E.A., Fujii, H., Fontoura, B.M., and Nussenzweig, V. (2007). Plasmodium 
circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 
131, 492-504. 
Singh, S., Alam, M.M., Pal-Bhowmick, I., Brzostowski, J.A., and Chitnis, C.E. (2010). Distinct 
external signals trigger sequential release of apical organelles during erythrocyte invasion 
by malaria parasites. PLoS pathogens 6, e1000746. 
Sirima, S.B., Nebie, I., Ouedraogo, A., Tiono, A.B., Konate, A.T., Gansane, A., Derme, A.I., 
Diarra, A., Soulama, I., Cuzzin-Ouattara, N., et al. (2007). Safety and immunogenicity of 
the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-
LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. 
Vaccine 25, 2723-2732. 
Smith, J.D., Chitnis, C.E., Craig, A.G., Roberts, D.J., Hudson-Taylor, D.E., Peterson, D.S., 
Pinches, R., Newbold, C.I., and Miller, L.H. (1995). Switches in expression of 
Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent 
phenotypes of infected erythrocytes. Cell 82, 101-110. 
Smith, T., Beck, H.P., Kitua, A., Mwankusye, S., Felger, I., Fraser-Hurt, N., Irion, A., Alonso, 
P., Teuscher, T., and Tanner, M. (1999). Age dependence of the multiplicity of 
Plasmodium falciparum infections and of other malariological indices in an area of high 
endemicity. T Roy Soc Trop Med H 93 Suppl 1, 15-20. 
Smith, T.G., Lourenco, P., Carter, R., Walliker, D., and Ranford-Cartwright, L.C. (2000). 
Commitment to sexual differentiation in the human malaria parasite, Plasmodium 
falciparum. Parasitology 121 ( Pt 2), 127-133. 
  66 
Smythe, J.A., Coppel, R.L., Brown, G.V., Ramasamy, R., Kemp, D.J., and Anders, R.F. (1988). 
Identification of two integral membrane proteins of Plasmodium falciparum. P Natl Acad 
Sci USA 85, 5195-5199. 
Smythe, J.A., Peterson, M.G., Coppel, R.L., Saul, A.J., Kemp, D.J., and Anders, R.F. (1990). 
Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium 
falciparum. Mol Biochem Parasit 39, 227-234. 
Snewin, V.A., Herrera, M., Sanchez, G., Scherf, A., Langsley, G., and Herrera, S. (1991). 
Polymorphism of the alleles of the merozoite surface antigens MSA1 and MSA2 in 
Plasmodium falciparum wild isolates from Colombia. Mol Biochem Parasit 49, 265-275. 
Snounou, G. (2002). Genotyping of Plasmodium spp. Nested PCR. Methods in molecular 
medicine 72, 103-116. 
Snow, R.W., Nahlen, B., Palmer, A., Donnelly, C.A., Gupta, S., and Marsh, K. (1998). Risk of 
severe malaria among African infants: direct evidence of clinical protection during early 
infancy. The Journal of infectious diseases 177, 819-822. 
Spadafora, C., Awandare, G.A., Kopydlowski, K.M., Czege, J., Moch, J.K., Finberg, R.W., 
Tsokos, G.C., and Stoute, J.A. (2010). Complement receptor 1 is a sialic acid-independent 
erythrocyte receptor of Plasmodium falciparum. PLoS pathogens 6, e1000968. 
Spycher, C., Rug, M., Pachlatko, E., Hanssen, E., Ferguson, D., Cowman, A.F., Tilley, L., and 
Beck, H.P. (2008). The Maurer's cleft protein MAHRP1 is essential for trafficking of 
PfEMP1 to the surface of Plasmodium falciparum-infected erythrocytes. Molecular 
microbiology 68, 1300-1314. 
Srinivasan, P., Beatty, W.L., Diouf, A., Herrera, R., Ambroggio, X., Moch, J.K., Tyler, J.S., 
Narum, D.L., Pierce, S.K., Boothroyd, J.C., et al. (2011). Binding of Plasmodium 
merozoite proteins RON2 and AMA1 triggers commitment to invasion. P Natl Acad Sci 
USA 108, 13275-13280. 
Stafford, W.H., Stockley, R.W., Ludbrook, S.B., and Holder, A.A. (1996). Isolation, expression 
and characterization of the gene for an ADP-ribosylation factor from the human malaria 
parasite, Plasmodium falciparum. European journal of biochemistry / FEBS 242, 104-113. 
Stanisic, D.I., Richards, J.S., McCallum, F.J., Michon, P., King, C.L., Schoepflin, S., Gilson, 
P.R., Murphy, V.J., Anders, R.F., Mueller, I., et al. (2009). Immunoglobulin G subclass-
specific responses against Plasmodium falciparum merozoite antigens are associated with 
control of parasitemia and protection from symptomatic illness. Infection and Immunity 
77, 1165-1174. 
Stanley, H.A., Howard, R.F., and Reese, R.T. (1985). Recognition of a Mr 56K glycoprotein on 
the surface of Plasmodium falciparum merozoites by mouse monoclonal antibodies. 
Journal of immunology 134, 3439-3444. 
Stoute, J.A., Slaoui, M., Heppner, D.G., Momin, P., Kester, K.E., Desmons, P., Wellde, B.T., 
Garcon, N., Krzych, U., and Marchand, M. (1997). A preliminary evaluation of a 
recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. 
RTS,S Malaria Vaccine Evaluation Group. The New England journal of medicine 336, 86-
91. 
Stubbs, J., Simpson, K.M., Triglia, T., Plouffe, D., Tonkin, C.J., Duraisingh, M.T., Maier, A.G., 
Winzeler, E.A., and Cowman, A.F. (2005). Molecular mechanism for switching of P. 
falciparum invasion pathways into human erythrocytes. Science 309, 1384-1387. 
Su, X.Z., Heatwole, V.M., Wertheimer, S.P., Guinet, F., Herrfeldt, J.A., Peterson, D.S., 
Ravetch, J.A., and Wellems, T.E. (1995). The large diverse gene family var encodes 
proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-
infected erythrocytes. Cell 82, 89-100. 
Sultan, A.A., Thathy, V., Frevert, U., Robson, K.J., Crisanti, A., Nussenzweig, V., 
Nussenzweig, R.S., and Menard, R. (1997). TRAP is necessary for gliding motility and 
infectivity of plasmodium sporozoites. Cell 90, 511-522. 
Sutherland, C.J. (2001). Stevor transcripts from Plasmodium falciparum gametocytes encode 
truncated polypeptides. Mol Biochem Parasit 113, 331-335. 
Takala, S., Branch, O., Escalante, A.A., Kariuki, S., Wootton, J., and Lal, A.A. (2002). 
Evidence for intragenic recombination in Plasmodium falciparum: identification of a novel 
allele family in block 2 of merozoite surface protein-1: Asembo Bay Area Cohort Project 
XIV. Mol Biochem Parasit 125, 163-171. 
  67 
Talman, A.M., Domarle, O., McKenzie, F.E., Ariey, F., and Robert, V. (2004). 
Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria J 3, 24. 
Tanabe, K., Mackay, M., Goman, M., and Scaife, J.G. (1987). Allelic dimorphism in a surface 
antigen gene of the malaria parasite Plasmodium falciparum. Journal of molecular biology 
195, 273-287. 
Tarun, A.S., Baer, K., Dumpit, R.F., Gray, S., Lejarcegui, N., Frevert, U., and Kappe, S.H. 
(2006). Quantitative isolation and in vivo imaging of malaria parasite liver stages. 
International journal for parasitology 36, 1283-1293. 
Taverne, J., Sheikh, N., de Souza, J.B., Playfair, J.H., Probert, L., and Kollias, G. (1994). 
Anaemia and resistance to malaria in transgenic mice expressing human tumour necrosis 
factor. Immunology 82, 397-403. 
Taylor, H.M., Grainger, M., and Holder, A.A. (2002). Variation in the expression of a 
Plasmodium falciparum protein family implicated in erythrocyte invasion. Infection and 
Immunity 70, 5779-5789. 
Taylor, R.R., Allen, S.J., Greenwood, B.M., and Riley, E.M. (1998). IgG3 antibodies to 
Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with 
age and association with clinical immunity to malaria. The American journal of tropical 
medicine and hygiene 58, 406-413. 
Taylor, W.R., Canon, V., and White, N.J. (2006). Pulmonary manifestations of malaria : 
recognition and management. Treatments in respiratory medicine 5, 419-428. 
Taylor, W.R., Hanson, J., Turner, G.D., White, N.J., and Dondorp, A.M. (2012). Respiratory 
manifestations of malaria. Chest 142, 492-505. 
Tham, W.H., Healer, J., and Cowman, A.F. (2012). Erythrocyte and reticulocyte binding-like 
proteins of Plasmodium falciparum. Trends in parasitology 28, 23-30. 
Tham, W.H., Schmidt, C.Q., Hauhart, R.E., Guariento, M., Tetteh-Quarcoo, P.B., Lopaticki, S., 
Atkinson, J.P., Barlow, P.N., and Cowman, A.F. (2011). Plasmodium falciparum uses a 
key functional site in complement receptor type-1 for invasion of human erythrocytes. 
Blood 118, 1923-1933. 
Tham, W.H., Wilson, D.W., Reiling, L., Chen, L., Beeson, J.G., and Cowman, A.F. (2009). 
Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of 
Plasmodium falciparum into human erythrocytes. Infection and Immunity 77, 2427-2435. 
Touray, M.G., Warburg, A., Laughinghouse, A., Krettli, A.U., and Miller, L.H. (1992). 
Developmentally regulated infectivity of malaria sporozoites for mosquito salivary glands 
and the vertebrate host. The Journal of experimental medicine 175, 1607-1612. 
Toure, F.S., Deloron, P., and Migot-Nabias, F. (2006). Analysis of human antibodies to 
erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum. Clinical medicine & 
research 4, 1-6. 
Toure, F.S., Mavoungou, E., Ndong, J.M., Tshipamba, P., and Deloron, P. (2001). Erythrocyte 
binding antigen (EBA-175) of Plasmodium falciparum: improved genotype determination 
by nested polymerase chain reaction. Tropical medicine & international health : TM & IH 
6, 767-769. 
Trager, W., and Jensen, J.B. (1976). Human malaria parasites in continuous culture. Science 
193, 673-675. 
Trape, J.F., Rogier, C., Konate, L., Diagne, N., Bouganali, H., Canque, B., Legros, F., Badji, 
A., Ndiaye, G., Ndiaye, P., et al. (1994). The Dielmo project: a longitudinal study of 
natural malaria infection and the mechanisms of protective immunity in a community 
living in a holoendemic area of Senegal. The American journal of tropical medicine and 
hygiene 51, 123-137. 
Treeck, M., Zacherl, S., Herrmann, S., Cabrera, A., Kono, M., Struck, N.S., Engelberg, K., 
Haase, S., Frischknecht, F., Miura, K., et al. (2009). Functional analysis of the leading 
malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in 
the invasion process. PLoS pathogens 5, e1000322. 
Treutiger, C.J., Hedlund, I., Helmby, H., Carlson, J., Jepson, A., Twumasi, P., Kwiatkowski, 
D., Greenwood, B.M., and Wahlgren, M. (1992). Rosette formation in Plasmodium 
falciparum isolates and anti-rosette activity of sera from Gambians with cerebral or 
uncomplicated malaria. The American journal of tropical medicine and hygiene 46, 503-
510. 
  68 
Treutiger, C.J., Scholander, C., Carlson, J., McAdam, K.P., Raynes, J.G., Falksveden, L., and 
Wahlgren, M. (1999). Rouleaux-forming serum proteins are involved in the rosetting of 
Plasmodium falciparum-infected erythrocytes. Experimental parasitology 93, 215-224. 
Triglia, T., Duraisingh, M.T., Good, R.T., and Cowman, A.F. (2005). Reticulocyte-binding 
protein homologue 1 is required for sialic acid-dependent invasion into human 
erythrocytes by Plasmodium falciparum. Molecular microbiology 55, 162-174. 
Triglia, T., Healer, J., Caruana, S.R., Hodder, A.N., Anders, R.F., Crabb, B.S., and Cowman, 
A.F. (2000). Apical membrane antigen 1 plays a central role in erythrocyte invasion by 
Plasmodium species. Molecular microbiology 38, 706-718. 
Triglia, T., Thompson, J.K., and Cowman, A.F. (2001). An EBA175 homologue which is 
transcribed but not translated in erythrocytic stages of Plasmodium falciparum. Mol 
Biochem Parasit 116, 55-63. 
Trimnell, A.R., Kraemer, S.M., Mukherjee, S., Phippard, D.J., Janes, J.H., Flamoe, E., Su, X.Z., 
Awadalla, P., and Smith, J.D. (2006). Global genetic diversity and evolution of var genes 
associated with placental and severe childhood malaria. Mol Biochem Parasit 148, 169-
180. 
Turner, C.M. (1999). Antigenic variation in Trypanosoma brucei infections: an holistic view. 
Journal of cell science 112 ( Pt 19), 3187-3192. 
Turner, G.D., Morrison, H., Jones, M., Davis, T.M., Looareesuwan, S., Buley, I.D., Gatter, 
K.C., Newbold, C.I., Pukritayakamee, S., Nagachinta, B., et al. (1994). An 
immunohistochemical study of the pathology of fatal malaria. Evidence for widespread 
endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral 
sequestration. The American journal of pathology 145, 1057-1069. 
Udomsangpetch, R., Aikawa, M., Berzins, K., Wahlgren, M., and Perlmann, P. (1989). 
Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition 
by a human monoclonal antibody. Nature 338, 763-765. 
Valecha, N., Pinto, R.G., Turner, G.D., Kumar, A., Rodrigues, S., Dubhashi, N.G., Rodrigues, 
E., Banaulikar, S.S., Singh, R., Dash, A.P., et al. (2009). Histopathology of fatal 
respiratory distress caused by Plasmodium vivax malaria. The American journal of tropical 
medicine and hygiene 81, 758-762. 
van Hensbroek, M.B., Palmer, A., Jaffar, S., Schneider, G., and Kwiatkowski, D. (1997). 
Residual neurologic sequelae after childhood cerebral malaria. The Journal of pediatrics 
131, 125-129. 
van Ooij, C., Tamez, P., Bhattacharjee, S., Hiller, N.L., Harrison, T., Liolios, K., Kooij, T., 
Ramesar, J., Balu, B., Adams, J., et al. (2008). The malaria secretome: from algorithms to 
essential function in blood stage infection. PLoS pathogens 4, e1000084. 
Vaughan, A.M., Wang, R., and Kappe, S.H. (2010). Genetically engineered, attenuated whole-
cell vaccine approaches for malaria. Human vaccines 6, 107-113. 
Vik, D.P., and Wong, W.W. (1993). Structure of the gene for the F allele of complement 
receptor type 1 and sequence of the coding region unique to the S allele. Journal of 
immunology 151, 6214-6224. 
Vogt, A.M., Barragan, A., Chen, Q., Kironde, F., Spillmann, D., and Wahlgren, M. (2003). 
Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-
infected erythrocytes via the DBL1alpha domain of PfEMP1. Blood 101, 2405-2411. 
Vogt, A.M., Pettersson, F., Moll, K., Jonsson, C., Normark, J., Ribacke, U., Egwang, T.G., 
Ekre, H.P., Spillmann, D., Chen, Q., et al. (2006). Release of sequestered malaria parasites 
upon injection of a glycosaminoglycan. PLoS pathogens 2, e100. 
Voss, T.S., Healer, J., Marty, A.J., Duffy, M.F., Thompson, J.K., Beeson, J.G., Reeder, J.C., 
Crabb, B.S., and Cowman, A.F. (2006). A var gene promoter controls allelic exclusion of 
virulence genes in Plasmodium falciparum malaria. Nature 439, 1004-1008. 
Wahlgren, M., Carlson, J., Helmby, H., Hedlund, I., and Treutiger, C.J. (1992). Molecular 
mechanisms and biological importance of Plasmodium falciparum erythrocyte rosetting. 
Mem I Oswaldo Cruz 87 Suppl 3, 323-329. 
Walker, O., Salako, L.A., Sowunmi, A., Thomas, J.O., Sodeine, O., and Bondi, F.S. (1992). 
Prognostic risk factors and post mortem findings in cerebral malaria in children. T Roy 
Soc Trop Med H 86, 491-493. 
  69 
Waller, K.L., Cooke, B.M., Nunomura, W., Mohandas, N., and Coppel, R.L. (1999). Mapping 
the binding domains involved in the interaction between the Plasmodium falciparum knob-
associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum 
erythrocyte membrane protein 1 (PfEMP1). The Journal of biological chemistry 274, 
23808-23813. 
Waller, R.F., Reed, M.B., Cowman, A.F., and McFadden, G.I. (2000). Protein trafficking to the 
plastid of Plasmodium falciparum is via the secretory pathway. The EMBO journal 19, 
1794-1802. 
Waters, A.P., Thomas, A.W., Deans, J.A., Mitchell, G.H., Hudson, D.E., Miller, L.H., 
McCutchan, T.F., and Cohen, S. (1990). A merozoite receptor protein from Plasmodium 
knowlesi is highly conserved and distributed throughout Plasmodium. The Journal of 
biological chemistry 265, 17974-17979. 
Weedall, G.D., and Conway, D.J. (2010). Detecting signatures of balancing selection to identify 
targets of anti-parasite immunity. Trends in parasitology 26, 363-369. 
White, N.J. (2008). Plasmodium knowlesi: the fifth human malaria parasite. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 46, 172-
173. 
WHO (2000a). Severe falciparum malaria. Trans R Soc Trop Med Hyg 94, 1-90. 
WHO (2000b). Severe falciparum malaria, World Health Organization, Communicable 
Diseases Cluster. Trans R Soc Trop Med Hyg 94 SUPPL, S1-S90. 
WHO (2010). Guidelines for the treatment of malaria. Second edition. 
WHO (2011). World Malaria report 2011. 
WHO (2012). World malaria report 2012. 
Wickham, M.E., Rug, M., Ralph, S.A., Klonis, N., McFadden, G.I., Tilley, L., and Cowman, 
A.F. (2001). Trafficking and assembly of the cytoadherence complex in Plasmodium 
falciparum-infected human erythrocytes. The EMBO journal 20, 5636-5649. 
Wickramasinghe, S.N., and Abdalla, S.H. (2000). Blood and bone marrow changes in malaria. 
Baillieres Best Pract Res Clin Haematol 13, 277-299. 
Williams, T.N. (2006). Red blood cell defects and malaria. Mol Biochem Parasit 149, 121-127. 
Williams, T.N., Mwangi, T.W., Roberts, D.J., Alexander, N.D., Weatherall, D.J., Wambua, S., 
Kortok, M., Snow, R.W., and Marsh, K. (2005a). An immune basis for malaria protection 
by the sickle cell trait. PLoS medicine 2, e128. 
Williams, T.N., Mwangi, T.W., Wambua, S., Alexander, N.D., Kortok, M., Snow, R.W., and 
Marsh, K. (2005b). Sickle cell trait and the risk of Plasmodium falciparum malaria and 
other childhood diseases. The Journal of infectious diseases 192, 178-186. 
Williams, T.N., Wambua, S., Uyoga, S., Macharia, A., Mwacharo, J.K., Newton, C.R., and 
Maitland, K. (2005c). Both heterozygous and homozygous alpha+ thalassemias protect 
against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 106, 
368-371. 
Wilson, D.W., Fowkes, F.J., Gilson, P.R., Elliott, S.R., Tavul, L., Michon, P., Dabod, E., Siba, 
P.M., Mueller, I., Crabb, B.S., et al. (2011). Quantifying the importance of MSP1-19 as a 
target of growth-inhibitory and protective antibodies against Plasmodium falciparum in 
humans. PLoS One 6, e27705. 
Wilson, J.G., Murphy, E.E., Wong, W.W., Klickstein, L.B., Weis, J.H., and Fearon, D.T. 
(1986). Identification of a restriction fragment length polymorphism by a CR1 cDNA that 
correlates with the number of CR1 on erythrocytes. The Journal of experimental medicine 
164, 50-59. 
Winter, G., Kawai, S., Haeggstrom, M., Kaneko, O., von Euler, A., Kawazu, S., Palm, D., 
Fernandez, V., and Wahlgren, M. (2005). SURFIN is a polymorphic antigen expressed on 
Plasmodium falciparum merozoites and infected erythrocytes. The Journal of experimental 
medicine 201, 1853-1863. 
Wu, Y., Ellis, R.D., Shaffer, D., Fontes, E., Malkin, E.M., Mahanty, S., Fay, M.P., Narum, D., 
Rausch, K., Miles, A.P., et al. (2008). Phase 1 trial of malaria transmission blocking 
vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3, 
e2636. 
Ye, J., Bromage, E.S., and Kaattari, S.L. (2010). The strength of B cell interaction with antigen 
determines the degree of IgM polymerization. Journal of immunology 184, 844-850. 
  70 
Yeka, A., Banek, K., Bakyaita, N., Staedke, S.G., Kamya, M.R., Talisuna, A., Kironde, F., 
Nsobya, S.L., Kilian, A., Slater, M., et al. (2005). Artemisinin versus nonartemisinin 
combination therapy for uncomplicated malaria: randomized clinical trials from four sites 
in Uganda. PLoS medicine 2, e190. 
 
 
 
